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Overview {#bph14752-sec-0003}
--------

Enzymes are protein catalysts facilitating the conversion of substrates into products. The Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC‐IUBMB) classifies enzymes into families, using a four number code, on the basis of the reactions they catalyse. There are six main families:

EC 1.‐.‐.‐ Oxidoreductases;

EC 2.‐.‐.‐ Transferases;

EC 3.‐.‐.‐ Hydrolases;

EC 4.‐.‐.‐ Lyases;

EC 5.‐.‐.‐ Isomerases;

EC 6.‐.‐.‐ Ligases.

Although there are many more enzymes than receptors in biology, and many drugs that target prokaryotic enzymes are effective medicines, overall the number of enzyme drug targets is relatively small \[<http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus>\], which is not to say that they are of modest importance.

The majority of drugs which act on enzymes act as inhibitors; one exception is metformin, which appears to stimulate activity of AMP‐activated protein kinase, albeit through an imprecisely‐defined mechanism. Kinetic assays allow discrimination of competitive, non‐competitive, and un‐competitive inhibitors. The majority of inhibitors are competitive (acting at the enzyme\'s ligand recognition site), non‐competitive (acting at a distinct site; potentially interfering with co‐factor or co‐enzyme binding) or of mixed type. One rare example of an uncompetitive inhibitor is lithium ions, which are effective inhibitors at inositol monophosphatase only in the presence of high substrate concentrations. Some inhibitors are irreversible, including a group known as suicide substrates, which bind to the ligand recognition site and then couple covalently to the enzyme. It is beyond the scope of the Guide to give mechanistic information about the inhibitors described, although generally this information is available from the indicated literature.

Many enzymes require additional entities for functional activity. Some of these are used in the catalytic steps, while others promote a particular conformational change. Co‐factors are tightly bound to the enzyme and include metal ions and heme groups. Co‐enzymes are typically small molecules which accept or donate functional groups to assist in the enzymatic reaction. Examples include ATP, NAD, NADP and S‐adenosylmethionine, as well as a number of vitamins, such as riboflavin (vitamin B1) and thiamine (vitamin B2). Where co‐factors/co‐enzymes have been identified, the Guide indicates their involvement.

Family structure {#bph14752-sec-0004}
----------------

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=933>

[S301 Acetylcholine turnover](#bph14752-sec-0005){ref-type="sec"}

[S302 Adenosine turnover](#bph14752-sec-0009){ref-type="sec"}

[S303 Amino acid hydroxylases](#bph14752-sec-0013){ref-type="sec"}

[S304 L‐Arginine turnover](#bph14752-sec-0016){ref-type="sec"}

[S304 2.1.1.‐ Protein arginine N‐methyltransferases](#bph14752-sec-0018){ref-type="sec"}

[S305 Arginase](#bph14752-sec-0020){ref-type="sec"}

[S305 Arginine:glycine amidinotransferase](#bph14752-sec-0023){ref-type="sec"}

[S305 Dimethylarginine dimethylaminohydrolases](#bph14752-sec-0024){ref-type="sec"}

[S306 Nitric oxide synthases](#bph14752-sec-0026){ref-type="sec"}

[S307 Carbonic anhydrases](#bph14752-sec-0031){ref-type="sec"}

[S308 Carboxylases and decarboxylases](#bph14752-sec-0034){ref-type="sec"}

[S308 Carboxylases](#bph14752-sec-0035){ref-type="sec"}

[S309 Decarboxylases](#bph14752-sec-0038){ref-type="sec"}

[S311 Catecholamine turnover](#bph14752-sec-0041){ref-type="sec"}

[S313 Ceramide turnover](#bph14752-sec-0044){ref-type="sec"}

[S313 Serine palmitoyltransferase](#bph14752-sec-0046){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=791>

[S314 Ceramide synthase](#bph14752-sec-0048){ref-type="sec"}

[S314 Sphingolipid ∆^4^‐desaturase](#bph14752-sec-0050){ref-type="sec"}

[S315 Sphingomyelin synthase](#bph14752-sec-0053){ref-type="sec"}

[S315 Sphingomyelin phosphodiesterase](#bph14752-sec-0055){ref-type="sec"}

[S316 Neutral sphingomyelinase coupling factors](#bph14752-sec-0057){ref-type="sec"}

[S316 Ceramide glucosyltransferase](#bph14752-sec-0059){ref-type="sec"}

[S316 Acid ceramidase](#bph14752-sec-0060){ref-type="sec"}

[S317 Neutral ceramidases](#bph14752-sec-0062){ref-type="sec"}

[S317 Alkaline ceramidases](#bph14752-sec-0065){ref-type="sec"}

[S318 Ceramide kinase](#bph14752-sec-0067){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=981>

[S319 Chromatin modifying enzymes](#bph14752-sec-0070){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=869>

[S319 2.1.1.‐ Protein arginine N‐methyltransferases](#bph14752-sec-0072){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=871>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=872>

[S320 3.5.1.‐ Histone deacetylases (HDACs)](#bph14752-sec-0074){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=873>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=884>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=558>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=626>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=631>

[S321 Cyclic nucleotide turnover/signalling](#bph14752-sec-0078){ref-type="sec"}

[S321 Adenylyl cyclases (ACs)](#bph14752-sec-0080){ref-type="sec"}

[S323 Exchange protein activated by cyclic AMP (EPACs)](#bph14752-sec-0084){ref-type="sec"}

[S323 Phosphodiesterases, 3',5'‐cyclic nucleotide (PDEs)](#bph14752-sec-0087){ref-type="sec"}

[S327 Cytochrome P450](#bph14752-sec-0091){ref-type="sec"}

[S327 CYP1 family](#bph14752-sec-0093){ref-type="sec"}

[S328 CYP2 family](#bph14752-sec-0094){ref-type="sec"}

[S329 CYP3 family](#bph14752-sec-0095){ref-type="sec"}

[S330 CYP4 family](#bph14752-sec-0096){ref-type="sec"}

[S331 CYP5, CYP7 and CYP8 families](#bph14752-sec-0097){ref-type="sec"}

[S332 CYP11, CYP17, CYP19, CYP20 and CYP21 families](#bph14752-sec-0098){ref-type="sec"}

[S333 CYP24, CYP26 and CYP27 families](#bph14752-sec-0099){ref-type="sec"}

[S333 CYP39, CYP46 and CYP51 families](#bph14752-sec-0100){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1020>

[S334 DNA topoisomerases](#bph14752-sec-0102){ref-type="sec"}

[S335 Endocannabinoid turnover](#bph14752-sec-0105){ref-type="sec"}

[S336 *N*‐Acylethanolamine turnover](#bph14752-sec-0107){ref-type="sec"}

[S337 2‐Acylglycerol ester turnover](#bph14752-sec-0109){ref-type="sec"}

[S338 Eicosanoid turnover](#bph14752-sec-0113){ref-type="sec"}

[S338 Cyclooxygenase](#bph14752-sec-0115){ref-type="sec"}

[S339 Prostaglandin synthases](#bph14752-sec-0117){ref-type="sec"}

[S341 Lipoxygenases](#bph14752-sec-0120){ref-type="sec"}

[S342 Leukotriene and lipoxin metabolism](#bph14752-sec-0123){ref-type="sec"}

[S343 GABA turnover](#bph14752-sec-0127){ref-type="sec"}

[S344 Glycerophospholipid turnover](#bph14752-sec-0130){ref-type="sec"}

[S344 Phosphoinositide‐specific phospholipase C](#bph14752-sec-0132){ref-type="sec"}

[S346 Phospholipase A~2~](#bph14752-sec-0136){ref-type="sec"}

[S348 Phosphatidylcholine‐specific phospholipase D](#bph14752-sec-0143){ref-type="sec"}

[S349 Lipid phosphate phosphatases](#bph14752-sec-0147){ref-type="sec"}

[S349 Phosphatidylinositol kinases](#bph14752-sec-0150){ref-type="sec"}

[S350 1‐phosphatidylinositol 4‐kinase family](#bph14752-sec-0153){ref-type="sec"}

[S351 Phosphatidylinositol‐4‐phosphate 3‐kinase family](#bph14752-sec-0154){ref-type="sec"}

[S351 Phosphatidylinositol 3‐kinase family](#bph14752-sec-0155){ref-type="sec"}

[S351 Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase family](#bph14752-sec-0156){ref-type="sec"}

[S352 1‐phosphatidylinositol‐3‐phosphate 5‐kinase family](#bph14752-sec-0158){ref-type="sec"}

[S353 Type I PIP kinases (1‐phosphatidylinositol‐4‐phosphate 5‐kinase family)](#bph14752-sec-0159){ref-type="sec"}

[S353 Type II PIP kinases (1‐phosphatidylinositol‐5‐phosphate 4‐kinase family)](#bph14752-sec-0161){ref-type="sec"}

[S354 Sphingosine kinase](#bph14752-sec-0163){ref-type="sec"}

[S356 Phosphatidylinositol phosphate kinases](#bph14752-sec-0169){ref-type="sec"}

[S356 Haem oxygenase](#bph14752-sec-0172){ref-type="sec"}

[S358 Hydrogen sulphide synthesis](#bph14752-sec-0176){ref-type="sec"}

[S358 Hydrolases](#bph14752-sec-0179){ref-type="sec"}

[S360 Inositol phosphate turnover](#bph14752-sec-0182){ref-type="sec"}

[S360 Inositol 1,4,5‐trisphosphate 3‐kinases](#bph14752-sec-0184){ref-type="sec"}

[S360 Inositol polyphosphate phosphatases](#bph14752-sec-0186){ref-type="sec"}

[S361 Inositol monophosphatase](#bph14752-sec-0189){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1004>

[S361 Kinases (EC 2.7.x.x)](#bph14752-sec-0193){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=677>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=454>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=500>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=573>

[S362 Rho kinase](#bph14752-sec-0195){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=283>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=507>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=508>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=937>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=583>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=587>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=604>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=285>

[S362 Protein kinase C (PKC) family](#bph14752-sec-0198){ref-type="sec"}

[S363 Alpha subfamily](#bph14752-sec-0200){ref-type="sec"}

[S363 Delta subfamily](#bph14752-sec-0201){ref-type="sec"}

[S364 Eta subfamily](#bph14752-sec-0202){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=535>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=287>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=601>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=466>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=539>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=540>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=541>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=705>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=614>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=616>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=644>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=678>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=448>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=468>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=469>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=450>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=471>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=472>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=556>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=874>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=558>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=576>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=463>

[S264 FRAP subfamily](#bph14752-sec-0204){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=528>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=530>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=531>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=598>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=465>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=536>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=537>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=538>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=596>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=608>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=626>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=631>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=679>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=561>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=562>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=452>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=474>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=475>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=476>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=477>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=478>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=479>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=480>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=700>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=481>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=482>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=483>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=484>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=563>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=566>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=571>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=572>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=459>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=512>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=513>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=585>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=599>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=600>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=605>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=607>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=609>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=630>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=635>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=636>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=680>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=564>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=627>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=640>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=681>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=568>

[S365 Cyclin‐dependent kinase (CDK) family](#bph14752-sec-0206){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=485>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=492>

[S365 CDK4 subfamily](#bph14752-sec-0208){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=495>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=496>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=497>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=489>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=494>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=490>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=498>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=491>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=570>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=455>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=503>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=504>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=505>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=506>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=457>

[S366 GSK subfamily](#bph14752-sec-0210){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=288>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=514>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=515>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=518>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=519>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=520>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=612>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=620>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=682>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=683>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=451>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=473>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=557>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=559>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=560>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=565>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=567>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=577>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=578>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=580>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=584>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=586>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=588>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=589>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=590>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=591>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=592>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=593>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=594>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=595>

[S367 Polo‐like kinase (PLK) family](#bph14752-sec-0212){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=462>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=526>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=527>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=597>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=617>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=618>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=628>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=633>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=634>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=637>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=639>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=641>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=642>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=643>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=684>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=449>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=470>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=615>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=890>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=685>

[S367 STE7 family](#bph14752-sec-0213){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=621>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=467>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=542>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=543>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=544>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=544>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=546>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=547>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=548>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=549>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=622>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=550>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=551>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=552>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=624>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=686>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=936>

[S368 Abl family](#bph14752-sec-0214){ref-type="sec"}

[S368 Ack family](#bph14752-sec-0215){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=569>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=574>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=575>

[S369 Janus kinase (JakA) family](#bph14752-sec-0216){ref-type="sec"}

[S369 Src family](#bph14752-sec-0218){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=625>

[S370 Tec family](#bph14752-sec-0221){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=687>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=579>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=582>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=458>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=510>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=511>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=461>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=521>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=522>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=523>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=524>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=525>

[S371 RAF family](#bph14752-sec-0222){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=613>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=632>

[S372 Lanosterol biosynthesis pathway](#bph14752-sec-0224){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=928>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=993>

[S374 Nucleoside synthesis and metabolism](#bph14752-sec-0227){ref-type="sec"}

[S376 Paraoxonase (PON) family](#bph14752-sec-0231){ref-type="sec"}

[S377 Peptidases and proteinases](#bph14752-sec-0234){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=707>

[S377 A1: Pepsin](#bph14752-sec-0236){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=708>

[S377 A22: Presenilin](#bph14752-sec-0237){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=709>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=728>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=731>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=729>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=730>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=732>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=931>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=711>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=733>

[S378 C14: Caspase](#bph14752-sec-0239){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=711>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=735>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=712>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=736>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=713>

[S378 M1: Aminopeptidase N](#bph14752-sec-0242){ref-type="sec"}

[S379 M2: Angiotensin‐converting (ACE and ACE2)](#bph14752-sec-0244){ref-type="sec"}

[S379 M10: Matrix metallopeptidase](#bph14752-sec-0245){ref-type="sec"}

[S380 M12: Astacin/Adamalysin](#bph14752-sec-0248){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=740>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=742>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=714>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=743>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=715>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=744>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=716>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=745>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=717>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=746>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=718>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=747>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=860>

[S380 M28: Aminopeptidase Y](#bph14752-sec-0251){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=719>

[S381 M19: Membrane dipeptidase](#bph14752-sec-0253){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=720>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=750>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=721>

[S381 S1: Chymotrypsin](#bph14752-sec-0254){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=722>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=878>

[S382 T1: Proteasome](#bph14752-sec-0255){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=753>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=723>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=754>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=724>

[S382 S8: Subtilisin](#bph14752-sec-0257){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=725>

[S383 S9: Prolyl oligopeptidase](#bph14752-sec-0259){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=756>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=757>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=917>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=947>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=980>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=948>

[S383 Poly ADP‐ribose polymerases](#bph14752-sec-0260){ref-type="sec"}

[S384 Prolyl hydroxylases](#bph14752-sec-0263){ref-type="sec"}

[S384 Sphingosine 1‐phosphate turnover](#bph14752-sec-0266){ref-type="sec"}

[S385 Sphingosine kinase](#bph14752-sec-0268){ref-type="sec"}

[S386 Sphingosine 1‐phosphate phosphatase](#bph14752-sec-0272){ref-type="sec"}

[S387 Sphingosine 1‐phosphate lyase](#bph14752-sec-0275){ref-type="sec"}

[S387 Thyroid hormone turnover](#bph14752-sec-0278){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=988>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=840>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=922>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=912>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=899>

[S388 1.14.13.9 Kynurenine 3‐monooxygenase](#bph14752-sec-0282){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=877>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=843>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=846>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=844>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=978>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1003>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=979>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=908>

[S389 2.5.1.58 Protein farnesyltransferase](#bph14752-sec-0284){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=926>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=994>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=880>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=850>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=841>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=909>

[S390 3.5.1.‐ Histone deacetylases (HDACs)](#bph14752-sec-0287){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=925>

[S391 3.5.3.15 Peptidyl arginine deiminases (PADI)](#bph14752-sec-0290){ref-type="sec"}

[S391 3.6.5.2 Small monomeric GTPases](#bph14752-sec-0293){ref-type="sec"}

[S391 RAS subfamily](#bph14752-sec-0295){ref-type="sec"}

[S392 RAB subfamily](#bph14752-sec-0298){ref-type="sec"}

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=849>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=845>

-- <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=847>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=765> {#bph14752-sec-0005}
===========================================================================

Overview {#bph14752-sec-0006}
--------

Acetylcholine is familiar as a neurotransmitter in the central nervous system and in the periphery. In the somatic nervous system, it activates <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=76> at the skeletal neuromuscular junction. It is also employed in the autonomic nervous system, in both parasympathetic and sympathetic branches; in the former, at the smooth muscle neuromuscular junction, activating <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2>. In the latter, acetylcholine is involved as a neurotransmitter at the ganglion, activating nicotinic acetylcholine receptors. Acetylcholine is synthesised in neurones through the action of choline O‐acetyltransferase and metabolised after release through the extracellular action of acetylcholinesterase and cholinesterase. Choline is accumulated from the extracellular medium by selective transporters (see <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=143#show_object_914> and the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=233> family). Acetylcholine is accumulated in synaptic vesicles through the action of the vesicular acetylcholine transporter <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2480><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471>Common abbreviationChATAChEBChEHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1912](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1912), <http://www.uniprot.org/uniprot/P28329>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:108](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:108), <http://www.uniprot.org/uniprot/P22303>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:983](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:983), <http://www.uniprot.org/uniprot/P06276>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.6](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.6): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.7](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.7): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> + H^+^[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.7](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.7): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551> + H^+^Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8807> (pIC50 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/3351860?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6687> (p*K* ~i~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6693> (pIC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/12182861?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602> (pIC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6687> (p*K* ~i~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus>\]Sub/family‐selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598> (pIC~50~ 7.6--7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598> (pIC~50~ 7.6--7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus>\]Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6599> (pIC~50~ 7.7--8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/1738151?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8039548?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6600> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6601> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus>\]CommentsSplice variants of choline O‐acetyltransferase are suggested to be differentially distributed in the periphery and CNS (see \[<http://www.ncbi.nlm.nih.gov/pubmed/21382474?dopt=AbstractPlus>\]).----

Comments {#bph14752-sec-0007}
--------

A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos‐oxon, and nerve agents such as tabun, soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule \[<http://www.ncbi.nlm.nih.gov/pubmed/13785664?dopt=AbstractPlus>\].

Further reading on Acetylcholine turnover {#bph14752-sec-0008}
-----------------------------------------

Li Q *et al*. (2017) Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer\'s disease. *Eur J Med Chem* **132**: 294--309 <https://www.ncbi.nlm.nih.gov/pubmed/28371641?dopt=AbstractPlus>

Lockridge O. (2015) Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. *Pharmacol Ther* **148**: 34--46 <https://www.ncbi.nlm.nih.gov/pubmed/25448037?dopt=AbstractPlus>

Masson P *et al*. (2016) Slow‐binding inhibition of cholinesterases, pharmacological and toxicological relevance. *Arch Biochem Biophys* **593**: 60--8 <https://www.ncbi.nlm.nih.gov/pubmed/26874196?dopt=AbstractPlus>

Rotundo RL. (2017) Biogenesis, assembly and trafficking of acetylcholinesterase. *J Neurochem* **142 Suppl 2**: 52--58 <https://www.ncbi.nlm.nih.gov/pubmed/28326552?dopt=AbstractPlus>

Silman I *et al*. (2017) Recent developments in structural studies on acetylcholinesterase. *J Neurochem* **142 Suppl 2**: 19--25 <https://www.ncbi.nlm.nih.gov/pubmed/28503857?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=248> {#bph14752-sec-0009}
===========================================================================

Overview {#bph14752-sec-0010}
--------

A multifunctional, ubiquitous molecule, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> acts at cell‐surface G protein‐coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase. Ex‐tracellular adenosine is thought to be produced either by export or by metabolism, predominantly through ecto‐5'‐nucleotidase activity (also producing inorganic phosphate). It is inactivated either by extracellular metabolism *via* adenosine deaminase (also producing ammonia) or, following uptake by nucleoside transporters, *via* adenosine deaminase or adenosine kinase (requiring <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> as co‐substrate). Intracellular adenosine may be produced by cytosolic 5'‐nucleotidases or through S‐adenosylhomocysteine hydrolase (also producing <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5198>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1230><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1231><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1233>Systematic nomenclature----CD73--Common abbreviationADAADKNT5ESAHHHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:186](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:186), <http://www.uniprot.org/uniprot/P00813>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:257](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:257), <http://www.uniprot.org/uniprot/P55263>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8021](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8021), <http://www.uniprot.org/uniprot/P21589>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:343](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:343), <http://www.uniprot.org/uniprot/P23526>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.4.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.4.4): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554> + NH~3~[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.20](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.20)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.5](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.5)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.1.1)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5109> *\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5123>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5124>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5125> *\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5120>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5122>--Endogenous substrates------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5110>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4556>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844>Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8392> (p*K* ~i~ 12.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/3457563?dopt=AbstractPlus>\] -- HamsterSelective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4805> (pIC50 10.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179> (p*K* ~i~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5130> (pIC~50~ 10.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/11160637?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5131> (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11082453?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5092> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/1169962?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5115> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7470463?dopt=AbstractPlus>\]Comments--The enzyme exists in two isoforms derived from alternative splicing of a single gene product: a short isoform, ADK‐S, located in the cytoplasm is responsible for the regulation of intra‐ and extracellular levels of adenosine and hence adenosine receptor activation; a long isoform, ADK‐L, located in the nucleus contributes to the regulation of DNA methylation \[<http://www.ncbi.nlm.nih.gov/pubmed/23592612?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23863710?dopt=AbstractPlus>\].Pharmacological inhibition of CD73 is being investigated as a novel cancer immunotherapy strategy \[<http://www.ncbi.nlm.nih.gov/pubmed/21537079?dopt=AbstractPlus>\].--

Comments {#bph14752-sec-0011}
--------

An extracellular adenosine deaminase activity, termed ADA2 or adenosine deaminase growth factor (ADGF, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1839](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1839), <http://www.uniprot.org/uniprot/Q9NZK5>) has been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/24933472?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16245011?dopt=AbstractPlus>\], which is insensitive to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179> \[<http://www.ncbi.nlm.nih.gov/pubmed/20147294?dopt=AbstractPlus>\]. Other forms of adenosine deaminase act on ribonucleic acids and may be divided into two families: [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:228](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:228) (<http://www.uniprot.org/uniprot/Q9BUB4>) deaminates transfer RNA; [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:225](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:225) ([http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.4.37](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.4.37), also known as 136 kDa double‐stranded RNA‐binding protein, P136, K88DSRBP, Interferon‐inducible protein 4); [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:226](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:226) (EC 3.5.‐.‐, , also known as dsRNA adenosine deaminase) and[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:227](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:227) (EC 3.5.‐.‐, also known as dsRNA adenosine deaminase B2, RNA‐dependent adenosine deaminase 3) act on double‐stranded RNA. Particular polymorphisms of the ADA gene result in loss‐of‐function and severe combined immunodeficiency syndrome. Adenosine deaminase is able to complex with dipeptidyl peptidase IV ([http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.14.5](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.14.5), [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3009](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3009), also known as T‐cell activation antigen CD26, TP103, adenosine deaminase complexing protein 2) to form a cell‐surface activity \[<http://www.ncbi.nlm.nih.gov/pubmed/8101391?dopt=AbstractPlus>\].

Further reading on Adenosine turnover {#bph14752-sec-0012}
-------------------------------------

Boison D. (2016) Adenosinergic signaling in epilepsy. *Neuropharmacology* **104**: 131--9 <https://www.ncbi.nlm.nih.gov/pubmed/26341819?dopt=AbstractPlus>

Cortés A *et al*. (2015) Moonlighting adenosine deaminase: a target protein for drug development. *Med Res Rev* **35**: 85--125 <https://www.ncbi.nlm.nih.gov/pubmed/24933472?dopt=AbstractPlus>

Nishikura K. (2016) A‐to‐I editing of coding and non‐coding RNAs by ADARs. *Nat Rev Mol Cell Biol* **17**: 83--96 <https://www.ncbi.nlm.nih.gov/pubmed/26648264?dopt=AbstractPlus>

Sawynok J. (2016) Adenosine receptor targets for pain. *Neuroscience* **338**: 1--18 <https://www.ncbi.nlm.nih.gov/pubmed/26500181?dopt=AbstractPlus>

Xiao Y *et al*. (2015) Role of S‐adenosylhomocysteine in cardiovascular disease and its potential epi‐genetic mechanism. *Int. J. Biochem. Cell Biol*. **67**: 158--66 <https://www.ncbi.nlm.nih.gov/pubmed/26117455?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=249> {#bph14752-sec-0013}
===========================================================================

Overview {#bph14752-sec-0014}
--------

The amino acid hydroxylases (monooxygenases), EC.1.14.16.‐, are iron‐containing enzymes which utilise molecular oxygen and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276> as co‐substrate and co‐factor, respectively. In humans, as well as in other mammals, there are two distinct L‐Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous enzymes, TPH1 and TPH2.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8582](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8582), <http://www.uniprot.org/uniprot/P00439>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11782](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11782), <http://www.uniprot.org/uniprot/P07101>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12008](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12008), <http://www.uniprot.org/uniprot/P17752>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20692](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20692), <http://www.uniprot.org/uniprot/Q8IWU9>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.1): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> + O~2~ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.2](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791> + O~2~ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.4)Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276>, Fe^2+^----Endogenous activatorsProtein kinase A‐mediated phosphorylation (Rat) \[<http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus>\]Protein kinase A‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus>\]Protein kinase A‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus>\]Protein kinase A‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus>\]Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9490> \[<http://www.ncbi.nlm.nih.gov/pubmed/26206858?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5093> \[<http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5114>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6956><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5126> \[<http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5126> \[<http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613>CommentsPAH is an iron bound homodimer or ‐tetramer from the same structural family as tyrosine 3‐monooxygenase and the tryptophan hydroxylases. Deficiency or loss‐of‐function of PAH is associated with <http://omim.org/entry/612349>TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway \[<http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus>\].----

Further reading on Amino acid hydroxylases {#bph14752-sec-0015}
------------------------------------------

Bauer IE *et al*. (2015) Serotonergic gene variation in substance use pharmacotherapy: a systematic review. *Pharmacogenomics* **16**: 1307--14 <https://www.ncbi.nlm.nih.gov/pubmed/26265436?dopt=AbstractPlus>

Daubner SC *et al*. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. *Arch Biochem Biophys* **508**: 1--12 <https://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus>

Flydal MI *et al*. (2013) Phenylalanine hydroxylase: function, structure, and regulation. *IUBMB Life* **65**: 341--9 <https://www.ncbi.nlm.nih.gov/pubmed/23457044?dopt=AbstractPlus>

Roberts KM *et al*. (2013) Mechanisms of tryptophan and tyrosine hydroxylase. *IUBMB Life* **65**: 350--7 <https://www.ncbi.nlm.nih.gov/pubmed/23441081?dopt=AbstractPlus>

Tekin I *et al*. (2014) Complex molecular regulation of tyrosine hydroxylase. *J Neural Transm* **121**: 1451--81 <https://www.ncbi.nlm.nih.gov/pubmed/24866693?dopt=AbstractPlus>

Walen K *et al*. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. *Expert Opin Ther Targets* **21**: 167--180 <https://www.ncbi.nlm.nih.gov/pubmed/27973928?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=239> {#bph14752-sec-0016}
===========================================================================

Overview {#bph14752-sec-0017}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721> is a basic amino acid with a guanidino sidechain. As an amino acid, metabolism of L‐arginine to form <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725>, catalysed by arginase, forms the last step of the urea production cycle. L‐Ornithine may be utilised as a precursor of polyamines (see <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240>) or recycled via <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5324> to L‐arginine. L‐Arginine <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240#Decarboxylases> to form <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127>, although the prominence of this pathway in human tissues is uncertain. L‐Arginine may be used as a precursor for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5325> formation in the <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496> synthesis pathway under the influence of arginine:glycine amidinotransferase with L‐ornithine as a byproduct. Nitric oxide synthase uses L‐arginine to generate nitric oxide, with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722> also as a byproduct. L‐Arginine in proteins may be subject to post‐translational modification through methylation, catalysed by protein arginine methyltransferases. Subsequent proteolysis can liberate asymmetric <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229> (ADMA), which is an endogenous inhibitor of nitric oxide synthase activities. ADMA is hydrolysed by dimethylarginine dimethylhydrolase activities to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5177>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254> {#bph14752-sec-0018}
===========================================================================

Overview {#bph14752-sec-0019}
--------

Protein arginine *N*‐methyltransferases (PRMT, EC 2.1.1.‐) encompass histone arginine *N*‐methyltransferases (PRMT4, PRMT7, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.125](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.125)) and myelin basic protein *N*‐methyltransferases (PRMT7, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.126](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.126)). They are dimeric or tetrameric enzymes which use <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786> as a methyl donor, generating <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265> as a by‐product. They generate both mono‐methylated and di‐methylated products; these may be symmetric (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5271>) or asymmetric (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229>) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=250> {#bph14752-sec-0020}
===========================================================================

Overview {#bph14752-sec-0021}
--------

Arginase ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.3.1](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.3.1)) are manganese‐containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is associated more with the kidney.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=250>.

Comments {#bph14752-sec-0022}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5227>, an intermediate in NOS metabolism of L‐arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform‐selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5091> \[<http://www.ncbi.nlm.nih.gov/pubmed/10637120?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5264> \[<http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11258879?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5107> \[<http://www.ncbi.nlm.nih.gov/pubmed/10454520?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=251> {#bph14752-sec-0023}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1246>Common abbreviationAGATHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4175](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4175), <http://www.uniprot.org/uniprot/P50440>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.4.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.4.1)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=252> {#bph14752-sec-0024}
===========================================================================

Overview {#bph14752-sec-0025}
--------

Dimethylarginine dimethylaminohydrolases (DDAH, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.3.18](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.3.18)) are cytoplasmic enzymes which hydrolyse <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229> to form <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5177> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1247><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1248>Common abbreviationDDAH1DDAH2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2715](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2715), <http://www.uniprot.org/uniprot/O94760>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2716](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2716), <http://www.uniprot.org/uniprot/O95865>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.3.18](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.3.18)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.3.18](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.3.18)Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8830> (p*K* ~i~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19013076?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=253> {#bph14752-sec-0026}
===========================================================================

Overview {#bph14752-sec-0027}
--------

Nitric oxide synthases (NOS, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.14.13.39](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.14.13.39)) are a family of oxidoreductases that synthesize nitric oxide (NO.) via the NADPH and oxygen‐dependent consumption of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721> with the resultant by‐product, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722>. There are 3 NOS isoforms and they are related by their capacity to produce NO, highly conserved organization of functional domains and significant homology at the amino acid level. NOS isoforms are functionally distinguished by the cell type where they are expressed, intracellular targeting and transcriptional and post‐translation mechanisms regulating enzyme activity. The nomenclature suggested by **NC‐IUPHAR** of NOS I, II and III \[<http://www.ncbi.nlm.nih.gov/pubmed/9228663?dopt=AbstractPlus>\] has not gained wide acceptance, and the 3 isoforms are more commonly referred to as neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS) which reflect the location of expression (nNOS and eNOS) and inducible expression (iNOS). All are dimeric enzymes that shuttle electrons from NADPH, which binds to a C‐terminal reductase domain, through the flavins FAD and FMN to the oxygenase domain of the other monomer to enable the BH4‐dependent reduction of heme bound oxygen for insertion into the substrate, L‐arginine. Electron flow from reductase to oxygenase domain is controlled by calmodulin binding to canonical calmodulin binding motif located between these domains. eNOS and nNOS isoforms are activated at concentrations of calcium greater than 100 nM, while iNOS shows higher affinity for Ca^2+^/<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442), <http://www.uniprot.org/uniprot/P62158>) with great avidity and is essentially calcium‐independent and constitutively active. Efficient stimulus‐dependent coupling of nNOS and eNOS is achieved *via* subcellular targeting through respective N‐terminal PDZ and fatty acid acylation domains whereas iNOS is largely cytosolic and function is independent of intracellular location. nNOS is primarily expressed in the brain and neuronal tissue, iNOS in immune cells such as macrophages and eNOS in the endothelial layer of the vasculature although exceptions in other cells have been documented. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5213> and related modified arginine analogues are inhibitors of all three isoforms, with IC~50~ values in the micromolar range.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1249><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1251>Common abbreviationeNOSiNOSnNOSHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7876](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7876), <http://www.uniprot.org/uniprot/P29474>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7873](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7873), <http://www.uniprot.org/uniprot/P35228>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7872](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7872), <http://www.uniprot.org/uniprot/P29475>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.39)Endogenous Substrate<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509>Cofactorsoxygen, BH4, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184>, oxygen, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>, BH4<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349>, oxygen, BH4, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5102> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9030556?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5111> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/8937711?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5246> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/7523409?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5231> (pIC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7525961?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5135> \[<http://www.ncbi.nlm.nih.gov/pubmed/1378415?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5113> (pIC~50~ 6.1--6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7544863?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5127> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/7693279?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0028}
--------

The reductase domain of NOS catalyses the reduction of cytochrome c and other redox‐active dyes \[<http://www.ncbi.nlm.nih.gov/pubmed/9433128?dopt=AbstractPlus>\]. NADPH:O~2~ oxidoreductase catalyses the formation of superoxide anion/<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448> in the absence of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276>.

Further reading on Nitric oxide synthases {#bph14752-sec-0029}
-----------------------------------------

Garcia‐Ortiz A and Serrador JM (2018) Nitric Oxide Signaling in T Cell‐Mediated Immunity *Trends Mol Med* **24**: 412--427 <https://www.ncbi.nlm.nih.gov/pubmed/29519621>

Lundberg JO *et al*. (2015) Strategies to increase nitric oxide signalling in cardiovascular disease. *Nat Rev Drug Discov* **14**: 623--41 <https://www.ncbi.nlm.nih.gov/pubmed/26265312?dopt=AbstractPlus>

Oliveira‐Paula GH *et al*. (2016) Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms. *Gene* **575**: 584--99 <https://www.ncbi.nlm.nih.gov/pubmed/26428312?dopt=AbstractPlus>

Stuehr DJ and Haque MM (2019) Nitric oxide synthase enzymology in the 20 years after the Nobel Prize. *BrJPharmacol* **176**: 177--188 <https://www.ncbi.nlm.nih.gov/pubmed/30402946>

Wallace JL (2019) Nitric oxide in the gastrointestinal tract: opportunities for drug development. *Br J Pharmacol* **176**: 147--154 <https://www.ncbi.nlm.nih.gov/pubmed/30357812>

Further reading on L‐Arginine turnover {#bph14752-sec-0030}
--------------------------------------

Lai L *et al*. (2016) Modulating DDAH/NOS Pathway to Discover Vasoprotective Insulin Sensitizers. *J Diabetes Res* **2016**: 1982096 <https://www.ncbi.nlm.nih.gov/pubmed/26770984?dopt=AbstractPlus>

Moncada S *et al*. (1997) International Union of Pharmacology Nomenclature in Nitric Oxide Re‐search. *Pharmacol. Rev*. **49**: 137--42 <https://www.ncbi.nlm.nih.gov/pubmed/9228663?dopt=AbstractPlus>

Pekarova M *et al*. (2015) The crucial role of l‐arginine in macrophage activation: What you need to know about it. *Life Sci*. **137**: 44--8 <https://www.ncbi.nlm.nih.gov/pubmed/26188591?dopt=AbstractPlus>

Pudlo M *et al*. (2017) Arginase Inhibitors: A Rational Approach Over One Century. *Med Res Rev* **37**: 475--513 <https://www.ncbi.nlm.nih.gov/pubmed/27862081?dopt=AbstractPlus>

Sudar‐Milovanovic E *et al*. (2016) Benefits of L‐Arginine on Cardiovascular System. *Mini Rev Med Chem* **16**: 94--103 <https://www.ncbi.nlm.nih.gov/pubmed/26471966?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=842> {#bph14752-sec-0031}
===========================================================================

Overview {#bph14752-sec-0032}
--------

Carbonic anhydrases facilitate the interconversion of water and carbon dioxide with bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identified in man. The enzymes function in acid‐base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2749><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2747><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2748><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2598>Common abbreviationCA ICA VIICA XIICA XIIICA XIVHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1368](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1368), <http://www.uniprot.org/uniprot/P00915>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1381](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1381), <http://www.uniprot.org/uniprot/P43166>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1371](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1371), <http://www.uniprot.org/uniprot/O43570>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14914](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14914), <http://www.uniprot.org/uniprot/Q8N1Q1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1372](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1372), <http://www.uniprot.org/uniprot/Q9ULX7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147> (p*K* ~i~ 6.5)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6828> (p*K* ~i~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6792> (p*K* ~i~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/20605094?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6797> (p*K* ~i~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147> (p*K* ~i~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/19119014?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10149> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/26233435?dopt=AbstractPlus>\]----

Further reading on Carbonic anhydrases {#bph14752-sec-0033}
--------------------------------------

Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F and Sly WS. (2013) Structure, function and applications of carbonic anhydrase isozymes. *Bioorg Med Chem* **21**: 1570--70 <https://www.ncbi.nlm.nih.gov/pubmed/22607884>

Supuran CT (2017) Advances in structure‐based drug discovery of carbonic anhydrase inhibitors. *Expert Opin Drug Discov* **12**: 61--88 <https://www.ncbi.nlm.nih.gov/pubmed/27783541>

Supuran CT (2018) Carbonic anhydrase activators. *Future Med Chem* **10**: 561--573 <https://www.ncbi.nlm.nih.gov/pubmed/29478330>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240> {#bph14752-sec-0034}
===========================================================================

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=255> {#bph14752-sec-0035}
===========================================================================

Overview {#bph14752-sec-0036}
--------

The carboxylases allow the production of new carbon‐carbon bonds by introducing HCO~3~ ^‐^ or CO~2~ into target molecules. Two groups of carboxylase activities, some of which are bidirectional, can be defined on the basis of the cofactor requirement, making use of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787> (EC 6.4.1.‐) or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5286> (EC 4.1.1.‐).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1262><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1263><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1265><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1268>Common abbreviationPCACC1ACC2PCCA,PCCBGGCXHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8636](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8636), <http://www.uniprot.org/uniprot/P11498>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:84](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:84), <http://www.uniprot.org/uniprot/Q13085>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:85](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:85), <http://www.uniprot.org/uniprot/O00763>--[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4247](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4247), <http://www.uniprot.org/uniprot/P38435>Subunits------<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1267>, <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1266>--EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.3](http://www.genome.jp/dbget‐bin/www_bget?ec:6.4.1.3)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.90](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.90)Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5248>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713>glutamyl peptidesProductsP~i~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5236>P~i~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219>P~i~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5223>, P~i~carboxyglutamyl peptidesCofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5286>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041>Inhibitors--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6960>Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8884> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23981033?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/14612531?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8884> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23981033?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/14612531?dopt=AbstractPlus>\]----Comments--Citrate and other dicarboxylic acids are allosteric activators of acetyl‐CoA carboxylase.Citrate and other dicarboxylic acids are allosteric activators of acetyl‐CoA carboxylase.Propionyl‐CoA carboxylase is able to function in both forward and reverse activity modes, as a ligase (carboxylase) or lyase (decarboxylase), respectively.Loss‐of‐function mutations in γ‐glutamyl carboxylase are associated with <http://omim.org/entry/277450>.

Comments {#bph14752-sec-0037}
--------

Dicarboxylic acids including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478> are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase (decarboxylase) activity, respectively. Loss‐of‐function mutations in GGCX are associated with clotting disorders.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=256> {#bph14752-sec-0038}
===========================================================================

Overview {#bph14752-sec-0039}
--------

The decarboxylases generate CO~2~ and the indicated products from acidic substrates, requiring <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249> or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809> as a co‐factor.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1274>Common abbreviationGAD1GAD2HDCHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4092](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4092), <http://www.uniprot.org/uniprot/Q99259>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4093](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4093), <http://www.uniprot.org/uniprot/Q05329>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4855](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4855), <http://www.uniprot.org/uniprot/P19113>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> + H^+^ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> + H^+^ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.22](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.22)Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5134>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5189> \[<http://www.ncbi.nlm.nih.gov/pubmed/7452304?dopt=AbstractPlus>\]Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309> is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β‐alanine \[<http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus>\]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1270><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1275><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1276><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1277><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1269>Common abbreviationADCAADCMLYCDODCPSDCSAMDCHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29957](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29957), <http://www.uniprot.org/uniprot/Q96A70>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2719](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2719), <http://www.uniprot.org/uniprot/P20711>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7150](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7150), <http://www.uniprot.org/uniprot/O95822>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8109](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8109), <http://www.uniprot.org/uniprot/P11926>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8999](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8999), <http://www.uniprot.org/uniprot/Q9UG56>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:457](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:457), <http://www.uniprot.org/uniprot/P17707>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.19](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.19)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.28](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.28): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> + CO~2~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> + CO~2~ This enzyme also catalyses the following reaction:: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.9](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.9)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.17](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.65](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.65)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.50](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.50)Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3638><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127> \[<http://www.ncbi.nlm.nih.gov/pubmed/14738999?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5121>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5116>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5217>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150> \[<http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5159>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5139> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/1573631?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5176> (p*K* ~d~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12859253?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5268> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8340919?dopt=AbstractPlus>\]CommentsThe presence of a functional ADC activity in human tissues has been questioned \[<http://www.ncbi.nlm.nih.gov/pubmed/14763899?dopt=AbstractPlus>\].AADC is a homodimer.Inhibited by AMP‐activated protein kinase‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/10854420?dopt=AbstractPlus>\]The activity of ODC is regulated by the presence of an antizyme ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104904;r=19:2269520‐2273487;t=ENST00000322297](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104904;r=19:2269520‐2273487;t=ENST00000322297)) and an ODC antizyme inhibitor ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155096;r=8:103838585‐103906092](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155096;r=8:103838585‐103906092)).S‐allylglycine is also an inhibitor of SAMDC \[<http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus>\].<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267> is also an inhibitor of SAMDC \[<http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus>\].

Further reading on Carboxylases and decarboxylases {#bph14752-sec-0040}
--------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=766> {#bph14752-sec-0041}
===========================================================================

Overview {#bph14752-sec-0042}
--------

Catecholamines are defined by the presence of two adjacent hydroxyls on a benzene ring with a sidechain containing an amine. The predominant catacholamines in mammalian biology are the neurotransmitter/hormones <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> (norepinephrine) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> (epinephrine). These hormone/transmitters are synthesized by sequential metabolism from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> via <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>. Hydroxylation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791> generates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>, which is decarboxylated to form <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940>. Hydroxylation of the ethylamine sidechain generates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> (norepinephrine), which can be methylated to form <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> (epinephrine). In particular neuronal and adrenal chromaffin cells, the catecholamines <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> are accumulated into vesicles under the influence of the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193> (VMAT1/SLC18A1 and VMAT2/SLC18A2). After release into the synapse or the blood‐stream, catecholamines are accumulated through the action cell‐surface transporters, primarily the dopamine (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144#Monoamine_transporter_subfamily>) and norepinephrine transporter ([http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144\#Monoamine transporter subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144#Monoaminetransportersubfamily)). The primary routes of metabolism of these catecholamines are oxidation via monoamine oxidase activities of methylation via catechol O‐methyltransferase.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2527><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2486>Common abbreviation--TAT--DBHHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8582](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8582), <http://www.uniprot.org/uniprot/P00439>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11573](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11573), <http://www.uniprot.org/uniprot/P17735>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11782](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11782), <http://www.uniprot.org/uniprot/P07101>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2689](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2689), <http://www.uniprot.org/uniprot/P09172>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.1): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313> + O~2~ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.5](http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.5): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6629> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.2](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.16.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791> + O~2~ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.17.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.17.1): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> + O~2~ = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> + H~2~OEndogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>--Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>--Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276>, Fe^2+^<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4781>Endogenous activatorsProtein kinase A‐mediated phosphorylation (Rat) \[<http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus>\]--Protein kinase A‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5093> \[<http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5114>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6956><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6630> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9283721?dopt=AbstractPlus>\]CommentsPAH is an iron bound homodimer or ‐tetramer from the same structural family as tyrosine 3‐monooxygenase and the tryptophan hydroxylases. Deficiency or loss‐of‐function of PAH is associated with <http://omim.org/entry/612349>Tyrosine may also be metabolized in the liver by tyrosine transaminase to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6629>, which can be further metabolized to homogentisic acid. TAT is a homodimer, where loss‐of‐function mutations are associated with <http://omim.org/entry/276600>.TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway \[<http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus>\].DBH is a homotetramer. A protein structurally‐related to DBH (<http://www.genenames.org/data/hgnc_data.php?hgnc_id=21063>, <http://www.uniprot.org/uniprot/Q6UVY6>) has been described and for which a function has yet to be identified \[<http://www.ncbi.nlm.nih.gov/pubmed/9751809?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2496><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2472>Common abbreviationAADCPNMTCOMTHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2719](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2719), <http://www.uniprot.org/uniprot/P20711>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9160](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9160), <http://www.uniprot.org/uniprot/P11086>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2228](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2228), <http://www.uniprot.org/uniprot/P21964>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.28](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.28): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> + CO~2~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> + CO~2~ This enzyme also catalyses the following reaction:: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.28](http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.28): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.6](http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.6): S‐adenosyl‐L‐methionine + a catechol = S‐adenosyl‐L‐homocysteine + a guaiacol <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6643> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6642> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6645> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6644>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940>--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646> (soluble enzyme) (p*K* ~i~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646> (membrane‐bound enzyme) (p*K* ~i~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6647> (soluble enzyme) (p*K* ~i~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6647> (membrane‐bound enzyme) (p*K* ~i~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus>\]Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786>--Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6631> (p*K* ~i~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/6268095?dopt=AbstractPlus>\]COMT appears to exist in both membrane‐bound and soluble forms. COMT has also been described to methylate steroids, particularly hydroxyestradiolsSelective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5116>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5217>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150> \[<http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5159>----CommentsAADC is a homodimer.----

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2489><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490>Common abbreviationMAO‐AMAO‐BHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6833](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6833), <http://www.uniprot.org/uniprot/P21397>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6834](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6834), <http://www.uniprot.org/uniprot/P27338>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.3.4) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633> + NH~3~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633> + NH~3~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6635> + NH~3~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6632> + NH~3~ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6634> + NH~3~[http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.3.4)Cofactors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184> +Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6641> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11159700?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266> (Irreversible inhibition) (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6640> (p*K* ~i~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/2122653?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16137882?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6639> (p*K* ~i~ 5.7--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/15974574?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8291> (p*K* ~i~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15027868?dopt=AbstractPlus>\]Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7428> (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/21680183?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266> (Irreversible inhibition) (p*K* ~i~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6639> (p*K* ~i~ 4.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6637> \[<http://www.ncbi.nlm.nih.gov/pubmed/10333983?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6636>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6638> \[<http://www.ncbi.nlm.nih.gov/pubmed/9564636?dopt=AbstractPlus>\]--

Further reading on Catecholamine turnover {#bph14752-sec-0043}
-----------------------------------------

Bastos P *et al*. (2017) Catechol‐O‐Methyltransferase (COMT): An Update on Its Role in Cancer, Neuro‐and Cardiovascular Diseases. *Rev Biochem Pharmacol* **173**: 1--39 <https://www.ncbi.nlm.nih.gov/pubmed/28456872>

Deshwal S *etal*. (2017) Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease. *Curr Opin Pharmacol* **33**: 64--69 <https://www.ncbi.nlm.nih.gov/pubmed/28528298?dopt=AbstractPlus>

Fisar Z. (2016) Drugs related to monoamine oxidase activity. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **69**: 112--24 <https://www.ncbi.nlm.nih.gov/pubmed/26944656?dopt=AbstractPlus>

Ramsay RR. (2016) Molecular aspects of monoamine oxidase B. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **69**: 81--9 <https://www.ncbi.nlm.nih.gov/pubmed/26891670?dopt=AbstractPlus>

Walen K *et al*. (2017) Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. *Expert Opin. Ther. Targets* **21**: 167--180 <https://www.ncbi.nlm.nih.gov/pubmed/27973928?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=767> {#bph14752-sec-0044}
===========================================================================

Overview {#bph14752-sec-0045}
--------

Ceramides are a family of sphingophospholipids synthesized in the endoplasmic reticulum, which mediate cell stress responses, including apoptosis, autophagy and senescence, Serine palmitoyltransferase generates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654>, which is reduced to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> (dihydrosphingosine). N‐Acylation allows the formation of dihydroceramides, which are subsequently reduced to form ceramides. Once synthesized, ceramides are trafficked from the ER to the Golgi bound to the ceramide transfer protein, CERT ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2205](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2205), <http://www.uniprot.org/uniprot/Q9Y5P4>). Ceramide can be metabolized via multiple routes, ensuring tight regulation of its cellular levels. Addition of phosphocholine generates sphingomyelin while carbohydrate is added to form glucosyl‐ or galactosylceramides.

Ceramidase re‐forms sphingosine or sphinganine from ceramide or dihydroceramide. Phosphorylation of ceramide generates ceramide phosphate. The determination of accurate kinetic parameters for many of the enzymes in the sphingolipid metabolic pathway is complicated by the lipophilic nature of the substrates.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=788> {#bph14752-sec-0046}
===========================================================================

Overview {#bph14752-sec-0047}
--------

The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb were most active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA \[<http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus>\]. Complexes involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with C16, C18 and C20 acylCoAs \[<http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2510><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2511><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2512><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2513>Common abbreviationSPT1SPT2SPT3SPTSSASPTSSBHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11277](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11277), <http://www.uniprot.org/uniprot/O15269>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11278](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11278), <http://www.uniprot.org/uniprot/O15270>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16253](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16253), <http://www.uniprot.org/uniprot/Q9NUV7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20361](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20361), <http://www.uniprot.org/uniprot/Q969W0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24045](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24045), <http://www.uniprot.org/uniprot/Q8NFR3>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765> ‐*\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654>+ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765> ‐*\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.50): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765> ‐*\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654>+ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> + CO~2~----Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249>----Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664> (p*K* ~i~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664> \[<http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664> \[<http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus>\]----

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=789> {#bph14752-sec-0048}
===========================================================================

Overview {#bph14752-sec-0049}
--------

This family of enzymes, also known as sphingosine *N*‐acyltransferase, is located in the ER facing the cytosol with an as‐yet undefined topology and stoichiometry. Ceramide synthase *in vitro* is sensitive to inhibition by the fungal derived toxin, fumonisin B1.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2474><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2475><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2476><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2477><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2478><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2479>Common abbreviationCERS1CERS2CERS3CERS4CERS5CERS6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14253](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14253), <http://www.uniprot.org/uniprot/P27544>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14076](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14076), <http://www.uniprot.org/uniprot/Q96G23>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23752](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23752), <http://www.uniprot.org/uniprot/Q8IU89>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23747](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23747), <http://www.uniprot.org/uniprot/Q9HA82>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23749](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23749), <http://www.uniprot.org/uniprot/Q8N5B7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23826](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23826), <http://www.uniprot.org/uniprot/Q6ZMG9>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24): acylCoA+ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> ‐*\>* dihydroceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + acylCoA ‐*\>* ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24): acylCoA + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> ‐*\>* dihydroceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + acylCoA ‐*\>* ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24): acylCoA + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> ‐*\>* dihydroceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + acylCoA ‐*\>* ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24): acylCoA + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> ‐*\>* dihydroceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + acylCoA ‐*\>* ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24): acylCoA + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> ‐*\>* dihydroceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + acylCoA ‐*\>* ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.24): acylCoA + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453> ‐*\>* dihydroceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + acylCoA ‐*\>* ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>SubstratesC18‐CoA \[<http://www.ncbi.nlm.nih.gov/pubmed/12105227?dopt=AbstractPlus>\]C24‐ and C26‐CoA \[<http://www.ncbi.nlm.nih.gov/pubmed/18165233?dopt=AbstractPlus>\]C26‐CoA and longer \[<http://www.ncbi.nlm.nih.gov/pubmed/14511335?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18308723?dopt=AbstractPlus>\]C18‐, C20‐ and C22‐CoA \[<http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus>\]C16‐CoA \[<http://www.ncbi.nlm.nih.gov/pubmed/16100120?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus>\]C14‐ and C16‐CoA \[<http://www.ncbi.nlm.nih.gov/pubmed/15823095?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=790> {#bph14752-sec-0050}
===========================================================================

Overview {#bph14752-sec-0051}
--------

DEGS1 and DEGS2 are 4TM proteins.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2484><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2485>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13709](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13709), <http://www.uniprot.org/uniprot/O15121>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20113](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20113), <http://www.uniprot.org/uniprot/Q6QHC5>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐)Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041> (p*K* ~i~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/24875537?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8879> (pIC~50~ 4.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22537678?dopt=AbstractPlus>\]--CommentsMyristoylation of DEGS1 enhances its activity and targets it to the mitochondria \[<http://www.ncbi.nlm.nih.gov/pubmed/19647031?dopt=AbstractPlus>\].--

Comments {#bph14752-sec-0052}
--------

DEGS1 activity is inhibited by a number of natural products, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7000> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424> \[<http://www.ncbi.nlm.nih.gov/pubmed/22200621?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=774> {#bph14752-sec-0053}
===========================================================================

Overview {#bph14752-sec-0054}
--------

Following translocation from the ER to the Golgi under the influence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of phosphocholine from the phospholipid phosphatidylcholine. Sphingomyelin synthase‐related protein 1 is structurally related but lacks sphingomyelin synthase activity.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2520><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2521><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2525>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29799](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29799), <http://www.uniprot.org/uniprot/Q86VZ5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28395](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28395), <http://www.uniprot.org/uniprot/Q8NHU3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26320](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26320), <http://www.uniprot.org/uniprot/Q96LT4>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.27](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.27): ceramide + phosphatidylcholine ‐*\>* sphingomyelin + diacylglycerol[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.27](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.27): ceramide + phosphatidylcholine ‐*\>* sphingomyelin + diacylglycerol[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.8.‐): ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796> ‐*\>* ceramide phosphoethanolamineInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8835> (pIC~50~ 5.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/26314925?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8834> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24374347?dopt=AbstractPlus>\]--Comments--Palmitoylation of sphingomyelin synthase 2 may allow targeting to the plasma membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/19233134?dopt=AbstractPlus>\].--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=773> {#bph14752-sec-0055}
===========================================================================

Overview {#bph14752-sec-0056}
--------

Also known as sphingomyelinase.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2514><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2515><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2516><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2517><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2518><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2519>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11120](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11120), <http://www.uniprot.org/uniprot/P17405>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11121](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11121), <http://www.uniprot.org/uniprot/O60906>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14240](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14240), <http://www.uniprot.org/uniprot/Q9NY59>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:32949](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:32949), <http://www.uniprot.org/uniprot/Q9NXE4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17389](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17389), <http://www.uniprot.org/uniprot/Q92484>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21416](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21416), <http://www.uniprot.org/uniprot/Q92485>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12): sphingomyelin ‐*\>* ceramide + phosphocholine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12): sphingomyelin ‐*\>* ceramide + phosphocholine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12): sphingomyelin ‐*\>* ceramide + phosphocholine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.12): sphingomyelin ‐*\>* ceramide + phosphocholine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.‐): sphingomyelin ‐*\>* ceramide + phosphocholine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.‐): sphingomyelin ‐*\>* ceramide + phosphocholineInhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8847> (p*K* ~i~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/12482429?dopt=AbstractPlus>\] -- Bovine--------

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=772> {#bph14752-sec-0057}
===========================================================================

Overview {#bph14752-sec-0058}
--------

Protein FAN \[<http://www.ncbi.nlm.nih.gov/pubmed/8808629?dopt=AbstractPlus>\] and polycomb protein EED \[<http://www.ncbi.nlm.nih.gov/pubmed/20080539?dopt=AbstractPlus>\] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2487><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2495>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3188](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3188), <http://www.uniprot.org/uniprot/O75530>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8017](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8017), <http://www.uniprot.org/uniprot/Q92636>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9525> (Binding) (p*K* ~i~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/28135237?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=775> {#bph14752-sec-0059}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2528>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12524](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12524), <http://www.uniprot.org/uniprot/Q16739>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.1.80](http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.1.80): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783> + ceramide = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749> + glucosylceramideInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4841> (p*K* ~i~ 5.1) \[[68](#bph14752-bib-0068){ref-type="ref"}\]CommentsGlycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=769> {#bph14752-sec-0060}
===========================================================================

Overview {#bph14752-sec-0061}
--------

The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2491>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:735](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:735), <http://www.uniprot.org/uniprot/Q13510>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23): ceramide ‐*\>* <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + a fatty acidCommentsThis lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product \[<http://www.ncbi.nlm.nih.gov/pubmed/8955159?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=770> {#bph14752-sec-0062}
===========================================================================

Overview {#bph14752-sec-0063}
--------

The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2492><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2493>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18860](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18860), <http://www.uniprot.org/uniprot/Q9NR71>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23456](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23456), <http://www.uniprot.org/uniprot/P0C7U1>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23): ceramide ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + a fatty acid--CommentsThe enzyme is associated with the plasma membrane \[<http://www.ncbi.nlm.nih.gov/pubmed/12499379?dopt=AbstractPlus>\].--

Comments {#bph14752-sec-0064}
--------

ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=768> {#bph14752-sec-0065}
===========================================================================

Overview {#bph14752-sec-0066}
--------

The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2468><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2469><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2470>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18356](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18356), <http://www.uniprot.org/uniprot/Q8TDN7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23675](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23675), <http://www.uniprot.org/uniprot/Q5QJU3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16066](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16066), <http://www.uniprot.org/uniprot/Q9NUN7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23): ceramide ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + a fatty acid[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.23): ceramide ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + a fatty acid[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.)‐CommentsACER1 is associated with the ER \[<http://www.ncbi.nlm.nih.gov/pubmed/17713573?dopt=AbstractPlus>\].ACER2 is associated with the Golgi apparatus \[<http://www.ncbi.nlm.nih.gov/pubmed/16940153?dopt=AbstractPlus>\].ACER3 is associated with the ER and Golgi apparatus \[<http://www.ncbi.nlm.nih.gov/pubmed/11356846?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=771> {#bph14752-sec-0067}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=771>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19256](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19256), <http://www.uniprot.org/uniprot/Q8TCT0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.138](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.138): ceramide + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> ‐\> ceramide 1‐phosphate + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6668> (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18612076?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0068}
--------

A ceramide kinase‐like protein has been identified in the human genome ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21699](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21699), <http://www.uniprot.org/uniprot/Q49MI3>).

Further reading on Ceramide turnover {#bph14752-sec-0069}
------------------------------------
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Hernández‐Corbacho MJ et al. (2017) Sphingolipids in mitochondria. *Biochim Biophys Acta* **1862**: 56‐68 <https://www.ncbi.nlm.nih.gov/pubmed/27697478?dopt=AbstractPlus>

Ilan Y. (2016) Compounds of the sphingomyelin‐ceramide‐glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. *Am. J. Physiol. Gastrointest. Liver Physiol*. **310**: G1102‐17 <https://www.ncbi.nlm.nih.gov/pubmed/27173510?dopt=AbstractPlus>
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Kihara A. (2016) Synthesis and degradation pathways, functions, and pathology of ceramides and epidermal acylceramides. *Prog. Lipid Res*. **63**: 50‐69 <https://www.ncbi.nlm.nih.gov/pubmed/27107674?dopt=AbstractPlus>

Ogretmen B (2018) Sphingolipid metabolism in cancer signalling and therapy. *Nat Rev Cancer* **18**: 33‐50 <https://www.ncbi.nlm.nih.gov/pubmed/29147025>

Parashuraman S and D'Angelo. (2019) Visualizing sphingolipid biosynthesis in cells. *Chem Phys Lipids* **218**: 103‐111 <https://www.ncbi.nlm.nih.gov/pubmed/30476485>

Rodriguez‐Cuenca S et al. (2017) Sphingolipids and glycerophospholipids ‐ The "ying and yang" of lipotoxicity in metabolic diseases. *Prog. Lipid Res*. **66**: 14‐29 <https://www.ncbi.nlm.nih.gov/pubmed/28104532?dopt=AbstractPlus>

Snider et al. (2019) Approaches for probing and evaluating mammalian sphingolipid metabolism. *Anal Biochem* **575**: 70‐86 <https://www.ncbi.nlm.nih.gov/pubmed/30917945>

Vogt D et al. (2017) Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism. *Med Res Rev* **37**: 3‐51 <https://www.ncbi.nlm.nih.gov/pubmed/27480072?dopt=AbstractPlus>

Wegner MS et al. (2016) The enigma of ceramide synthase regulation in mammalian cells. *Prog. Lipid Res*. **63**: 93‐119 <https://www.ncbi.nlm.nih.gov/pubmed/27180613?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=865> {#bph14752-sec-0070}
===========================================================================

Overview {#bph14752-sec-0071}
--------

Chromatin modifying enzymes, and other chromatin‐modifying proteins, fall into three broad categories: **writers**, **readers** and **erasers**. The function of these proteins is to dynamically maintain cell identity and regulate processes such as differentiation, development, proliferation and genome integrity *via* recognition of specific 'marks' (covalent post‐translational modifications) on histone proteins and DNA \[<http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus>\]. In normal cells, tissues and organs, precise co‐ordination of these proteins ensures expression of only those genes required to specify phenotype or which are required at specific times, for specific functions. Chromatin modifications allow DNA modifications not coded by the DNA sequence to be passed on through the genome and underlies heritable phenomena such as X chromosome inactivation, aging, heterochromatin formation, reprogramming, and gene silencing (epigenetic control).

To date at least eight distinct types of modifications are found on histones. These include small covalent modifications such as acetylation, methylation, and phosphorylation, the attachment of larger modifiers such as ubiquitination or sumoylation, and ADP ribosylation, proline isomerization and deimination. Chromatin modifications and the functions they regulate in cells are reviewed by Kouzarides (2007) \[<http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus>\].

**Writer** proteins include the histone methyltransferases, histone acetyltransferases, some kinases and ubiquitin ligases.

**Readers** include proteins which contain methyl‐lysinerecognition motifs such as bromodomains, chromodomains, tudor domains, PHD zinc fingers, PWWP domains and MBT domains.

**Erasers** include the histone demethylases and histone deacetylases (HDACs and sirtuins).

Dysregulated epigenetic control can be associated with human diseases such as cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/18337604?dopt=AbstractPlus>\], where awide variety of cellular and protein abberations are known to perturb chromatin structure, gene transcription and ultimately cellular pathways \[<http://www.ncbi.nlm.nih.gov/pubmed/21941284?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24104525?dopt=AbstractPlus>\]. Due to the reversible nature of epigenetic modifications, chromatin regulators are very tractable targets for drug discovery and the development of novel therapeutics. Indeed, small molecule inhibitors of writers (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6796> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6805> target the DNA methyltransferases DNMT1 and DNMT3 for the treatment of myelodysplastic syndromes \[<http://www.ncbi.nlm.nih.gov/pubmed/21220589?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24523604?dopt=AbstractPlus>\]) and erasers (*e.g*. the HDAC inhibitors <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496> for the treatment of T‐cell lymphomas \[<http://www.ncbi.nlm.nih.gov/pubmed/21493798?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22124371?dopt=AbstractPlus>\]) are already being used in the clinic. The search for the next generation of compounds with improved specificity against chromatin‐associated proteins is an area of intense basic and clinical research \[<http://www.ncbi.nlm.nih.gov/pubmed/25974248?dopt=AbstractPlus>\]. Current progress in this field is reviewed by Simó‐Riudalbas and Esteller (2015) \[<http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254> {#bph14752-sec-0072}
===========================================================================

Overview {#bph14752-sec-0073}
--------

Protein arginine N‐methyltransferases (PRMT, EC 2.1.1.‐) encompass histone arginine N‐methyltransferases (PRMT4, PRMT7, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.125](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.125)) and myelin basic protein *N*‐methyltransferases (PRMT7, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.126](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.1.1.126)). They are dimeric or tetrameric enzymes which use <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786> as a methyl donor, generating <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265> as a by‐product. They generate both mono‐methylated and dimethylated products; these may be symmetric (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5271>) or asym metric (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229>) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=848> {#bph14752-sec-0074}
===========================================================================

Overview {#bph14752-sec-0075}
--------

Histone deacetylases act as erasers of epigenetic acetylation marks on lysine residues in histones. Removal of the acetyl groups facilitates tighter packing of chromatin (heterochromatin formation) leading to transcriptional repression.

The histone deacetylase family has been classified in to five subfamilies based on phylogenetic comparison with yeast homologues:

Class I contains HDACs 1, 2, 3 and 8

Class IIa contains HDACs 4, 5, 7 and 9

Class IIb contains HDACs 6 and 10

Class III contains the sirtuins (SIRT1‐7)

Class IV contains only HDAC11.

Classes I, II and IV use Zn^+^ as a co‐factor, whereas catalysis by Class III enzymes requires NAD^+^ as a co‐factor, and members of this subfamily have ADP‐ribosylase activity in addition to protein deacetylase function \[<http://www.ncbi.nlm.nih.gov/pubmed/20132909?dopt=AbstractPlus>\].

HDACs have more general protein deacetylase activity, being able to deacetylate lysine residues in non‐histone proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/19608861?dopt=AbstractPlus>\] such as microtubules \[<http://www.ncbi.nlm.nih.gov/pubmed/12024216?dopt=AbstractPlus>\], the hsp90 chaperone \[<http://www.ncbi.nlm.nih.gov/pubmed/15916966?dopt=AbstractPlus>\] and the tumour suppressor p53 \[<http://www.ncbi.nlm.nih.gov/pubmed/11099047?dopt=AbstractPlus>\].

Dysregulated HDACactivity has been identified in cancer cells and tumour tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/11704848?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19383284?dopt=AbstractPlus>\], making HDACs attractive molecular targets in the search for novel mechanisms to treat cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/24382387?dopt=AbstractPlus>\]. Several small molecule HDAC inhibitors are already approved for clinical use: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7009> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8305>. HDACs and HDAC inhibitors currently in development as potential anti‐cancer therapeutics are reviewed by Simó‐Riudalbas and Esteller (2015) \[<http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14064](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14064), <http://www.uniprot.org/uniprot/Q9UBN7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.98](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.98)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852> (p*K* ~i~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus>\], romidepsin (p*K* ~i~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/22262760?dopt=AbstractPlus>\]

Further reading on 3.5.1.‐ Histone deacetylases (HDACs) {#bph14752-sec-0076}
-------------------------------------------------------
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Further reading on Chromatin modifying enzymes {#bph14752-sec-0077}
----------------------------------------------

Angus SP *et al*. (2018) Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer. *Annu Rev Pharmacol Toxicol* **58**: 209‐229 <https://www.ncbi.nlm.nih.gov/pubmed/28934561?dopt=AbstractPlus>

Bennett RL *et al*. (2018) Targeting Epigenetics in Cancer. *Annu Rev Pharmacol Toxicol* **58**: 187‐207 <https://www.ncbi.nlm.nih.gov/pubmed/28992434?dopt=AbstractPlus>

Lauschke VM *et al*. (2018) Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. *Annu Rev Pharmacol Toxicol* **58**: 161‐185 <https://www.ncbi.nlm.nih.gov/pubmed/29029592?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=241> {#bph14752-sec-0078}
===========================================================================

Overview {#bph14752-sec-0079}
--------

Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides are mediated through activation of protein kinases (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284>‐ and <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=287>‐dependent protein kinases), ion channels (<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71>, and <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71>) and guanine nucleotide exchange factors (GEFs, <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=259>).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=257> {#bph14752-sec-0080}
===========================================================================

Overview {#bph14752-sec-0081}
--------

Adenylyl cyclase, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=4.6.1.1](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=4.6.1.1), converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> and pyrophosphate. Mammalian membranedelimited adenylyl cyclases (**nomenclature as approved by the [NC‐IUPHAR]{.ul} Subcommittee on Adenylyl cyclases** \[<http://www.ncbi.nlm.nih.gov/pubmed/28255005?dopt=AbstractPlus>\]) are typically made up of two clusters of six TM domains separating two intracellular, overlapping catalytic domains that are the target for the nonselective activators Gα~s~ (the stimulatory G protein α subunit) and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5190> (except AC9, \[<http://www.ncbi.nlm.nih.gov/pubmed/8662814?dopt=AbstractPlus>\]). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> and its derivatives (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5108>), acting through the P‐site,are inhibitors of adenylyl cyclase activity \[<http://www.ncbi.nlm.nih.gov/pubmed/11087399?dopt=AbstractPlus>\]. Four families of membranous adenylyl cyclase are distinguishable: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449), <http://www.uniprot.org/uniprot/P62158>)‐stimulated (AC1, AC3 and AC8), Ca^2+^‐ and Gβγ‐inhibitable (AC5, AC6 and AC9), Gβγ‐stimulated and Ca^2+^‐insensitive (AC2, AC4 and AC7), and forskolin‐insensitive (AC9) forms. A soluble adenylyl cyclase (AC10) lacks membrane spanning regions and is insensitive to G proteins.It functions as a cytoplasmic bicarbonate (pH‐insensitive) sensor \[<http://www.ncbi.nlm.nih.gov/pubmed/10915626?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1278><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1279><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1280><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1281><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1282>Common abbreviationAC1AC2AC3AC4AC5HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:232), <http://www.uniprot.org/uniprot/Q08828>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:233](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:233), <http://www.uniprot.org/uniprot/Q08462>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:234](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:234), <http://www.uniprot.org/uniprot/O60266>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:235](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:235), <http://www.uniprot.org/uniprot/Q8NFM4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:236](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:236), <http://www.uniprot.org/uniprot/O95622>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445), <http://www.uniprot.org/uniprot/P62158>), PKC‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/2022671?dopt=AbstractPlus>\]Gβγ, PKC‐evoked phosphorylation, Raf‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/8389756?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8390980?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445), <http://www.uniprot.org/uniprot/P62158>), PKC‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/1633161?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus>\]Gβγ \[<http://www.ncbi.nlm.nih.gov/pubmed/1946437?dopt=AbstractPlus>\]PKC‐evoked phophorylation, Gβγ, Raf‐evoked phophorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8206971?dopt=AbstractPlus>\]Activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8809> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/8709105?dopt=AbstractPlus>\] -- Bovine<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10214> \[<http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10215> \[<http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus>\]Endogenous inhibitorsGα~i~, Gα~o~, G~bg~ \[<http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2808>, Gβγ, CaM kinase II‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/16275644?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11234015?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7665559?dopt=AbstractPlus>\]PKC‐evoked phophorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/8900209?dopt=AbstractPlus>\]Gα~i~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707>, PKA‐evoked phosphorylation, Gβγ, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509> \[<http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10781930?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1618857?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7759492?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus>\]Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=944> \[<http://www.ncbi.nlm.nih.gov/pubmed/24008337?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5233> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10092> (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/28223412?dopt=AbstractPlus>\]--------Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1283><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1284><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1285><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1286><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3068>Common abbreviationAC6AC7AC8AC9AC10HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:237](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:237), <http://www.uniprot.org/uniprot/O43306>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:238](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:238), <http://www.uniprot.org/uniprot/P51828>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:239](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:239), <http://www.uniprot.org/uniprot/P40145>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:240](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:240), <http://www.uniprot.org/uniprot/O60503>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21285](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21285), <http://www.uniprot.org/uniprot/Q96PN6>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.6.1.1)--Endogenous activatorsGβγ, Raf‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/15385642?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17110384?dopt=AbstractPlus>\]Gβγ, PKC‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/15581358?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7961850?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445), <http://www.uniprot.org/uniprot/P62158>) \[<http://www.ncbi.nlm.nih.gov/pubmed/8163524?dopt=AbstractPlus>\]--Bicarbonate, Ca^2+^ \[<http://www.ncbi.nlm.nih.gov/pubmed/10915626?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12609998?dopt=AbstractPlus>\]Endogenous inhibitorsGα~i~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707>, PKA‐evoked phosphorylation, PKC‐evoked phosphorylation, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509> \[<http://www.ncbi.nlm.nih.gov/pubmed/9391159?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10781930?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10462552?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1379717?dopt=AbstractPlus>\]--PKA‐evoked phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/22976297?dopt=AbstractPlus>\]Ca^2+^/calcineurin \[<http://www.ncbi.nlm.nih.gov/pubmed/10987815?dopt=AbstractPlus>\]--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5233> (pIC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus>\]------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10216> (pIC~50~ 5--5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16054031?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10023> (pIC~50~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/27547922?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0082}
--------

Many of the activators and inhibitors listed are only somewhat selective or have not been tested against all AC isoforms \[<http://www.ncbi.nlm.nih.gov/pubmed/24006339?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24008337?dopt=AbstractPlus>\]. AC3 shows only modest *in vitro* activation by Ca^2+^/CaM.

Further reading on Adenylyl cyclases (ACs) {#bph14752-sec-0083}
------------------------------------------

Dessauer CW *et al*. (2017) International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases. *Pharmacol. Rev*. **69**: 93‐139 <https://www.ncbi.nlm.nih.gov/pubmed/28255005?dopt=AbstractPlus>

Halls ML et al. (2017) Adenylyl cyclase signalling complexes ‐ Pharmacological challenges and opportunities. *Pharmacol. Ther*. **172**: 171‐180 <https://www.ncbi.nlm.nih.gov/pubmed/28132906?dopt=AbstractPlus>

Wiggins SV *et al*. (2018) Pharmacological modulation of the CO~2~/HCO^‐^ ~3~/pH‐, calcium‐, and ATP‐sensing soluble adenylyl cyclase. *Pharmacol Ther* **190**: 173‐186 <https://www.ncbi.nlm.nih.gov/pubmed/29807057>

Wu L *et al*. (2016) Adenylate cyclase 3: a new target for anti‐obesity drug development. *Obes Rev* **17**: 907‐14 <https://www.ncbi.nlm.nih.gov/pubmed/27256589?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=259> {#bph14752-sec-0084}
===========================================================================

Overview {#bph14752-sec-0085}
--------

Epacs are members of a family of guanine nucleotide exchange factors (<http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000000899>), which also includes [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16862](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16862) (GFR, KIAA0277, MR‐GEF, <http://www.uniprot.org/uniprot/Q92565>) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17428](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17428) (Link‐GEFII, <http://www.uniprot.org/uniprot/Q9UHV5>). They are activated endogenously by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> and with some pharmacological selectivity by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5172> \[<http://www.ncbi.nlm.nih.gov/pubmed/12402047?dopt=AbstractPlus>\]. Once activated, Epacs induce an enhanced activity of the monomeric G proteins, Rap1 and Rap2 by facilitating binding of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742> in place of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2410>, leading to activation of <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244> \[<http://www.ncbi.nlm.nih.gov/pubmed/11715024?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1292><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1293>Common abbreviationEpac1Epac2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16629](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16629), <http://www.uniprot.org/uniprot/O95398>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16626](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16626), <http://www.uniprot.org/uniprot/Q8WZA2>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7917> (pIC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/23066090?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6556> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/23286832?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7917> (pIC~50~ 4.4--5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23066090?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24256330?dopt=AbstractPlus>\]

Further reading on Exchange protein activated by cyclic AMP (EPACs) {#bph14752-sec-0086}
-------------------------------------------------------------------

Fujita T *et al*. (2017) The role of Epac in the heart. *Cell. Mol. Life Sci*. **74**: 591‐606 <https://www.ncbi.nlm.nih.gov/pubmed/27549789?dopt=AbstractPlus>

Robichaux WG and Cheng X. (2018) Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development. *Physiol Rev* **98**: 919‐1053 <https://www.ncbi.nlm.nih.gov/pubmed/29537337>

Wang P *et al*. (2017) Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets. *Bioorg. Med. Chem. Lett*. **27**: 1633‐1639 <https://www.ncbi.nlm.nih.gov/pubmed/28283242?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260> {#bph14752-sec-0087}
===========================================================================

Overview {#bph14752-sec-0088}
--------

3',5'‐Cyclic nucleotide phosphodiesterases (PDEs, 3',5'‐cyclic‐nucleotide 5'‐nucleotidohydrolase), [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.4.17](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.4.17), catalyse the hydrolysis of a 3',5'‐cyclic nucleotide (usually <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>). <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=388> is a nonselective inhibitor with an IC50 value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2',3'‐cyclic nucleotide 3'‐phosphodiesterase ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.4.37](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.4.37) CNPase) activity is associated with myelin formation in the development of the CNS.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1294><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1295><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1296>Common abbreviationPDE1APDE1BPDE1CHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8774](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8774), <http://www.uniprot.org/uniprot/P54750>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8775](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8775), <http://www.uniprot.org/uniprot/Q01064>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8776](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8776), <http://www.uniprot.org/uniprot/Q14123>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449), <http://www.uniprot.org/uniprot/P62158>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449), <http://www.uniprot.org/uniprot/P62158>)<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449), <http://www.uniprot.org/uniprot/P62158>)Endogenous inhibitors------Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9151> (pIC~50~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19303290?dopt=AbstractPlus>\]----Sub/family‐selective inhibitors------Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5285> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus>\], vinpocetine (pIC~50~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus>\]Comments------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1297><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1298><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1299>Common abbreviationPDE2APDE3APDE3BHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8777](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8777), <http://www.uniprot.org/uniprot/O00408>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8778](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8778), <http://www.uniprot.org/uniprot/Q14432>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8779](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8779), <http://www.uniprot.org/uniprot/Q13370>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>----Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>----Endogenous inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225> (pIC~50~ \<6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202> (pIC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/2536438?dopt=AbstractPlus>\]--Sub/family‐selective inhibitors------Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5147> (pIC~50~ 8.3--8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15555642?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/8730511?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7114> (pIC~50~ 7.1--7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/3027338?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1311763?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1321910?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225> (pIC~50~ 6.3--6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/14592490?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202> (pIC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus>\]Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179> is also an inhibitor of <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=248#show_object_1230> ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.4.4](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.5.4.4)).----

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1302><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304>Common abbreviationPDE4APDE4BPDE4CPDE4DPDE5AHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8780](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8780), <http://www.uniprot.org/uniprot/P27815>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8781](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8781), <http://www.uniprot.org/uniprot/Q07343>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8782](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8782), <http://www.uniprot.org/uniprot/Q08493>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8783](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8783), <http://www.uniprot.org/uniprot/Q08499>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8784](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8784), <http://www.uniprot.org/uniprot/O76074>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>Activators------PKA‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus>\]Protein kinase A, protein kinase G \[<http://www.ncbi.nlm.nih.gov/pubmed/10785399?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6962> (pIC~50~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19195882?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9776> (pIC~50~ \>7.3) \[[446](#bph14752-bib-0453){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9610> (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/28613871?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6558> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22100260?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225> (pIC~50~ 7.3)Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9330> (p*K* ~i~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9330> (p*K* ~i~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258> (pIC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9330> (p*K* ~i~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9631241?dopt=AbstractPlus>\], *rolipram* (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/10991987?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372> (pIC~50~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7372> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/24882690?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7320> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/15837326?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5275> (pIC~50~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12450574?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743> (pIC~50~ 8.4--9) \[<http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23137303?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7299> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919> (pIC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1312><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1313><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1314><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1315><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1316><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1317>Common abbreviationPDE6APDE6BPDE6CPDE6DPDE6GPDE6HHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8785](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8785), <http://www.uniprot.org/uniprot/P16499>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8786](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8786), <http://www.uniprot.org/uniprot/P35913>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8787](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8787), <http://www.uniprot.org/uniprot/P51160>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8788](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8788), <http://www.uniprot.org/uniprot/O43924>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8789](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8789), <http://www.uniprot.org/uniprot/P18545>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8790](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8790), <http://www.uniprot.org/uniprot/Q13956>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8811> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/19631533?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23137303?dopt=AbstractPlus>\]------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1305><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1306><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1307><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1308>Common abbreviationPDE7APDE7BPDE8APDE8BHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8791](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8791), <http://www.uniprot.org/uniprot/Q13946>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8792](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8792), <http://www.uniprot.org/uniprot/Q9NP56>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8793](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8793), <http://www.uniprot.org/uniprot/O60658>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8794](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8794), <http://www.uniprot.org/uniprot/O95263>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \[<http://www.ncbi.nlm.nih.gov/pubmed/8389765?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \[<http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \[<http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \[<http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9151> (pIC~50~ 6.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/19303290?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus>\]----Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154> (pIC~50~ 6.7--6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/15371556?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> (pIC~50~ 5.7--6) \[<http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9659> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/24687066?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> (pIC~50~ 4.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus>\]CommentsPDE7A appears to be membrane‐bound or soluble for PDE7A1 and 7A2 splice variants, respectively------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1309><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1310><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1311>Common abbreviationPDE9APDE10APDE11AHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8795](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8795), <http://www.uniprot.org/uniprot/O76083>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8772](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8772), <http://www.uniprot.org/uniprot/Q9Y233>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8773](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8773), <http://www.uniprot.org/uniprot/Q9HCR9>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.17)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> \[<http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \[<http://www.ncbi.nlm.nih.gov/pubmed/10373451?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> \[<http://www.ncbi.nlm.nih.gov/pubmed/10725373?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919> (pIC~50~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7299> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6559> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22284362?dopt=AbstractPlus>\]Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9617> (pIC~50~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19630403?dopt=AbstractPlus>\]--

Comments {#bph14752-sec-0089}
--------

PDE1A, 1B and 1C appear to act as soluble homodimers, while PDE2A is a membrane‐bound homodimer. PDE3A and PDE3B are membrane‐bound.

PDE4 isoforms are essentially <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352> specific. The potency of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292> at other members of the PDE4 family has not been reported. PDE4B‐D long forms are inhibited by extracellular signal‐regulated kinase (ERK)‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/10022832?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9639573?dopt=AbstractPlus>\]. PDE4A‐D splice variants can be membrane‐bound or cytosolic \[<http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus>\]. PDE4 isoforms may be labelled with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5313>.

PDE6 is a membrane‐bound tetramer composed of two catalytic chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G or PDE6H) and the PDE6D chain. The enzyme is essentially <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347> specific and is activated by the a‐subunit of transducin (Gat) and inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807> with potencies lower than those observed for PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and congenital stationary night blindness.

Further reading on Phosphodiesterases, 3',5'‐cyclic nucleotide (PDEs) {#bph14752-sec-0090}
---------------------------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242> {#bph14752-sec-0091}
===========================================================================

Overview {#bph14752-sec-0092}
--------

The cytochrome P450 enzyme family (CYP450), E.C. 1.14.‐.‐, were originally defined by their strong absorbance at 450 nm due to the reduced carbon monoxide‐complexed haem component of the cytochromes. They are an extensive family of haemcontaining monooxygenases with a huge range of both endogenous and exogenous substrates. These include sterols, fat‐soluble vitamins, pesticides and carcinogens as well as drugs. The substrates of some orphan CYP are not known. Listed below are the human enzymes; their relationship with rodent CYP450 enzyme activities is obscure in that the species orthologuemay not catalyse the metabolism of the same substrates. Although the majority of CYP450 enzyme activities are concentrated in the liver, the extrahepatic enzyme activities also contribute to patho/physiological processes. Genetic variation of CYP450 isoforms is widespread and likely underlies a significant proportion of the individual variation to drug administration.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=261> {#bph14752-sec-0093}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1318><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1319><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1320>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2595](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2595), <http://www.uniprot.org/uniprot/P04798>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2596](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2596), <http://www.uniprot.org/uniprot/P05177>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2597](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2597), <http://www.uniprot.org/uniprot/Q16678>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.1.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8748> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23600958?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8748> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23600958?dopt=AbstractPlus>\]stilbenes \[<http://www.ncbi.nlm.nih.gov/pubmed/28458135?dopt=AbstractPlus>\]CommentsCYP1A1 is an extra‐hepatic enzyme. It shows a preference for linear planar aromatic molecules \[<http://www.ncbi.nlm.nih.gov/pubmed/28698457?dopt=AbstractPlus>\].CYP1A2 is constitutively expressed in liver. It shows a preference for triangular planar aromatic molecules \[<http://www.ncbi.nlm.nih.gov/pubmed/28698457?dopt=AbstractPlus>\].Mainly expressed in extra‐hepatic tissues. Can metabolise 17β‐estradiol \[<http://www.ncbi.nlm.nih.gov/pubmed/28458135?dopt=AbstractPlus>\], leukotrienes and eicosanoids \[<http://www.ncbi.nlm.nih.gov/pubmed/23956430?dopt=AbstractPlus>\]. Mutations have been associated with primary congenitial glaucoma \[<http://www.ncbi.nlm.nih.gov/pubmed/9097971?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=262> {#bph14752-sec-0094}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1321><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1322><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1323><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1324><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1325>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2610](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2610), <http://www.uniprot.org/uniprot/P11509>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2611](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2611), <http://www.uniprot.org/uniprot/P20853>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2608](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2608), <http://www.uniprot.org/uniprot/Q16696>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2615](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2615), <http://www.uniprot.org/uniprot/P20813>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2622](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2622), <http://www.uniprot.org/uniprot/P10632>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585>--------Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7307> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus>\], sibutramine (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23777987?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7622> (p*K* ~i~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/17682072?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus>\]CommentsMetabolises coumarin \[<http://www.ncbi.nlm.nih.gov/pubmed/2322567?dopt=AbstractPlus>\].CYP2A7 does not incorporate haem and is functionally inactive \[<http://www.ncbi.nlm.nih.gov/pubmed/16636685?dopt=AbstractPlus>\]Metabolises tobacco carcinogen, 4‐methylnitrosoamino)‐1‐(3‐pyridyl)‐1‐butanone \[<http://www.ncbi.nlm.nih.gov/pubmed/11016631?dopt=AbstractPlus>\].Substrates include: efavirenz, bupropion, cyclophosphamide, ketamine, propofol \[<http://www.ncbi.nlm.nih.gov/pubmed/23152403?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> to 11(R)‐12(S)‐epoxyeicosatrienoic acid or 14(R)‐15(S)‐epoxyeicosatrienoic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/7574697?dopt=AbstractPlus>\]. Drug substrates include <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10018> \[<http://www.ncbi.nlm.nih.gov/pubmed/26721703?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1328><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1329><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1330><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1331><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1332><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1333>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2621](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2621), <http://www.uniprot.org/uniprot/P33261>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2625](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2625), <http://www.uniprot.org/uniprot/P10635>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2631](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2631), <http://www.uniprot.org/uniprot/P05181>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2632](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2632), <http://www.uniprot.org/uniprot/P24903>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2634](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2634), <http://www.uniprot.org/uniprot/P51589>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20580](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20580), <http://www.uniprot.org/uniprot/Q6VVX0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.51](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.51) (S)‐limonene + \[reduced NADPH--hemoprotein reductase\] + O(2) \<=\> (‐)‐trans‐carveol + \[oxidized NADPH--hemoprotein reductase\] + H(2)O[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.15](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.15)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8777> (pIC~50~ 7.3) \[[120](#bph14752-bib-0121){ref-type="ref"}\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8756> (p*K* ~i~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17125252?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8832> (pIC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2608> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/16495056?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8749> (p*K* ~i~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22239545?dopt=AbstractPlus>\]----------CommentsSubstrates include: omeprazole, proguanil, mephenytoin, diazepam \[<http://www.ncbi.nlm.nih.gov/pubmed/2495208?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12222994?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/2291871?dopt=AbstractPlus>\].Substrates include: debrisoquine, metoprolol, codeine \[<http://www.ncbi.nlm.nih.gov/pubmed/19102711?dopt=AbstractPlus>\].Substrates: Ethanol, p‐nitrophenol \[<http://www.ncbi.nlm.nih.gov/pubmed/30380359?dopt=AbstractPlus>\].Substrate: naphthalene \[<http://www.ncbi.nlm.nih.gov/pubmed/20408502?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> to 14(R)‐15(S)‐epoxyeicosatrienoic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/8631948?dopt=AbstractPlus>\]. Hydroxylates albendazole\[<http://www.ncbi.nlm.nih.gov/pubmed/23959307?dopt=AbstractPlus>\]. Expressed in cardiomyocytes \[<http://www.ncbi.nlm.nih.gov/pubmed/29695613?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2747> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6921> \[<http://www.ncbi.nlm.nih.gov/pubmed/12867411?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=263> {#bph14752-sec-0095}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1337><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1338><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1339><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1340>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2637](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2637), <http://www.uniprot.org/uniprot/P08684>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2638](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2638), <http://www.uniprot.org/uniprot/P20815>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2640](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2640), <http://www.uniprot.org/uniprot/P24462>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17450](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17450), <http://www.uniprot.org/uniprot/Q9HB55>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.56](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.56): 1,8‐cineole + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + O~2~ = 2‐exo‐hydroxy‐1,8‐cineole + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> + H~2~O [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.97](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.97): Taurochenodeoxycholate + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + O~2~ = taurohyocholate + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> + H~2~O Lithocholate + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + O~2~ = hyodeoxycholate + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> + H~2~O [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.55](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.55): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + O~2~ = 3‐hydroxyquinine + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2514> \[<http://www.ncbi.nlm.nih.gov/pubmed/3514607?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3342> \[<http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus>\]------Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10209> (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/26002732?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2568> (p*K* ~i~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/25923589?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804> (p*K* ~i~ \>7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18285471?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8804> (p*K* ~i~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/16248836?dopt=AbstractPlus>\]----CommentsMetabolises a vast range of xenobiotics, including antidepressants, benzodiazepines, calcium channel blockers, and chemotherapeutic agents \[<http://www.ncbi.nlm.nih.gov/pubmed/18473749?dopt=AbstractPlus>\]. The active site is plastic, with both homotropic and heterotropic cooperativity observed with some substrates \[<http://www.ncbi.nlm.nih.gov/pubmed/26002732?dopt=AbstractPlus>\]. CYP3A4 catalyses the 25‐hydroxylation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2767> in liver microsomes \[<http://www.ncbi.nlm.nih.gov/pubmed/9931427?dopt=AbstractPlus>\].CYP3A5 is expressed extrahepatically, including in the small intestine. It has overlapping substrate specificity with CYP3A4 \[<http://www.ncbi.nlm.nih.gov/pubmed/16430309?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus>\].Fetal form, rarely expressed in adults. Has overlapping substrate specificity with CYP3A4 \[<http://www.ncbi.nlm.nih.gov/pubmed/16430309?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12124305?dopt=AbstractPlus>\].Fetal expression only and considered an orphan fCYP \[<http://www.ncbi.nlm.nih.gov/pubmed/21737533?dopt=AbstractPlus>\]. Testosterone may be a substrate \[<http://www.ncbi.nlm.nih.gov/pubmed/11160875?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=264> {#bph14752-sec-0096}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1341><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1342><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1343><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1344><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1345>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2642](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2642), <http://www.uniprot.org/uniprot/Q02928>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20575](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20575), <http://www.uniprot.org/uniprot/Q5TCH4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2644](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2644), <http://www.uniprot.org/uniprot/P13584>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2645](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2645), <http://www.uniprot.org/uniprot/P78329>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2646](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2646), <http://www.uniprot.org/uniprot/Q08477>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.80](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.80)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.80](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.80)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.94](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.94)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.94](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.94)Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8851> (p*K* ~i~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/2997155?dopt=AbstractPlus>\]--CommentsConverts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5534> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6922>.Reported to be enzymatically inactive \[<http://www.ncbi.nlm.nih.gov/pubmed/15611369?dopt=AbstractPlus>\].--Responsible for *ω*‐hydroxylation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216> \[<http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus>\], and tocopherols, including vitamin E \[<http://www.ncbi.nlm.nih.gov/pubmed/11997390?dopt=AbstractPlus>\]Responsible for *ω*‐hydroxylation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216> \[<http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus>\], and polyunsaturated fatty acids \[<http://www.ncbi.nlm.nih.gov/pubmed/18577768?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16820285?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1346><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1347><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1348><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1349><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1350><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1351><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1352>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2648](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2648), <http://www.uniprot.org/uniprot/P98187>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13265](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13265), <http://www.uniprot.org/uniprot/Q9HBI6>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18857](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18857), <http://www.uniprot.org/uniprot/Q9HCS2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26820](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26820), <http://www.uniprot.org/uniprot/Q6NT55>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23198](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23198), <http://www.uniprot.org/uniprot/Q6ZWL3>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20244](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20244), <http://www.uniprot.org/uniprot/Q8N118>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20583](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20583), <http://www.uniprot.org/uniprot/Q86W10>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.78)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.79)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.1)CommentsConverts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> to 19‐hydroxyPGH~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/10791960?dopt=AbstractPlus>\] and 8,9‐EET or 11,12‐EET to 18‐hydroxy‐8,9‐EET or 18‐hydroxy‐11,12‐EET \[<http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus>\].--AC004597.1 ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000225607;r=19:15880826‐15890774;t=ENST00000412610](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000225607;r=19:15880826‐15890774;t=ENST00000412610)) is described as being highly similar to CYP4F12Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6923> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6924> \[<http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806> to 14‐hydroxymyristic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/19661213?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> to 14,15‐poxyeicosatrienoic ethanolamide \[<http://www.ncbi.nlm.nih.gov/pubmed/18549450?dopt=AbstractPlus>\].Converts lauric acid to 12‐hydroxylauric acid.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=265> {#bph14752-sec-0097}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1353><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1354><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1355><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1356><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1357>Common abbreviationThromboxane synthase----Prostacyclin synthase--HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11609](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11609), <http://www.uniprot.org/uniprot/P24557>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2651](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2651), <http://www.uniprot.org/uniprot/P22680>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2652](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2652), <http://www.uniprot.org/uniprot/O75881>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9603](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9603), <http://www.uniprot.org/uniprot/Q16647>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2653](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2653), <http://www.uniprot.org/uniprot/Q9UNU6>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.5](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.5): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.23](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.23)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.29](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.29)[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.4](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.139](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.139) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.18.8](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.18.8)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9866> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/3093741?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8795> (pIC~50~ \>6) \[<http://www.ncbi.nlm.nih.gov/pubmed/7861416?dopt=AbstractPlus>\]--CommentsInhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5175> \[<http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5157> \[<http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus>\] and furegrelate sodium (U‐63557A: PubChem <https://pubchem.ncbi.nlm.nih.gov/compound/23663954>) \[<http://www.ncbi.nlm.nih.gov/pubmed/6316421?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4351> \[<http://www.ncbi.nlm.nih.gov/pubmed/2384150?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370> to 7α‐DHEA \[<http://www.ncbi.nlm.nih.gov/pubmed/9144166?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915> \[<http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus>\]. Inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281> \[<http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus>\]Converts 7α‐hydroxycholest‐4‐en‐3‐one to 7‐alpha, 12α‐dihydroxycholest‐4‐en‐3‐one (in rabbit) \[<http://www.ncbi.nlm.nih.gov/pubmed/1400444?dopt=AbstractPlus>\] in the biosynthesis of bile acids.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=266> {#bph14752-sec-0098}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1358><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1359><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1360><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1362><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1363><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1364>Common abbreviation----Aldosterone synthase--Aromatase----HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2590](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2590), <http://www.uniprot.org/uniprot/P05108>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2591](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2591), <http://www.uniprot.org/uniprot/P15538>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2592](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2592), <http://www.uniprot.org/uniprot/P19099>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2593](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2593), <http://www.uniprot.org/uniprot/P05093>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2594](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2594), <http://www.uniprot.org/uniprot/P11511>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20576](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20576), <http://www.uniprot.org/uniprot/Q6UW02>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2600](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2600), <http://www.uniprot.org/uniprot/P08686>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.6](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.6)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.4) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.5](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.5)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.19](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.19) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.32](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.32)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.14](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.14)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.16](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.16)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6957> \[<http://www.ncbi.nlm.nih.gov/pubmed/23254310?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17395972?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5224> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21129965?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6957><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8310> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/24899257?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6745> (pIC~50~ 7.1--8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/18672868?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7608911?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5137> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20413308?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7054> \[<http://www.ncbi.nlm.nih.gov/pubmed/19470632?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8871> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/1495014?dopt=AbstractPlus>\] -- RatSelective inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5209> (p*K* ~i~ 10.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22386564?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7073> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/2951074?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7303> (p*K* ~i~ 4.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7083195?dopt=AbstractPlus>\]----CommentsConverts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376> plus 4‐methylpentanal.Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5100> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5171> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868>, respectively. Loss‐of‐function mutations are associated with familial adrenal hyperplasia and hypertension. Inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5224> \[<http://www.ncbi.nlm.nih.gov/pubmed/412519?dopt=AbstractPlus>\]Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872>Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5104> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103>, respectively. Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2860>, respectively. Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868>.Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2860> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013>, respectively. Inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5137> \[<http://www.ncbi.nlm.nih.gov/pubmed/7949201?dopt=AbstractPlus>\], and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5209> \[<http://www.ncbi.nlm.nih.gov/pubmed/2149502?dopt=AbstractPlus>\]--Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5100>, respectively

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=267> {#bph14752-sec-0099}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1365><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1366><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1367><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1368><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1369><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1370><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1371>Common abbreviation--------Sterol 27‐hydroxylase----HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2602](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2602), <http://www.uniprot.org/uniprot/Q07973>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2603](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2603), <http://www.uniprot.org/uniprot/O43174>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20581](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20581), <http://www.uniprot.org/uniprot/Q9NR63>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:20577](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:20577), <http://www.uniprot.org/uniprot/Q6V0L0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2605](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2605), <http://www.uniprot.org/uniprot/Q02318>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2606](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2606), <http://www.uniprot.org/uniprot/O15528>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:33480](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:33480), <http://www.uniprot.org/uniprot/Q4G0S4>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.16](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.16)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.‐.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.15](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.15)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.18](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.15.18)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.19.53](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.19.53)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8858> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8819> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8852> (pIC~50~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20655626?dopt=AbstractPlus>\]------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8852> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/20655626?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8858> (pIC~50~ \<6) \[<http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8858> (pIC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/15615534?dopt=AbstractPlus>\]--Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8790> (pIC~50~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21838328?dopt=AbstractPlus>\]----------CommentsConverts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779> (calcitriol) to 1α,24R,25‐trihydroxyvitamin D~3~.Converts retinoic acid to 4‐hydroxyretinoic acid. Inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5210>Converts retinoic acid to 4‐hydroxyretinoic acid.Converts retinoic acid to 4‐hydroxyretinoic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/14532297?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752>.Converts 25‐hydroxyvitamin D~3~ to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779> (calcitriol)Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4053> (vitamin A1) to 3,4‐didehydroretinol (vitamin A2) \[<http://www.ncbi.nlm.nih.gov/pubmed/27059013?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=268> {#bph14752-sec-0100}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1372><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1373><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1374>Common abbreviation--Cholesterol 24‐hydroxylaseLanosterol 14‐α‐demethylaseHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17449), <http://www.uniprot.org/uniprot/Q9NYL5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2641](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2641), <http://www.uniprot.org/uniprot/Q9Y6A2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2649](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2649), <http://www.uniprot.org/uniprot/Q16850>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.26](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.26)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.25](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.25)--Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8799> (p*K* ~i~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/8340925?dopt=AbstractPlus>\]CommentsConverts 24‐hydroxycholesterol to 7α,24‐dihydroxycholesterol \[<http://www.ncbi.nlm.nih.gov/pubmed/10748047?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750>.Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746> to 4,4‐dimethylcholesta‐8.14.24‐trienol.

Further reading on Cytochrome P450 {#bph14752-sec-0101}
----------------------------------

Backman JT *et al*. (2016) Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. *Pharmacol Rev* **68**: 168‐241 <https://www.ncbi.nlm.nih.gov/pubmed/26721703?dopt=AbstractPlus>
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Jamieson KL *et al*. (2017) Cytochrome P450‐derived eicosanoids and heart function. *Pharmacol Ther* **179**: 47--83 <https://www.ncbi.nlm.nih.gov/pubmed/28551025?dopt=AbstractPlus>

Mak PJ *et al*. (2018) Spectroscopic studies of the cytochrome P450 reaction mechanisms. *Biochim Biophys Acta* **1866**: 178‐204 <https://www.ncbi.nlm.nih.gov/pubmed/28668640?dopt=AbstractPlus>

Moutinho M *et al*. (2016) Cholesterol 24‐hydroxylase: Brain cholesterol metabolism and beyond. *Biochim Biophys Acta* **1861**: 1911‐1920 <https://www.ncbi.nlm.nih.gov/pubmed/27663182?dopt=AbstractPlus>
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=851> {#bph14752-sec-0102}
===========================================================================

Overview {#bph14752-sec-0103}
--------

DNA topoisomerases regulate the supercoiling of nuclear DNA to influence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the DNA to allow unwinding, followed by re‐attachment to reseal the backbone. Members of the family are targetted in anti‐cancer chemotherapy.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2637>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11986](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11986), <http://www.uniprot.org/uniprot/P11387>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11989](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11989), <http://www.uniprot.org/uniprot/P11388>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:5.99.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:5.99.1.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:5.99.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:5.99.1.2)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6823> \[<http://www.ncbi.nlm.nih.gov/pubmed/9655905?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8182764?dopt=AbstractPlus>\] -- Bovine<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6815> (pIC~50~ 7.3), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6843> \[<http://www.ncbi.nlm.nih.gov/pubmed/2557897?dopt=AbstractPlus>\] -- Mouse

Further reading on DNA topoisomerases {#bph14752-sec-0104}
-------------------------------------

Bansal S *et al*. (2017) Topoisomerases: Resistance versus Sensitivity, How Far We Can Go? *Med Res Rev* **37**: 404‐438 <https://www.ncbi.nlm.nih.gov/pubmed/27687257?dopt=AbstractPlus>

Capranico G *et al*. (2017) Type I DNA Topoisomerases. *J. Med. Chem*. **60**: 2169‐2192 <https://www.ncbi.nlm.nih.gov/pubmed/28072526?dopt=AbstractPlus>

Nagaraja V *et al*. (2017) DNA topoisomerase I and DNA gyrase as targets for TB therapy. *Drug Discov. Today* **22**: 510‐518 <https://www.ncbi.nlm.nih.gov/pubmed/27856347?dopt=AbstractPlus>

Pommier Y *et al*. (2016) Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. *Nat. Rev. Mol. Cell Biol*. **17**: 703‐721 <https://www.ncbi.nlm.nih.gov/pubmed/27649880?dopt=AbstractPlus>

Seol Y *et al*. (2016) The dynamic interplay between DNA topoisomerases and DNA topology. *Biophys Rev* **8**: 101‐111 <https://www.ncbi.nlm.nih.gov/pubmed/28510219?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=943> {#bph14752-sec-0105}
===========================================================================

Overview {#bph14752-sec-0106}
--------

The principle endocannabinoids are 2‐acylglycerol esters, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729> (2‐AG), and *N*‐acylethanolamines, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> (*N*‐arachidonoylethanolamine, AEA). The glycerol esters and ethanolamides are synthesised and hydrolysed by parallel, independent pathways. Mechanisms for release and re‐uptake of endocannabinoids are unclear, although potent and selective inhibitors of facilitated diffusion of endocannabinoids across cell membranes have been developed \[<http://www.ncbi.nlm.nih.gov/pubmed/29531087?dopt=AbstractPlus>\]. <http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2535> (<https://www.uniprot.org/uniprot/Q01469>) has been suggested to act as a canonical intracellular endocannabinoid transporter *in vivo* \[<http://www.ncbi.nlm.nih.gov/pubmed/28584105?dopt=AbstractPlus>\]. For the generation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729>, the key enzyme involved is diacylglycerol lipase (DAGL), whilst several routes for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> synthesis have been described, the best characterized of which involves *N*‐acylphosphatidylethanolamine‐phospholipase D (NAPE‐PLD, \[<http://www.ncbi.nlm.nih.gov/pubmed/20393650?dopt=AbstractPlus>\]). A transacylation enzyme which forms *N*‐acylphosphatidylethanolamines has been identified as a cytosolic enzyme, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24791](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24791) (<http://www.uniprot.org/uniprot/Q3MJ16>) \[<http://www.ncbi.nlm.nih.gov/pubmed/27399000?dopt=AbstractPlus>\]. *In vitro* experiments indicate that the endocannabinoids are also substrates for oxidative metabolism *via* cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities \[<http://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17618306?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20133390?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273> {#bph14752-sec-0107}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1398><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1401><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1402>Common abbreviationNAPE‐PLDFAAHFAAH2NAAAHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21683](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21683), <http://www.uniprot.org/uniprot/Q6IQ20>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3553](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3553), <http://www.uniprot.org/uniprot/O00519>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26440](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26440), <http://www.uniprot.org/uniprot/Q6GMR7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:736](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:736), <http://www.uniprot.org/uniprot/Q02083>EC number--[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99): anandamide + H~2~O \<=\> arachidonic acid + ethanolamine oleamide + H~2~O \<=\> oleic acid + NH~3~[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.99): anandamide + H~2~O \<=\> arachidonic acid + ethanolamine oleamide + H~2~O \<=\> oleic acid + NH~3~[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.‐)Rank order of affinity--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622> \[<http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622> \[<http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5221> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621> ≥ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> \[<http://www.ncbi.nlm.nih.gov/pubmed/11463796?dopt=AbstractPlus>\]Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10248> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5206> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18693015?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5244> (pIC~50~ 6.3--7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17949010?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9944> (pIC~50~ 7), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339> (pIC~50~ 6.3--7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5243> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/19389627?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235> (pIC~50~ 7.9--8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339> (pIC~50~ 7.5--8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19095868?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10248> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/29017758?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10121> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/28802121?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/29572189?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9178> (Irreversible inhibition) (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25874594?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6493> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19926854?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5161> (pIC~50~ 5.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/14686878?dopt=AbstractPlus>\]CommentsNAPE‐PLD activity appears to be enhanced by polyamines in the physiological range \[<http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus>\], but fails to transphosphatidylate with alcohols \[<http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus>\] unlike phosphatidylcholine‐specific phospholipase D.--The FAAH2 gene is found in many primate genomes, marsupials, and other distantly related vertebrates, but not a variety of lower placental mammals, including mouse and rat \[<http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\].--

Comments {#bph14752-sec-0108}
--------

Routes for *N*‐acylethanolamine biosynthesis other than through NAPE‐PLD activity have been identified \[<http://www.ncbi.nlm.nih.gov/pubmed/23394527?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=944> {#bph14752-sec-0109}
===========================================================================

Overview {#bph14752-sec-0110}
--------

ABHD12 is a 398‐aa protein, with serine hydrolase activity. It has a molecular weight of 45 kDa. A single TM is predicted at 75‐95, with an extracellular catalytic domain. ABHD12 is a monoacylglycerol hydrolase \[<http://www.ncbi.nlm.nih.gov/pubmed/22969151?dopt=AbstractPlus>\], but may also regulate lysophosphatidylserine levels \[<http://www.ncbi.nlm.nih.gov/pubmed/25580854?dopt=AbstractPlus>\]. Loss‐of‐function mutations in ABHD12 are associated with a disorder known as PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataracts) \[<http://www.ncbi.nlm.nih.gov/pubmed/20797687?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1396><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1397><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1399><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2919><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3070>Common abbreviationDAGLαDAGLßMAGLABHD6--HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1165](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1165), <http://www.uniprot.org/uniprot/Q9Y4D2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:28923](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:28923), <http://www.uniprot.org/uniprot/Q8NCG7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17038](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17038), <http://www.uniprot.org/uniprot/Q99685>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21398](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21398), <http://www.uniprot.org/uniprot/Q9BV23>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15868](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15868), <http://www.uniprot.org/uniprot/Q8N2K0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.‐)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.23)Endogenous substratesdiacylglyceroldiacylglycerol<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729> ≫ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> \[<http://www.ncbi.nlm.nih.gov/pubmed/15492019?dopt=AbstractPlus>\]1‐arachidonoylglycerol \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729> \> 1‐oleoylglycerol \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112> \[<http://www.ncbi.nlm.nih.gov/pubmed/22969151?dopt=AbstractPlus>\]--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10246> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/26083464?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10244> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10243> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10245> (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23103940?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10244> (pIC~50~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10243> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/26668358?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10246> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/26083464?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10245> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23103940?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10028> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23731016?dopt=AbstractPlus>\]----Selective inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9481> (pIC~50~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/23521796?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9482> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22542104?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5207> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/19029917?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5289> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17629278?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9480> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/21084632?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10250> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/30720278?dopt=AbstractPlus>\]Comments------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5289> has also been suggested to have activity at oxidative metabolic pathways independent of ABHD6 \[<http://www.ncbi.nlm.nih.gov/pubmed/28086912?dopt=AbstractPlus>\].--

Comments on Endocannabinoid turnover {#bph14752-sec-0111}
------------------------------------

Many of the compounds described as inhibitors are irreversible and so potency estimates will vary with incubation time. FAAH2 is not found in rodents \[<http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus>\] and a limited range of inhibitors have been assessed at this enzyme activity. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729> has been reported to be hydrolysed by multiple enzyme activities from neural preparations \[<http://www.ncbi.nlm.nih.gov/pubmed/29751000?dopt=AbstractPlus>\], including [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21398](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21398) (<http://www.uniprot.org/uniprot/Q9BV23>) \[<http://www.ncbi.nlm.nih.gov/pubmed/26989199?dopt=AbstractPlus>\] and carboxylesterase 1 ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1863](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1863), <http://www.uniprot.org/uniprot/P23141> \[<http://www.ncbi.nlm.nih.gov/pubmed/21049984?dopt=AbstractPlus>\]). [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21398](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21398) (<http://www.uniprot.org/uniprot/Q9BV23>) has also been described as a triacylglycerol lipase and ester hydrolase \[<http://www.ncbi.nlm.nih.gov/pubmed/27247428?dopt=AbstractPlus>\], while [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15868](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15868) (<http://www.uniprot.org/uniprot/Q8N2K0>) is also able to hydrolyse lysophosphatidylserine \[<http://www.ncbi.nlm.nih.gov/pubmed/2397193?dopt=AbstractPlus>\]. [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15868](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15868) (<http://www.uniprot.org/uniprot/Q8N2K0>) has been described to be inhibited selectively by pentacyclic triterpenoids, such as oleanolic acid \[<http://www.ncbi.nlm.nih.gov/pubmed/24879289?dopt=AbstractPlus>\].

Further reading on Endocannabinoid turnover {#bph14752-sec-0112}
-------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=243> {#bph14752-sec-0113}
===========================================================================

Overview {#bph14752-sec-0114}
--------

Eicosanoids are 20‐carbon fatty acids, where the usual focus is the polyunsaturated analogue <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> and its metabolites. Arachidonic acid is thought primarily to derive from [http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244\#Phospholipase A2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244#PhospholipaseA2) action on membrane phosphatidylcholine, andmay be re‐cycled to form phospholipid through conjugation with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> and subsequently glycerol derivatives. Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450‐like epoxygenases, particularly <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1332>. Isoprostanes are structural analogues of the prostanoids (hence the nomenclature D‐, E‐, F‐isoprostanes and isothromboxanes), which are produced in the presence of elevated free radicals in a nonenzymaticmanner, leading to suggestions for their use as biomarkers of oxidative stress. Molecular targets for their action have yet to be defined.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=269> {#bph14752-sec-0115}
===========================================================================

Overview {#bph14752-sec-0116}
--------

Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)‐icosa‐5,8,11,14‐tetraenoate,hydrogen‐donor : oxygen oxidoreductase) activity, catalyses the formation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245> from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>. Hydroperoxidase activity inherent in the enzyme catalyses the formation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245>. COX‐1 and ‐2 can be nonselectively inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5230>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5239> (acetaminophen). PGH~2~ may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an apparently tissue‐dependent manner.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1375><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9604](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9604), <http://www.uniprot.org/uniprot/P23219>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9605](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9605), <http://www.uniprot.org/uniprot/P35354>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.99.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.99.1): Hydrogen donor + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + 2O~2~ = hydrogen acceptor + H~2~O + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245> =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> This enzyme is also associated with the following reaction:: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051> =\> PGH~3~[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.99.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.99.1): Hydrogen donor + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + 2O~2~ = hydrogen acceptor + H~2~O + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245> =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> This enzyme is also associated with the following reaction:: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051> =\> PGH~3~Selective activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10242> (Inhibition) (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9135032?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7131> (pIC~50~ 8.1) \[22\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714> (pIC~50~ 7.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/16252917?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7219> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4820> (pIC~50~ 6.8) \[22\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7298> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7124> (pIC~50~ 8.3) \[22\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10091674?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7219> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7141> (pIC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21873070?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6661> (pIC~50~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22091869?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7401> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/15993594?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6661> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10241> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/21745460?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10240> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9789085?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5191> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/10720634?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2892> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/12643942?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2894> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/10715145?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17341061?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2893> (pIC~50~ 6.1--6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2897> (p*K* ~i~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17434872?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7220> (pIC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/9083488?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2896> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11160644?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=270> {#bph14752-sec-0117}
===========================================================================

Overview {#bph14752-sec-0118}
--------

Subsequent to the formation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483>, the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242> thromboxane synthase (CYP5A1, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11609](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11609), <http://www.uniprot.org/uniprot/P24557>, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=5.3.99.5](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=5.3.99.5)) and prostacyclin synthase (CYP8A1, [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9603](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9603), <http://www.uniprot.org/uniprot/Q16647>, [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=5.3.99.4](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=5.3.99.4)) generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482> and prostacyclin (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915>), respectively. Additionally, multiple enzyme activities are able to generate prostaglandin E~2~ (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>), prostaglandin D~2~ (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881>) and prostaglandin F~2α~ (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884>). PGD~2~ can bemetabolised to 9α,11ß‐prostacyclin F~2α~ through the multifunctional enzyme activity of AKR1C3. PGE2 can be metabolised to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5129> through the 9‐ketoreductase activity of CBR1. Conversion of the 15‐hydroxyecosanoids, including prostaglandins, lipoxins and leukotrienes to their keto derivatives by the NAD‐dependent enzyme HPGD leads to a reduction in their biological activity.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1353><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1356><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1377><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1378><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1379><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1380>Common abbreviationThromboxane synthaseProstacyclin synthase--------HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11609](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11609), <http://www.uniprot.org/uniprot/P24557>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9603](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9603), <http://www.uniprot.org/uniprot/Q16647>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9599](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9599), <http://www.uniprot.org/uniprot/O14684>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17822](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17822), <http://www.uniprot.org/uniprot/Q9H7Z7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:16049](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:16049), <http://www.uniprot.org/uniprot/Q15185>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9592](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9592), <http://www.uniprot.org/uniprot/P41222>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.5](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.5): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482>[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.4](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.3): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883>[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.2](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881>Cofactors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6737><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6738>----Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9866> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/3093741?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8795> (pIC~50~ \> 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/7861416?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8761> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19748780?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8812> (pIC~50~ \<6) \[<http://www.ncbi.nlm.nih.gov/pubmed/15953724?dopt=AbstractPlus>\]----Selective inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8875> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23623673?dopt=AbstractPlus>\]----AT‐56 (pKi 4.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/19131342?dopt=AbstractPlus>\]CommentsInhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5175> \[<http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5157> \[<http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus>\] and furegrelate sodium (U‐63557A: PubChem <https://pubchem.ncbi.nlm.nih.gov/compound/23663954>) \[<http://www.ncbi.nlm.nih.gov/pubmed/6316421?dopt=AbstractPlus>\].Converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915> \[<http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus>\]. Inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281> \[<http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus>\]----Phosphorylated and activated by casein kinase 2 (<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?familyId=565&objectId=1548&familyType=ENZYME>) \[<http://www.ncbi.nlm.nih.gov/pubmed/15040786?dopt=AbstractPlus>\]. Appears to regulate steroid hormone function by interaction with dimeric hsp90 \[<http://www.ncbi.nlm.nih.gov/pubmed/11050175?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8603045?dopt=AbstractPlus>\].--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1381><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1382><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1383><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1384>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17890](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17890), <http://www.uniprot.org/uniprot/O60760><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1382>, <http://www.uniprot.org/uniprot/P42330><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1383>, <http://www.uniprot.org/uniprot/P16152><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1384>, <http://www.uniprot.org/uniprot/P15428>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.2](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.99.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.3.1.20](http://www.genome.jp/dbget‐bin/www_bget?ec:1.3.1.20) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.188](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.188): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + H^+^ [http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.64](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.64) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.239](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.239) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.213](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.213)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.184](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.184) [http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.189](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.189): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + H^+^ [http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.197](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.197)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.141](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.141) 15‐hydroxyprostaglandins =\> 15‐ketoprostaglandins <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034> =\> 15‐keto‐lipoxin A~4~Cofactors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045>--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6662> (pIC~50~ 5.3--5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16547010?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8769> (p*K* ~i~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17166832?dopt=AbstractPlus>\] <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909>, flavonoids such as 2′‐Hydroxyflavanone (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9792917?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19007764?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5551> (pIC~50~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19097799?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8745> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/21650226?dopt=AbstractPlus>\]Comments--AKR1C3 also exhibits an hydroxysteroid dehydrogenase activity.----

Comments {#bph14752-sec-0119}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5293> has been reported to inhibit mPGES1 and 5‐LOX with a *p*IC~50~ value of 5.5 \[<http://www.ncbi.nlm.nih.gov/pubmed/19053751?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=271> {#bph14752-sec-0120}
===========================================================================

Overview {#bph14752-sec-0121}
--------

The lipoxygenases (LOXs) are a structurally related family of non‐heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are five lipoxygenases, the 5S‐(arachidonate : oxygen 5‐oxidoreductase), 12R‐(arachidonate 12‐lipoxygenase, 12R‐type), 12S‐(arachidonate : oxygen 12‐oxidoreductase), and two distinct 15S‐(arachidonate : oxygen 15‐oxidoreductase) LOXs that oxygenate arachidonic acid in different positions along the carbon chain and form the corresponding 5S‐, 12S‐, 12R‐, or 15S‐hydroperoxides, respectively.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1385><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1386><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1387><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1388><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1389><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1390>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:435](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:435), <http://www.uniprot.org/uniprot/P09917>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:430](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:430), <http://www.uniprot.org/uniprot/O75342>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:429](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:429), <http://www.uniprot.org/uniprot/P18054>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:433](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:433), <http://www.uniprot.org/uniprot/P16050>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:434), <http://www.uniprot.org/uniprot/O15296>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13743](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13743), <http://www.uniprot.org/uniprot/Q9BYJ1>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.34](http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.34): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + O~2~ = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214> + H~2~O[http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31](http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + O~2~ =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31](http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.31) <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + O~2~ =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33](http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + O~2~ = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052> + O~2~ =\> 13S‐HPODE[http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33](http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.33): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391> + O~2~ = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:1.13.11.‐)Substrates--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5222>--------Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101>Endogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5183> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:436](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:436), <http://www.uniprot.org/uniprot/P20292>)----------Endogenous inhibitorsProtein kinase A‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/15280375?dopt=AbstractPlus>\]----------Inhibitors------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10263> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/24672829?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8750> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/17656086?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5169> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/15197110?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9054> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/20378715?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/1848634?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8752> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/24393039?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8751> (p*K* ~i~ \>8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20866075?dopt=AbstractPlus>\]----CommentsFLAP activity can be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2655> \[<http://www.ncbi.nlm.nih.gov/pubmed/2300173?dopt=AbstractPlus>\] and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5148> \[<http://www.ncbi.nlm.nih.gov/pubmed/8381000?dopt=AbstractPlus>\] leading to a selective inhibition of 5‐LOX activity------Inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10264> (pK~i~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25111178?dopt=AbstractPlus>\].E‐LOX metabolises the product from the 12R‐lipoxygenase (12R‐HPETE) to a specific epoxyalcohol compound \[<http://www.ncbi.nlm.nih.gov/pubmed/12881489?dopt=AbstractPlus>\].

Comments {#bph14752-sec-0122}
--------

An 8‐LOX([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.13.11.40](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.13.11.40), arachidonate:oxygen 8‐oxidoreductase) may be the mouse orthologue of 15‐LOX‐2 \[<http://www.ncbi.nlm.nih.gov/pubmed/12432921?dopt=AbstractPlus>\]. Some general LOX inhibitors are <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4265> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5180>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5155> are used as 5‐lipoxygenase inhibitors, while <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5144> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5162> are 12‐lipoxygenase inhibitors. The specificity of these inhibitors has not been rigorously assessed with all LOX forms: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5144>, along with other flavonoids, such as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5182> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5215>, also inhibits 15‐LOX‐1 \[<http://www.ncbi.nlm.nih.gov/pubmed/12628491?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=272> {#bph14752-sec-0123}
===========================================================================

Overview {#bph14752-sec-0124}
--------

Leukotriene A~4~ (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214>), produced by 5‐LOX activity, and lipoxins may be subject to further oxidative metabolism; ω‐hydroxylation is mediated by <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1344> and <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1345>, while ß‐oxidation in mitochondria and peroxisomes proceeds in a manner dependent on coenzyme A conjugation. Conjugation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214> at the 6 position with reduced glutathione to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354> occurs under the influence of leukotriene C~4~ synthase, with the subsequent formation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352>, all three of which are agonists at <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> formation is catalysed by γ‐glutamyltransferase, and subsequently dipeptidase 2 removes the terminal <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727> from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352>. Leukotriene A~4~ hydrolase converts the 5,6‐epoxide LTA~4~ to the 5‐hydroxylated LTB~4~, an agonist for <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214> is also acted upon by 12S‐LOX to produce the trihydroxyeicosatetraenoic acids lipoxins <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216>. Treatment with a LTA~4~ hydrolase inhibitor in a murine model of allergic airway inflammation increased LXA~4~ levels, in addition to reducing <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487>, in lung lavage fluid \[<http://www.ncbi.nlm.nih.gov/pubmed/20110560?dopt=AbstractPlus>\]. LTA~4~ hydrolase is also involved in biosynthesis of <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=134>. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4139> has been reported to increase endogenous formation of 18S‐hydroxyeicosapentaenoate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5105>) compared with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3400>, a resolvin precursor. Both enantiomers may be metabolised by human recombinant 5‐LOX; recombinant LTA~4~ hydrolase converted chiral 5S(6)‐epoxide‐containing intermediates to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5106> \[<http://www.ncbi.nlm.nih.gov/pubmed/21206090?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1391><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1392><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1393><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1394><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1395>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6719](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6719), <http://www.uniprot.org/uniprot/Q16873>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21705](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21705), <http://www.uniprot.org/uniprot/O75223>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3002](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3002), <http://www.uniprot.org/uniprot/P16444>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23028](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23028), <http://www.uniprot.org/uniprot/Q9H4A9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6710](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6710), <http://www.uniprot.org/uniprot/P09960>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.20](http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.20): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6737> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.2.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.2.2): (5‐L‐glutamyl)‐peptide + an amino acid = a peptide + a 5‐L‐glutamyl amino acid <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354> + H~2~O =\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> + L‐glutamate[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>[http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.2.6](http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.2.6)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9555> (pIC~50~ 8.1) \[[508](#bph14752-bib-0516){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8875> (pIC~50~ \<5.5) \[551\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10265> (p*K* ~i~ 3.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17260973?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5166> (p*K* ~i~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5151> (p*K* ~i~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/1846352?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0125}
--------

LTA4H is a member of a family of arginyl aminopeptidases (<http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001675>), which also includes aminopeptidase B ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10078](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10078), <http://www.uniprot.org/uniprot/9H4A4>) and aminopeptidase B‐like 1 ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10079](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10079), <http://www.uniprot.org/uniprot/Q9HAU8>). Dipeptidase 1 and 2 are members of a family of membrane dipeptidases, which also includes ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23029), <http://www.uniprot.org/uniprot/Q9H4B8>) for which <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> appears not to be a substrate.

Further reading on Eicosanoid turnover {#bph14752-sec-0126}
--------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=764> {#bph14752-sec-0127}
===========================================================================

Overview {#bph14752-sec-0128}
--------

The inhibitory neurotransmitter γ‐aminobutyrate (GABA, 4‐aminobutyrate) is generated in neurones by glutamic acid decarboxylase. GAD1 and GAD2 are differentially expressed during development, whereGAD2 is thought to subserve a trophic role in early life and is distributed throughout the cytoplasm. GAD1 is expressed in later life and is more associated with nerve terminals \[<http://www.ncbi.nlm.nih.gov/pubmed/8126575?dopt=AbstractPlus>\] where GABA is principally accumulated in vesicles through the action of the vesicular inhibitory amino acid transporter <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=219>. The role of γ‐aminobutyraldehyde dehydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is less clear. Following release from neurons, GABA may interact with either GABA~A~ or GABA~B~ receptors and may be accumulated in neurones and glia through the action of members of the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144>. Successive metabolism through GABA transaminase and succinate semialdehyde dehydrogenase generates succinic acid, which may be further metabolized in the mitochondria in the tricarboxylic acid cycle.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273>Common abbreviationGAD1GAD2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4092](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4092), <http://www.uniprot.org/uniprot/Q99259>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4093](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4093), <http://www.uniprot.org/uniprot/Q05329>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> + H^+^ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> + CO~2~[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.15): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> + H^+^ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> + CO~2~Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309>Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267>Comments<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309> is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating ß‐alanine \[<http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus>\]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2467><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2464><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2466>Common abbreviation--GABA‐TSSADHHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:412](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:412), <http://www.uniprot.org/uniprot/P49189>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23), <http://www.uniprot.org/uniprot/P80404>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:408](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:408), <http://www.uniprot.org/uniprot/P51649>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.19](http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.19): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6606> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487> + H^+^ [http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.47](http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.47): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6604> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6605> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + 2H^+^ [http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.3](http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.3): an aldehyde + H~2~O + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451> = a carboxylate + 2H^+^ + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.19](http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.19): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6608> [http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.22](http://www.genome.jp/dbget‐bin/www_bget?ec:2.6.1.22): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6610> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6611> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.24](http://www.genome.jp/dbget‐bin/www_bget?ec:1.2.1.24): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6608> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487> + 2H^+^ 4‐hydroxy‐trans‐2‐nonenal + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451> + H~2~O = 4‐hydroxy‐trans‐2‐nonenoate + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487> + 2H^+^Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451> \[<http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus>\]Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4821> (Irreversible inhibition) (p*K* ~i~ 3.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/856582?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22168767?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8841> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16290145?dopt=AbstractPlus>\]

Further reading on GABA turnover {#bph14752-sec-0129}
--------------------------------

Koenig MK *et al*. (2017) Phenotype of GABA‐transaminase deficiency. *Neurology* **88**: 1919--1924 <https://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=AbstractPlus>

Lee H *et al*. (2015) Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs. *Med Res Rev* **35**: 286--305 <https://www.ncbi.nlm.nih.gov/pubmed/25145640?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244> {#bph14752-sec-0130}
===========================================================================

Overview {#bph14752-sec-0131}
--------

Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=274> {#bph14752-sec-0132}
===========================================================================

Overview {#bph14752-sec-0133}
--------

Phosphoinositide‐specific phospholipase C (PLC, EC 3.1.4.11), catalyses the hydrolysis of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> to <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> and 1,2‐diacylglycerol, each of which have major second messenger functions. Two domains, X and Y, essential for catalytic activity, are conserved in the different forms of PLC. Isoforms of PLC‐ß are activated primarily by G protein‐coupled receptors through members of the G~q/11~ family of G proteins. The receptor‐mediated activation of PLC‐γ involves their phosphorylation by <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304> in response to activation of a variety of growth factor receptors and immune system receptors. PLC‐ ∈1 may represent a point of convergence of signalling via both G protein‐coupled and catalytic receptors. Ca^2+^ ions are required for catalytic activity of PLC isoforms and have been suggested to be the major physiological form of regulation of PLC‐δ activity. PLC has been suggested to be activated non‐selectively by the small molecule <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5097> \[<http://www.ncbi.nlm.nih.gov/pubmed/12695532?dopt=AbstractPlus>\], although this mechanism of action has been questioned \[<http://www.ncbi.nlm.nih.gov/pubmed/15302681?dopt=AbstractPlus>\]. The aminosteroid <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5283> has been described as an inhibitor of phosphoinositide‐specific PLC \[<http://www.ncbi.nlm.nih.gov/pubmed/2338654?dopt=AbstractPlus>\], although its selectivity among the isoforms is untested and it has been reported to occupy the H1 histamine receptor \[<http://www.ncbi.nlm.nih.gov/pubmed/11138848?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1403><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1404><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1405><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1406>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:15917](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:15917), <http://www.uniprot.org/uniprot/Q9NQ66>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9055](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9055), <http://www.uniprot.org/uniprot/Q00722>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9056](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9056), <http://www.uniprot.org/uniprot/Q01970>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9059](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9059), <http://www.uniprot.org/uniprot/Q15147>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11): 1‐phosphatidyl‐1D‐*myo*‐inositol 4,5‐bisphosphate + H~2~O = 1D‐*myo*‐inositol 1,4,5‐trisphosphate + diacylglycerolEndogenous activatorsGαq, Gα11, Gßγ \[<http://www.ncbi.nlm.nih.gov/pubmed/8314796?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1846707?dopt=AbstractPlus>\]Gα16, Gßγ, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251>, <http://www.uniprot.org/uniprot/P15153>) \[<http://www.ncbi.nlm.nih.gov/pubmed/1465133?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12441352?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12509427?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus>\]Gαq, Gßγ \[<http://www.ncbi.nlm.nih.gov/pubmed/8380773?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus>\]Gαq \[<http://www.ncbi.nlm.nih.gov/pubmed/8454637?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1407><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1408><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1409><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1410><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1411>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9065](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9065), <http://www.uniprot.org/uniprot/P19174>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9066](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9066), <http://www.uniprot.org/uniprot/P16885>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9060](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9060), <http://www.uniprot.org/uniprot/P51178>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9061](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9061), <http://www.uniprot.org/uniprot/Q8N3E9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9062](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9062), <http://www.uniprot.org/uniprot/Q9BRC7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11): 1‐phosphatidyl‐1D‐*myo*‐inositol 4,5‐bisphosphate + H~2~O = 1D‐*myo*‐inositol 1,4,5‐trisphosphate + diacylglycerolEndogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353> \[<http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5250> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5250>, <http://www.uniprot.org/uniprot/P63000>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251> (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251>, <http://www.uniprot.org/uniprot/P15153>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5252> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9803](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9803), <http://www.uniprot.org/uniprot/P60763>) \[<http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16172125?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18728011?dopt=AbstractPlus>\]Transglutaminase II, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5237> {Rat}, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710>, Gßγ \[<http://www.ncbi.nlm.nih.gov/pubmed/1654825?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/7835339?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/10518533?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus>\]----Endogenous inhibitors----Sphingomyelin \[<http://www.ncbi.nlm.nih.gov/pubmed/1497353?dopt=AbstractPlus>\]----Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8820> (pIC~50~ 5.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/19303309?dopt=AbstractPlus>\]------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1412><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1413><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1414><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1415>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17175](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17175), <http://www.uniprot.org/uniprot/Q9P212>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19218](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19218), <http://www.uniprot.org/uniprot/Q86YW0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29185](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29185), <http://www.uniprot.org/uniprot/Q4KWH8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29037](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29037), <http://www.uniprot.org/uniprot/O75038>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.11): 1‐phosphatidyl‐1D‐*myo*‐inositol 4,5‐bisphosphate + H~2~O = 1D‐myo‐inositol 1,4,5‐trisphosphate + diacylglycerolEndogenous activatorsRas, rho \[<http://www.ncbi.nlm.nih.gov/pubmed/11022048?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/14993441?dopt=AbstractPlus>\]----Gßγ \[<http://www.ncbi.nlm.nih.gov/pubmed/16107206?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0134}
--------

A series of PLC‐like proteins ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9063](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9063), <http://www.uniprot.org/uniprot/Q15111>; [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9064](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9064), <http://www.uniprot.org/uniprot/Q9UPR0> and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:29185](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:29185), <http://www.uniprot.org/uniprot/Q4KWH8>) form a family with PLCδ and PLCζ1 isoforms, but appear to lack catalytic activity. PLC‐δ2 has been cloned from bovine sources \[<http://www.ncbi.nlm.nih.gov/pubmed/1848183?dopt=AbstractPlus>\].

Further reading on Phosphoinositide‐specific phospholipase C {#bph14752-sec-0135}
------------------------------------------------------------

Cocco L *et al*. (2015) Phosphoinositide‐specific phospholipase C in health and disease. *J. Lipid Res*.**56**: 1853--60 <https://www.ncbi.nlm.nih.gov/pubmed/25821234?dopt=AbstractPlus>

Cockcroft S *et al*. (2016) Topological organisation of the phosphatidylinositol 4,5‐bisphosphatephospholipase C resynthesis cycle: PITPs bridge the ER‐PM gap. *Biochem. J*. **473**: 4289--4310 <https://www.ncbi.nlm.nih.gov/pubmed/27888240?dopt=AbstractPlus>

Litosch I. (2015) Regulating G protein activity by lipase‐independent functions of phospholipase C. *Life Sci*. **137**: 116--24 <https://www.ncbi.nlm.nih.gov/pubmed/26239437?dopt=AbstractPlus>

Nakamura Y *et al*. (2017) Regulation and physiological functions of mammalian phospholipase C. *J. Biochem*. **161**: 315--321 <https://www.ncbi.nlm.nih.gov/pubmed/28130414?dopt=AbstractPlus>

Swann K *et al*. (2016) The sperm phospholipase C‐ζ and Ca2+ signalling at fertilization in mammals. *Biochem. Soc. Trans*. **44**: 267--72 <https://www.ncbi.nlm.nih.gov/pubmed/26862214?dopt=AbstractPlus>

[http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244\#Phospholipase A2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244#PhospholipaseA2) {#bph14752-sec-0136}
========================================================================================================================================================================================

Overview {#bph14752-sec-0137}
--------

Phospholipase A~2~ (PLA~2~, EC 3.1.1.4) cleaves the *sn*‐2 fatty acid of phospholipids, primarily phosphatidylcholine, to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391>. Most commonly‐used inhibitors (*e.g*. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5149>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5142> or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5218>) are either non‐selective within the family of phospholipase A~2~ enzymes or have activity against other eicosanoid‐metabolising enzymes.

Secreted or extracellular forms {#bph14752-sec-0138}
-------------------------------

sPLA~2~‐1B, sPLA~2~‐2A, sPLA~2~‐2D, sPLA~2~‐2E, sPLA~2~‐2F, sPLA~2~‐3, sPLA~2~‐10 and sPLA~2~‐12A

Cytosolic, calcium‐dependent forms {#bph14752-sec-0139}
----------------------------------

cPLA~2~‐4A, cPLA~2~‐4B, cPLA~2~‐4C, cPLA~2~‐4D, cPLA~2~‐4E and cPLA~2~‐4F

Other forms {#bph14752-sec-0140}
-----------

PLA~2~‐G5, iPLA~2~‐G6, PLA~2~‐G7 and PAFAH2 (platelet‐activating factor acetylhydrolase 2)

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1416><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1417><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1418><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1419><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1420><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1421>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9030](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9030), <http://www.uniprot.org/uniprot/P04054>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9031](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9031), <http://www.uniprot.org/uniprot/P14555>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9033](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9033), <http://www.uniprot.org/uniprot/Q9UNK4>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13414](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13414), <http://www.uniprot.org/uniprot/Q9NZK7>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30040](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30040), <http://www.uniprot.org/uniprot/Q9BZM2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17934](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17934), <http://www.uniprot.org/uniprot/Q9NZ20>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8764> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/8809154?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus>\]--Comments------------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1424><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1425><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1426><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1427><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1428><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1429>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9035](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9035), <http://www.uniprot.org/uniprot/P47712>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9036](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9036), <http://www.uniprot.org/uniprot/P0C869>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9037](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9037), <http://www.uniprot.org/uniprot/Q9UP65>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:30038](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:30038), <http://www.uniprot.org/uniprot/Q86XP0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:24791](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:24791), <http://www.uniprot.org/uniprot/Q3MJ16>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:27396](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:27396), <http://www.uniprot.org/uniprot/Q68DD2>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8771> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/16610804?dopt=AbstractPlus>\]----------CommentscPLA~2~‐4A also expresses lysophospholipase ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.1.5](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.1.5)) activity \[<http://www.ncbi.nlm.nih.gov/pubmed/8083230?dopt=AbstractPlus>\].----------

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1430><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1431><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1422><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1423><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2508>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9038](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9038), <http://www.uniprot.org/uniprot/P39877>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9039](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9039), <http://www.uniprot.org/uniprot/O60733>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9040](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9040), <http://www.uniprot.org/uniprot/Q13093>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9029](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9029), <http://www.uniprot.org/uniprot/O15496>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18554](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18554), <http://www.uniprot.org/uniprot/Q9BZM1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8579](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8579), <http://www.uniprot.org/uniprot/Q99487>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.47](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.47)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6696> (pIC~50~ 10) \[<http://www.ncbi.nlm.nih.gov/pubmed/12643913?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8787> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18605714?dopt=AbstractPlus>\]----Selective inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7376> (Competitive) (pIC~50~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/19667981?dopt=AbstractPlus>\]------Comments----------PAFAH2 also expresses PAF hydrolase activity (EC 3.1.1.47)

Comments {#bph14752-sec-0141}
--------

The sequence of PLA~2~‐2C suggests a lack of catalytic activity, while PLA~2~‐12B (GXIIB, GXIII sPLA~2~‐like) appears to be catalytically inactive \[<http://www.ncbi.nlm.nih.gov/pubmed/14516201?dopt=AbstractPlus>\]. A further fragment has been identified with sequence similarities to Group II PLA~2~ members. Otoconin 90 (OC90) shows sequence homology to PLA~2~‐G10.

A binding protein for secretory phospholipase A~2~ has been identified which shows modest selectivity for sPLA~2~‐1B over sPLA~2~‐2A, and also binds snake toxin phospholipase A~2~ \[<http://www.ncbi.nlm.nih.gov/pubmed/7548076?dopt=AbstractPlus>\]. The binding protein appears to have clearance function for circulating secretory phospholipase A~2~, as well as signalling functions, and is a candidate antigen for idiopathic membraneous nephropathy \[<http://www.ncbi.nlm.nih.gov/pubmed/19571279?dopt=AbstractPlus>\].

PLA~2~‐G7 and PAFAH2 also express platelet‐activating factor acetylhydrolase activity ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.1.47](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.1.47)).

Further reading on Phospholipase A~2~ {#bph14752-sec-0142}
-------------------------------------

Astudillo AM. (2019) Selectivity of phospholipid hydrolysis by phospholipase A2 enzymes in activated cells leading to polyunsaturated fatty acid mobilization. *Biochim Biophys Acta Mol Cell Biol Lipids* **1864**: 772--783 <https://www.ncbi.nlm.nih.gov/pubmed/30010011>

Kita Y *etal*. (2019) Cytosolic phospholipase A2 and lysophospholipid acyltransferases. *Biochim Biophys Acta Mol Cell Biol Lipids* **1864**: 838--845 <https://www.ncbi.nlm.nih.gov/pubmed/30905348>

Mouchlis VD and Dennis EA. (2019) Phospholipase A2 catalysis and lipid. mediator lipidomics. *Biochim Biophys Acta Mol Cell Biol Lipids* **1864**: 766--771 <https://www.ncbi.nlm.nih.gov/pubmed/30905345>

Murakami M *et al*. (2019) Group IID, IIE, IIF and III secreted phospholipase A2s. *Biochim Biophys Acta Mol Cell Biol Lipids*. **1864**: 803--818 <https://www.ncbi.nlm.nih.gov/pubmed/30905347>

Samuchiwal SK and Balestrieri B. (2019) Harmful and protective roles of group V phospholipase A2: Current perspectives and future directions. *Biochim Biophys Acta Mol Cell Biol Lipids* **1864**: 819--826 <https://www.ncbi.nlm.nih.gov/pubmed/30308324>

Shayman JA and Tesmer JJG. (2019) Lysosomal phospholipase A2. *Biochim Biophys Acta Mol Cell Biol Lipids*. **1864**: 932--940 <https://www.ncbi.nlm.nih.gov/pubmed/30077006>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=276> {#bph14752-sec-0143}
===========================================================================

Overview {#bph14752-sec-0144}
--------

Phosphatidylcholine‐specific phospholipase D (PLD, EC 3.1.4.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols, such as butanol in a transphosphatidylation reaction \[<http://www.ncbi.nlm.nih.gov/pubmed/2186929?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1433><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1434>HGNC, UniProt<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1433>, <http://www.uniprot.org/uniprot/Q13393><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1434>, <http://www.uniprot.org/uniprot/O14939>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.4.4) A phosphatidylcholine + H~2~O \<=\> choline + a phosphatidateEndogenous activators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5305> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:652](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:652), <http://www.uniprot.org/uniprot/P84077>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387>, RhoA, PKC evoked phosphorylation, RalA \[<http://www.ncbi.nlm.nih.gov/pubmed/9013646?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9207251?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5305> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:652](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:652), <http://www.uniprot.org/uniprot/P84077>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> \[<http://www.ncbi.nlm.nih.gov/pubmed/9582313?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054> \[<http://www.ncbi.nlm.nih.gov/pubmed/12374567?dopt=AbstractPlus>\]Endogenous inhibitorsGßγ \[<http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus>\]Gßγ \[<http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8781> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/19136975?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8782> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19136975?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5287> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20735042?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0145}
--------

A lysophospholipase D activity ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3357](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3357), <http://www.uniprot.org/uniprot/Q13822>, also known as ectonucleotide pyrophosphatase/ phosphodiesterase 2, phosphodiesterase I, nucleotide pyrophosphatase 2, autotaxin) has been described, which not only catalyses the production of lysophosphatidic acid (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906>) from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508>, but also cleaves <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> (see Goding *et al*., 2003 \[<http://www.ncbi.nlm.nih.gov/pubmed/12757929?dopt=AbstractPlus>\]). Additionally, an N‐acylethanolaminespecific phospholipase D ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21683](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21683), <http://www.uniprot.org/uniprot/Q6IQ20>) has been characterized, which appears to have a role in the generation of <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273>/endovanilloids, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364> \[<http://www.ncbi.nlm.nih.gov/pubmed/14634025?dopt=AbstractPlus>\]. This enzyme activity appears to be enhanced by polyamines in the physiological range \[<http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus>\] and fails to transphosphatidylate with alcohols \[<http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus>\].

Three further, less well‐characterised isoforms are PLD3 ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17158](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17158), <http://www.uniprot.org/uniprot/Q8IV08>, other names Choline phosphatase 3, HindIII K4L homolog, Hu‐K4), PLD4 ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23792](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23792), <http://www.uniprot.org/uniprot/Q96BZ4>, other names Choline phosphatase 4, Phosphatidylcholine‐hydrolyzing phospholipase, D4C14orf175 UNQ2488/PRO5775) and PLD5 ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:26879](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:26879), <http://www.uniprot.org/uniprot/Q8N7P1>). PLD3 has been reported to be involved in myogenesis \[<http://www.ncbi.nlm.nih.gov/pubmed/22428023?dopt=AbstractPlus>\]. PLD4 is described not to have phospholipase D catalytic activity \[<http://www.ncbi.nlm.nih.gov/pubmed/21085684?dopt=AbstractPlus>\], but has been associated with inflammatory disorders \[<http://www.ncbi.nlm.nih.gov/pubmed/22446963?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23577190?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23124809?dopt=AbstractPlus>\]. Sequence analysis suggests that PLD5 is catalytically inactive.

Further reading on Phosphatidylcholine‐specific phospholipase D {#bph14752-sec-0146}
---------------------------------------------------------------

Brown HA *et al*. (2017) Targeting phospholipase D in cancer, infection and neurodegenerative disorders. *Nat Rev Drug Discov* **16**: 351‐367 <https://www.ncbi.nlm.nih.gov/pubmed/28209987?dopt=AbstractPlus>

Frohman MA. (2015) The phospholipase D superfamily as therapeutic targets. *Trends Pharmacol. Sci*. **36**: 137‐44 <https://www.ncbi.nlm.nih.gov/pubmed/25661257?dopt=AbstractPlus>

Nelson RK *et al*. (2015) Physiological and pathophysiological roles for phospholipase D. *J. Lipid Res*. **56**: 2229‐37 <https://www.ncbi.nlm.nih.gov/pubmed/25926691?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=277> {#bph14752-sec-0147}
===========================================================================

Overview {#bph14752-sec-0148}
--------

Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5‐trisphosphate 3‐phosphatase which acts as a tumour suppressor by reducing cellular levels of PI 3,4,5‐P, thereby toning down activity of PDK1 and PKB. Loss‐of‐function mutations are frequently identified as somatic mutations in cancers.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1435><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1436><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1437><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1438><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1439><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1440><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2497>Common abbreviation------------PTENHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:13345](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13345), <http://www.uniprot.org/uniprot/Q14693>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14450](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14450), <http://www.uniprot.org/uniprot/Q92539>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14451](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14451), <http://www.uniprot.org/uniprot/Q9BQK8>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9228](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9228), <http://www.uniprot.org/uniprot/O14494>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9229](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9229), <http://www.uniprot.org/uniprot/O14495>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9230](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9230), <http://www.uniprot.org/uniprot/O43688>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9588](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9588), <http://www.uniprot.org/uniprot/P60484>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.67](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.67) [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.48](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.48) [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.16](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.16)Substrates--phosphatidic acid----phosphatidic acid--phosphatidylinositol (3,4,5)‐trisphosphate

Further reading on Lipid phosphate phosphatases {#bph14752-sec-0149}
-----------------------------------------------

Knafo S and Esteban JA. (2017) PTEN: Local and Global Modulation of Neuronal Function in Health and Disease. *Trends Neurosci* **40**: 83‐91 <https://www.ncbi.nlm.nih.gov/pubmed/28081942>

Lee YR *et al*. (2018) The functions and regulation of the PTEN tumour suppressor: new modes and prospects. *Nat Rev Mol Cell Biol* **19**: 547‐562 <https://www.ncbi.nlm.nih.gov/pubmed/29858604>

Yehia L *et al*. (2019) PTEN‐opathies: from biological insights to evidence‐based precision medicine. *J Clin Invest* **129**: 452‐464 <https://www.ncbi.nlm.nih.gov/pubmed/30614812>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=781> {#bph14752-sec-0150}
===========================================================================

Overview {#bph14752-sec-0151}
--------

Phosphatidylinositol may be phosphorylated at either 3‐ or 4‐ positions on the inositol ring by PI 3‐kinases or PI 4‐kinases, respectively.

Phosphatidylinositol 3‐kinases {#bph14752-sec-0152}
------------------------------

Phosphatidylinositol 3‐kinases (PI3K, provisional nomenclature) catalyse the introduction of a phosphate into the 3‐position of phosphatidylinositol (PI), phosphatidylinositol 4‐phosphate (PIP) or phosphatidylinositol 4,5‐bisphosphate (PIP~2~). There is evidence that PI3K can also phosphorylate serine/threonine residues on proteins. In addition to the classes described below, further serine/threonine protein kinases, including [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:795](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:795) (<http://www.uniprot.org/uniprot/Q13315>) and [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3942](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3942) (<http://www.uniprot.org/uniprot/P42345>), have been described to phosphorylate phosphatidylinositol and have been termed PI3Krelated kinases. Structurally, PI3Ks have common motifs of at least one C2, calcium‐binding domain and helical domains, alongside structurally‐conserved catalytic domains. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6004> are widely‐used inhibitors of PI3K activities. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060> is irreversible and shows modest selectivity between Class I and Class II PI3K, while LY294002 is reversible and selective for Class I compared to Class II PI3K.

**Class I PI3Ks** (EC 2.7.1.153) phosphorylate phosphatidylinositol 4,5‐bisphosphate to generate phosphatidylinositol 3,4,5‐trisphosphate and are heterodimeric, matching catalytic and regulatory subunits. Class IA PI3Ks include p110α, p110ß and p110δ catalytic subunits, with predominantly p85 and p55 regulatory subunits. The single catalytic subunit that forms Class IB PI3K is p110γ. Class IA PI3Ks are more associated with receptor tyrosine kinase pathways, while the Class IB PI3K is linkedmore with GPCR signalling.

**Class II PI3Ks** (EC 2.7.1.154) phosphorylate phosphatidylinositol to generate phosphatidylinositol 3‐phosphate (and possibly phosphatidylinositol 4‐phosphate to generate phosphatidylinositol 3,4‐bisphosphate). Three monomeric members exist, PI3KC2α, ß and ß, and include Ras‐binding, Phox homology and two C2domains.

The only **class III PI3K** isoform (EC 2.7.1.137) is a heterodimer formed of a catalytic subunit (VPS34) and regulatory subunit (VPS15).

**Phosphatidylinositol 4‐kinases**

Phosphatidylinositol 4‐kinases (EC 2.7.1.67) generate phosphatidylinositol 4‐phosphate and may be divided into higher molecular weight type III and lower molecular weight type II forms.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=638> {#bph14752-sec-0153}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2148><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2149>Common abbreviationPI4KIIIα/PIK4CAPI4KIIIß/PIK4CBHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8983](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8983), <http://www.uniprot.org/uniprot/P42356>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8984](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8984), <http://www.uniprot.org/uniprot/Q9UBF8>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67)Endogenous activation--PKD‐mediated phosphorylation \[<http://www.ncbi.nlm.nih.gov/pubmed/16100512?dopt=AbstractPlus>\]Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060> (pIC~50~ 6.7--6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060> (pIC~50~ 6.7--6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus>\]Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6062> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18077555?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=671> {#bph14752-sec-0154}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288>Common abbreviationC2α/PIK3C2AC2ß/PIK3C2BC2γ/PIK3C2GHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8971](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8971), <http://www.uniprot.org/uniprot/O00443>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8972](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8972), <http://www.uniprot.org/uniprot/O00750>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8973](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8973), <http://www.uniprot.org/uniprot/O75747>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8839> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21322566?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=672> {#bph14752-sec-0155}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2152>Common abbreviationVPS34HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8974](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8974), <http://www.uniprot.org/uniprot/Q8NEB9>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.137](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.137)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=673> {#bph14752-sec-0156}
===========================================================================

Overview {#bph14752-sec-0157}
--------

PI3K activation is one of the most important signal transduction pathways used to transmit signals from cell‐surface receptors to regulate intracellular processes (cell growth, survival, proliferation and movement). PI3K catalytic (and regulatory) subunits play vital roles in normal cell function and in disease. Progress made in developing PI3K‐targeted agents as potential therapeutics for treating cancer and other diseases is reviewed by Fruman *et al*. (2017) \[<http://www.ncbi.nlm.nih.gov/pubmed/28802037?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2153><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154>Common abbreviationPI3KαPI3KßHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8975](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8975), <http://www.uniprot.org/uniprot/P42336>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8976](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8976), <http://www.uniprot.org/uniprot/P42338>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153) [http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012> (pIC~50~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940> (pIC~50~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936> (p*K* ~i~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011> (pIC~50~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/22906130?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965> (pIC~50~ 7.4--7.8) \[665, <http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus>\]Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9826> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900173?dopt=AbstractPlus>\]--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155>Common abbreviationPI3KγPI3KδHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8978](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8978), <http://www.uniprot.org/uniprot/P48736>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8977](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8977), <http://www.uniprot.org/uniprot/O00329>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965> (pIC~50~ 7.3--7.3) \[665, <http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17685602?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011> (pIC~50~ \> 10) \[<http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741> (*in vitro* activity against recombinant enzyme) (pIC~50~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/20959606?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965> (pIC~50~ 8.2--8.3) \[665, <http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus>\]Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=913> {#bph14752-sec-0158}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2857>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23785](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23785), <http://www.uniprot.org/uniprot/Q9Y2I7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.150](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.150): ATP + 1‐phosphatidyl‐1D‐myo‐inositol 3‐phosphate = ADP + 1‐phosphatidyl‐1D‐myo‐inositol 3,5‐bisphosphate

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=675> {#bph14752-sec-0159}
===========================================================================

Overview {#bph14752-sec-0160}
--------

Type I PIP kinases are required for the production of the second messenger phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(4)P \[<http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus>\]. This enzyme family is also known as type I PIP(5)Ks.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2164><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2165>Common abbreviationPIP5K1APIP5K1CHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8994](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8994), <http://www.uniprot.org/uniprot/Q99755>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8996](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8996), <http://www.uniprot.org/uniprot/O60331>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8444> \[<http://www.ncbi.nlm.nih.gov/pubmed/25071204?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=674> {#bph14752-sec-0161}
===========================================================================

Overview {#bph14752-sec-0162}
--------

Type II PIP kinases are essential for the production of the second messenger phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(5)P \[<http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus>\]. This enzyme family is also known as type II PIP(5)Ks.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2858><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2162><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2163>Common abbreviationPIP4K2APIP4K2BPIP4K2CHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8997](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8997), <http://www.uniprot.org/uniprot/P48426>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8998](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8998), <http://www.uniprot.org/uniprot/P78356>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23786](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23786), <http://www.uniprot.org/uniprot/Q8TBX8>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149) ATP + 1‐phosphatidyl‐1D‐*myo*‐inositol 5‐phosphate \<=\> ADP + 1‐phosphatidyl‐1D‐*myo*‐inositol 4,5‐bisphosphate[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=787> {#bph14752-sec-0163}
===========================================================================

Overview {#bph14752-sec-0164}
--------

SPHK1 and SPHK2 are encoded by different genes with some redundancy of function; genetic deletion of both Sphk1 and Sphk2, but not either alone, is embryonic lethal in mice. There are splice variants of each isoform (SphK1a‐c and SphK2a, b), distinguished by their N‐terminal sequences. SPHK1 and SPHK2 differ in tissue distribution, sub‐cellular localisation, biochemical properties and regulation. They regulate discrete pools of S1P. Receptor stimulation induces SPHK1 translocation from the cytoplasm to the plasma membrane. SPHK1 translocation is regulated by phosphorylation/dephosphorylation, specific protein:protein interactions and interaction with specific lipids at the plasma membrane. SPHK1 is a dimeric protein, as confirmed by its crystal structure which forms a positive cluster, between protomers, essential for interaction with anionic phospholipids in the plasma membrane. SPHK2 is localised to the ER or associated with mitochondria or shuttles in/out of the nucleus, regulated by phosphorylation. Intracellular targets of nuclear S1P include the catalytic subunit of telomerase (TERT) and regulators of gene expression including histone deacetylases (HDAC 1/2) and peroxisome proliferator‐activated receptor gamma (PPARγ). SPHK2 phosphorylates the pro‐drug FTY720 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407>, which is used to treat some forms of multiple sclerosis) to a mimic of S1P and that acts as a functional antagonist of S1P~1~ receptors. Inhibitors of SPHK1 and SPHK2 have therapeutic potential in many diseases.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205>Common abbreviationSPHK1SPHK2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11240](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11240), <http://www.uniprot.org/uniprot/Q9NYA1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18859](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18859), <http://www.uniprot.org/uniprot/Q9NRA0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> dihydrosphingosine + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> dihydrosphingosine + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> \[<http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041> (p*K* ~i~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219> (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219> (p*K* ~i~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22970244?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6623> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10217> (p*K* ~i~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/28406646?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10218> (pIC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/28231433?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624> (p*K* ~i~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6625> (p*K* ~i~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus>\]CommentsSK1 inhibitors induce its proteasomal degradation \[<http://www.ncbi.nlm.nih.gov/pubmed/20926375?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus>\]. SK1 crystal structures confirm that it is dimeric \[<http://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus>\]; there is no crystal structure available for SK2.There is no crystal structure available for SK2.

Comments {#bph14752-sec-0165}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219> is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624>) has known off‐target effects on dihydroceramide desaturase (*DEGS1*) \[<http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26494858?dopt=AbstractPlus>\]) and induces proteasomal degradation of SK1 \[<http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus>\]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma (to view ClinicalTrials.gov list click <https://clinicaltrials.gov/ct2/results?cond=&term=ABC294640>).

Further reading on Sphingosine kinase {#bph14752-sec-0166}
-------------------------------------

Adams DR *et al*. (2016) Sphingosine Kinases: Emerging Structure‐Function Insights. *Trends Biochem. Sci*. **41**: 395‐409 <https://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus>

Lynch KR *et al*. (2016) Sphingosine kinase inhibitors: a review of patent literature (2006‐2015). *Expert Opin Ther Pat* **26**: 1409‐1416 <https://www.ncbi.nlm.nih.gov/pubmed/27539678?dopt=AbstractPlus>

Pitman MR *et al*. (2016) Recent advances in the development of sphingosine kinase inhibitors. *Cell. Signal*. **28**: 1349‐63 <https://www.ncbi.nlm.nih.gov/pubmed/27297359?dopt=AbstractPlus>

Pulkoski‐Gross MJ *et al*. (2018) An intrinsic lipid‐binding interface controls sphingosine kinase 1 function. *J. Lipid Res*. **59**: 462‐474 <https://www.ncbi.nlm.nih.gov/pubmed/29326159?dopt=AbstractPlus>

Pyne NJ *et al*. (2017) Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. *Trends Pharmacol. Sci*. **38**: 581‐591 <https://www.ncbi.nlm.nih.gov/pubmed/28606480?dopt=AbstractPlus>

Pyne S *et al*. (2018) Sphingosine Kinases as Druggable Targets. *Handb Exp Pharmacol* <https://www.ncbi.nlm.nih.gov/pubmed/29460151?dopt=AbstractPlus>

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2499><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2152>Common abbreviationPI3KγPI4KIIß/PI4K2BPI3KδC2α/PIK3C2AC2ß/PIK3C2BC2γ/PIK3C2GVPS34HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8978](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8978), <http://www.uniprot.org/uniprot/P48736>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18215](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18215), <http://www.uniprot.org/uniprot/Q8TCG2>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8977](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8977), <http://www.uniprot.org/uniprot/O00329>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8971](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8971), <http://www.uniprot.org/uniprot/O00443>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8972](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8972), <http://www.uniprot.org/uniprot/O00750>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8973](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8973), <http://www.uniprot.org/uniprot/O75747>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8974](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8974), <http://www.uniprot.org/uniprot/Q8NEB9>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.67)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.153)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.154)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.137](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.137)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965> (pIC~50~ 7.3--7.3) \[[651](#bph14752-bib-0664){ref-type="ref"}, <http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/17685602?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011> (pIC~50~ 6.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011> (pIC~50~ \> 10) \[<http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741> (*in vitro* activity against recombinant enzyme) (pIC~50~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/20959606?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965> (pIC~50~ 8.2--8.3) \[[651](#bph14752-bib-0664){ref-type="ref"}, <http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8839> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/21322566?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus>\]----Sub/family‐selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682> (pIC~50~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844> (pIC~50~ 4.5--5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21704602?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus>\]--------Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus>\]------------

Comments {#bph14752-sec-0167}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060> also inhibits type III phosphatidylinositol 4‐kinases and polo‐like kinase \[<http://www.ncbi.nlm.nih.gov/pubmed/15664519?dopt=AbstractPlus>\]. PIK93 also inhibits PI 3‐kinases \[<http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus>\]. Adenosine activates <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=3>.

Further reading on Phosphatidylinositol kinases {#bph14752-sec-0168}
-----------------------------------------------

Raphael J *et al*. (2018) Phosphoinositide 3‐kinase inhibitors in advanced breast cancer: A systematic review and meta‐analysis. *Eur J Cancer* **91**: 38‐46 <https://www.ncbi.nlm.nih.gov/pubmed/29331750>

Wang D *et al*. (2019) Upstream regulators of phosphoinositide 3‐kinase and their role in diseases. *J Cell Physiol*. <https://www.ncbi.nlm.nih.gov/pubmed/30710358>

Goncalves MD *et al*. (2018) Phosphatidylinositol 3‐Kinase, Growth Disorders, and Cancer. *N Engl J Med* **379**: 2052‐2062 <https://www.ncbi.nlm.nih.gov/pubmed/30462943>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=782> {#bph14752-sec-0169}
===========================================================================

Overview {#bph14752-sec-0170}
--------

PIP~2~ is generated by phosphorylation of PI 4‐phosphate or PI 5‐phosphate by type I PI 4‐phosphate 5‐kinases or type II PI 5‐phosphate 4‐kinases.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2164><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2500><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2165><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2858><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2162><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2163>Common abbreviationPIP5K1APIP5K1BPIP5K1CPIP4K2APIP4K2BPIP4K2CHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8994](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8994), <http://www.uniprot.org/uniprot/Q99755>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8995](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8995), <http://www.uniprot.org/uniprot/O14986>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8996](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8996), <http://www.uniprot.org/uniprot/O60331>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8997](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8997), <http://www.uniprot.org/uniprot/P48426>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8998](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8998), <http://www.uniprot.org/uniprot/P78356>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23786](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23786), <http://www.uniprot.org/uniprot/Q8TBX8>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.68)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149) ATP + 1‐phosphatidyl‐1D‐*myo*‐inositol 5‐phosphate \<=\> ADP + 1‐phosphatidyl‐1D‐*myo*‐inositol 4,5‐bisphosphate[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.149)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8444> \[<http://www.ncbi.nlm.nih.gov/pubmed/25071204?dopt=AbstractPlus>\]----------

Further reading on Glycerophospholipid turnover {#bph14752-sec-0171}
-----------------------------------------------

Cauvin C *et al*. (2015) Phosphoinositides: Lipids with informative heads and mastermind functions in cell division. *Biochim. Biophys. Acta* **1851**: 832‐43 <https://www.ncbi.nlm.nih.gov/pubmed/25449648?dopt=AbstractPlus>

Irvine RF. (2016) A short history of inositol lipids. *J. Lipid Res*. **57**: 1987‐1994 <https://www.ncbi.nlm.nih.gov/pubmed/27623846?dopt=AbstractPlus>

Poli A *et al*. (2016) Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. *J. Cell. Physiol*. **231**: 1645‐55 <https://www.ncbi.nlm.nih.gov/pubmed/26626942?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=278> {#bph14752-sec-0172}
===========================================================================

Overview {#bph14752-sec-0173}
--------

Haem oxygenase (heme,hydrogen‐donor:oxygen oxidoreductase (α‐methene‐oxidizing, hydroxylating)), [http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.14.99.3](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=1.14.99.3), converts <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349> into <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5153> and carbonmonoxide, utilizing <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> as cofactor.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1441><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1442>Common abbreviationHO1HO2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5013](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5013), <http://www.uniprot.org/uniprot/P09601>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5014](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5014), <http://www.uniprot.org/uniprot/P30519>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.18](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.18) Protoheme + 3 \[reduced NADPH‐hemoprotein reductase\] + 3 O(2) \<=\> biliverdin + Fe(2+) + CO + 3 \[oxidized NADPH‐hemoprotein reductase\] + 3 H(2)O[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.18](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.14.18) Protoheme + 3 \[reduced NADPH--hemoprotein reductase\] + 3 O(2) \<=\> biliverdin + Fe(2+) + CO + 3 \[oxidized NADPH--hemoprotein reductase\] + 3 H(2)OInhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8873> (pIC~50~ 3.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/16821802?dopt=AbstractPlus>\] -- Rat

Comments {#bph14752-sec-0174}
--------

The existence of a third non‐catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene \[<http://www.ncbi.nlm.nih.gov/pubmed/15246535?dopt=AbstractPlus>\]. The chemical <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5279> acts as a haem oxygenase inhibitor in rat liver with an IC~50~ value of 11 nM \[<http://www.ncbi.nlm.nih.gov/pubmed/6947237?dopt=AbstractPlus>\].

Further reading on Haem oxygenase {#bph14752-sec-0175}
---------------------------------

Magierowska K *et al*. (2018) Emerging role of carbon monoxide in regulation of cellular pathways and in the maintenance of gastric mucosal integrity. *Pharmacol Res* **129**: 56‐64 <https://www.ncbi.nlm.nih.gov/pubmed/29360501>

Rochette L *et al*. (2018) Redox Functions of Heme Oxygenase‐1 and Biliverdin Reductase in Diabetes Trends. *Endocrinol Metab*. **29**: 74‐85 <https://www.ncbi.nlm.nih.gov/pubmed/29249571>

Salerno L *et al*. (2017) Heme oxygenase‐1: A new druggable target in the management of chronic and acute myeloid leukemia. *Eur J Med Chem*. **142**: 163‐178 <https://www.ncbi.nlm.nih.gov/pubmed/28756878>

Sebastian VP *et al*. (2018) Heme Oxygenase‐1 as a Modulator of Intestinal Inflammation Development and Progression. *Front Immunol*. **9**: 1956 <https://www.ncbi.nlm.nih.gov/pubmed/30258436>

Tomczyk M *et al*. (2019) Modulation of the monocyte/macrophage system in heart failure by targeting heme oxygenase‐1. *Vascul Pharmacol*. **112**: 79‐90 <https://www.ncbi.nlm.nih.gov/pubmed/30213580>

Vijayan V *et al*. (2018) The macrophage heme‐heme oxygenase‐1 system and its role in inflammation. *Biochem Pharmacol*. **153**: 159‐167 <https://www.ncbi.nlm.nih.gov/pubmed/29452096>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=279> {#bph14752-sec-0176}
===========================================================================

Overview {#bph14752-sec-0177}
--------

Hydrogen sulfide is a gasotransmitter, with similarities to nitric oxide and carbon monoxide. Although the enzymes indicated below have multiple enzymatic activities, the focus here is the generation of hydrogen sulphide (H~2~S) and the enzymatic characteristics are described accordingly. Cystathionine β‐synthase (CBS) and cystathionine γ‐lyase (CSE) are pyridoxal phosphate (PLP)‐dependent enzymes. 3‐mercaptopyruvate sulfurtransferase (3‐MPST) functions to generate H~2~S; only CAT is PLP‐dependent, while 3‐MPST is not. Thus, this third pathway is sometimes referred to as PLP‐independent. CBS and CSE are predominantly cytosolic enzymes, while 3‐MPST is found both in the cytosol and the mitochondria. For an authoritative review on the pharmacological modulation of H~2~S levels, see Szabo and Papapetropoulos, 2017 \[<http://www.ncbi.nlm.nih.gov/pubmed/28978633?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1443><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1444><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1445><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1446>Common abbreviationCBSCSECATMPSTHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1550](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1550), <http://www.uniprot.org/uniprot/P35520>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2501](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2501), <http://www.uniprot.org/uniprot/P32929>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1564](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1564), <http://www.uniprot.org/uniprot/Q16773>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7223](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7223), <http://www.uniprot.org/uniprot/P25325>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.22](http://www.genome.jp/dbget‐bin/www_bget?ec:4.2.1.22)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.13](http://www.genome.jp/dbget‐bin/www_bget?ec:4.4.1.13)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.8.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.8.1.2)Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782> (*K* ~m~ 6×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/15520012?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5198> \[<http://www.ncbi.nlm.nih.gov/pubmed/15520012?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5118> (*K* ~m~ 1.2×10^‐3^M) \[<http://www.ncbi.nlm.nih.gov/pubmed/7608189?dopt=AbstractPlus>\]Products<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5173>NH~3~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>NH~3~, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5136> (pIC~50~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8860> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5136> (pIC~50~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8859> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5247> (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10210> (pIC~50~ 5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/28079151?dopt=AbstractPlus>\]

Further reading on Hydrogen sulphide synthesis {#bph14752-sec-0178}
----------------------------------------------

Asimakopoulou A *et al*. (2013) Selectivity of commonly used pharmacological inhibitors for cystathionine β synthase (CBS) and cystathionine γ lyase (CSE). *Br J Pharmacol*. **169**: 922‐32 <https://www.ncbi.nlm.nih.gov/pubmed/23488457?dopt=AbstractPlus>

Szabo C *et al*. (2017) International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors. *Pharmacol. Rev*. **69**: 497‐564 <https://www.ncbi.nlm.nih.gov/pubmed/28978633?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=799> {#bph14752-sec-0179}
===========================================================================

Overview {#bph14752-sec-0180}
--------

Listed in this section are hydrolases not accumulated in other parts of the Concise Guide, such as monoacylglycerol lipase and acetylcholinesterase. Pancreatic lipase is the predominant mechanism of fat digestion in the alimentary system; its inhibition is associated with decreased fat absorption. CES1 is present at lower levels in the gut than CES2 (<http://www.uniprot.org/uniprot/P23141>), but predominates in the liver, where it is responsible for the hydrolysis of many aliphatic, aromatic and steroid esters. Hormone‐sensitive lipase is also a relatively non‐selective esterase associated with steroid ester hydrolysis and triglyceride metabolism, particularly in adipose tissue. Endothelial lipase is secreted from endothelial cells and regulates circulating cholesterol in high density lipoproteins.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2590><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2593><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2591><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2888><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2889>Systematic nomenclature--------CD39CD39L1Common abbreviationPNLIPLIPELIPGCES1NTPDase‐1NTPDase‐2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9155](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9155), <http://www.uniprot.org/uniprot/P16233>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6621](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6621), <http://www.uniprot.org/uniprot/Q05469>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6623](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6623), <http://www.uniprot.org/uniprot/Q9Y5X9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1863](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1863), <http://www.uniprot.org/uniprot/P23141>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3363](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3363), <http://www.uniprot.org/uniprot/P49961>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3364](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3364), <http://www.uniprot.org/uniprot/Q9Y5L3>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.3](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.3)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.79](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.79)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.3](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.3)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.6.1.5](http://www.genome.jp/dbget‐bin/www_bget?ec:3.6.1.5) Hydrolyzes NTPs to nucleotide monophosphates (NMPs): A nucleoside 5′‐triphosphate + 2 H~2~O \<=\> a nucleoside 5′‐phosphate + 2 phosphate[http://www.genome.jp/dbget‐bin/www_bget?ec:3.6.1.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.6.1.‐) Hydrolyzes extracellular nucleotide 5′‐triphosphates: NTP\>NMP + 2 phosphateInhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277> (pIC~50~ 8.9) \[[66](#bph14752-bib-0066){ref-type="ref"}\]----------Selective inhibitors----------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9033> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18630897?dopt=AbstractPlus>\]Comments--------ENTPD1 sequentially converts extracellular purine nucleotides (ATP and ADP) to the monophosphate form. Adenosine is then generated by the action of <http://www.guidetopharmacology.org/GRAC/guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232> (CD73). ENTPD1 is the rate‐limiting step. Extracellular ATP acts as a damage‐associated molecular pattern (DAMP) that activates innate immune cells through adenosine‐induced activation of P2X and P2Y purinogenic receptors.--

Further reading on Hydrolases {#bph14752-sec-0181}
-----------------------------

Allard B *et al*.. (2017) The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunol Rev*. **276**: 121‐144 <https://www.ncbi.nlm.nih.gov/pubmed/28258700>

Kishore BK *et al*. (2018) CD39‐adenosinergic axis in renal pathophysiology and therapeutics. *Purinergic Signal* **14**: 109‐120 <https://www.ncbi.nlm.nih.gov/pubmed/29332180>

Rasmussen HB *et al*. (2018) Carboxylesterase 1 genes: systematic review and evaluation of existing genotyping procedures. *Drug Metab Pers Ther* **33**: 3‐14 <https://www.ncbi.nlm.nih.gov/pubmed/29427553>

Zou LW *et al*. (2018) Carboxylesterase Inhibitors: An Update. *Curr Med Chem*. **25**: 1627‐1649 <https://www.ncbi.nlm.nih.gov/pubmed/29210644>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=245> {#bph14752-sec-0182}
===========================================================================

Overview {#bph14752-sec-0183}
--------

The sugar alcohol D‐*myo*‐inositol is a component of the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244>, where the principal second messenger is inositol 1,4,5‐trisphosphate, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222>, which acts at intracellular ligand‐gated ion channels, <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=123> to elevate intracellular calcium. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> is recycled to inositol by phosphatases or phosphorylated to form other active inositol polyphosphates. Inositol produced from dephosphorylation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> is recycled into membrane phospholipid under the influence of phosphatidyinositol synthase activity (CDP‐diacylglycerol‐inositol 3‐phosphatidyltransferase \[[http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.8.11](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.8.11)\]).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=280> {#bph14752-sec-0184}
===========================================================================

Overview {#bph14752-sec-0185}
--------

Inositol 1,4,5‐trisphosphate 3‐kinases ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.1.127](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.1.127), <http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001260>) catalyse the generation of inositol 1,3,4,5‐tetrakisphosphate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5202>) from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222>. IP~3~ kinase activity is enhanced in the presence of calcium/<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1442](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1442) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1445](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1445) [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1449](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1449), <http://www.uniprot.org/uniprot/P62158>) \[<http://www.ncbi.nlm.nih.gov/pubmed/2559811?dopt=AbstractPlus>\].

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=280>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=281> {#bph14752-sec-0186}
===========================================================================

Overview {#bph14752-sec-0187}
--------

Members of this family exhibit phosphatase activity towards IP~3~, as well as towards other inositol derivatives, including the phospholipids <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353>. With <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> as substrate, 1‐phosphatase ([http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.57](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.57)) generates <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5119>, 4‐phosphatases ([http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.66](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.66), <http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001432>) generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5099> and 5‐phosphatases ([http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.36](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.36) or [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.56](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.56)) generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5098>.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=281>.

Comments {#bph14752-sec-0188}
--------

*In vitro* analysis suggested <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5202> were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353> were more efficiently hydrolysed \[<http://www.ncbi.nlm.nih.gov/pubmed/15474001?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=282> {#bph14752-sec-0189}
===========================================================================

Overview {#bph14752-sec-0190}
--------

Inositol monophosphatase ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.3.25](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.1.3.25), IMPase, *myo*‐inositol‐1(or 4)‐phosphate phosphohydrolase) is a magnesium‐dependent homodimer which hydrolyses myoinositol monophosphate to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495> and phosphate. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5195> may be a physiological phosphate acceptor. <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212> is a nonselective un‐competitive inhibitor more potent at IMPase 1 (*p*K~i~ *ca*. 3.5, \[<http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus>\]; *p*IC~50~ 3.2, \[<http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus>\]) than IMPase 2 (*p*IC~50~ 1.8‐2.1, \[<http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus>\]). IMPase activity may be inhibited competitively by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5208> (*p*K~i~ 5.5, \[<http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus>\]), although the enzyme selectivity is not yet established.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1463><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1464>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6050](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6050), <http://www.uniprot.org/uniprot/P29218>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6051](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6051), <http://www.uniprot.org/uniprot/O14732>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.25](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.25)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.25](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.25)Rank order of affinity<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5205> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5204> \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5203> \[<http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus>\]--Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212> (p*K* ~i~ 3.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus>\]--

Comments {#bph14752-sec-0191}
--------

Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder \[<http://www.ncbi.nlm.nih.gov/pubmed/10822345?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9339367?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9322233?dopt=AbstractPlus>\]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears to mimic the effects of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212> in mice \[<http://www.ncbi.nlm.nih.gov/pubmed/16841073?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17460611?dopt=AbstractPlus>\].

Further reading on Inositol phosphate turnover {#bph14752-sec-0192}
----------------------------------------------

Irvine R. (2016) A tale of two inositol trisphosphates. *Biochem. Soc. Trans*. **44**: 202‐11 <https://www.ncbi.nlm.nih.gov/pubmed/26862207?dopt=AbstractPlus>

Livermore TM *et al*. (2016) Phosphate, inositol and polyphosphates. *Biochem. Soc. Trans*. **44**: 253‐9 <https://www.ncbi.nlm.nih.gov/pubmed/26862212?dopt=AbstractPlus>

Miyamoto A *et al*. (2017) Probes for manipulating and monitoring IP_3. *Cell Calcium* **64**: 57‐64 <https://www.ncbi.nlm.nih.gov/pubmed/27887748?dopt=AbstractPlus>

Windhorst S *et al*. (2017) Inositol‐1,4,5‐trisphosphate 3‐kinase‐A (ITPKA) is frequently over‐expressed and functions as an oncogene in several tumor types. *Biochem. Pharmacol*. **137**: 1‐9 <https://www.ncbi.nlm.nih.gov/pubmed/28377279?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=698> {#bph14752-sec-0193}
===========================================================================

Overview {#bph14752-sec-0194}
--------

Protein kinases ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.11.1](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=2.7.11.1)) use the co‐substrate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> to phosphorylate serine and/or threonine residues on target proteins. Analysis of the human genome suggests the presence of 518 protein kinases in man (divided into 15 subfamilies), with over 100 protein kinase‐like pseudogenes \[<http://www.ncbi.nlm.nih.gov/pubmed/12471243?dopt=AbstractPlus>\]. It is beyond the scope of the Concise Guide to list all these protein kinase activities, but full listings are available on the 'Detailed page' provided for each enzyme.

Most inhibitors of these enzymes have been assessed in cell‐free investigations and so may appear to 'lose' potency and selectivity in intact cell assays. In particular, ambient <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> concentrations may be influential in responses to inhibitors, since the majority are directed at the ATP binding site \[<http://www.ncbi.nlm.nih.gov/pubmed/10998351?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=289> {#bph14752-sec-0195}
===========================================================================

Overview {#bph14752-sec-0196}
--------

Rho kinase (also known as P160ROCK, Rho‐activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:681](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:681) (<http://www.uniprot.org/uniprot/Q92888>, p115‐RhoGEF), which in turn may be activated by Gα~12/13~ subunits \[<http://www.ncbi.nlm.nih.gov/pubmed/9641915?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504>Systematic nomenclatureROCK1ROCK2Common abbreviationRho kinase 1Rho kinase 2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10251](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10251), <http://www.uniprot.org/uniprot/Q13464>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10252](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10252), <http://www.uniprot.org/uniprot/O75116>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152> (pIC~50~ \>9) \[<http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290> (pIC~50~ 5.9--7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181> (p*K* ~i~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290> (p*K* ~i~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181> (pIC~50~ 5.5--5.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152> (pIC~50~ \>9) \[<http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8197> (pIC~50~ \>9) \[[95](#bph14752-bib-0096){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8184> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/20471253?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8205> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290> (pIC~50~ 6.3--7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290> (p*K* ~i~ 6.8--6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181> (pIC~50~ 5.9--5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19597037?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037> (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus>\]--

Further reading on Rho kinase {#bph14752-sec-0197}
-----------------------------

Feng Y *et al*. (2016) Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. *J. Med. Chem*. **59**: 2269‐300 <https://www.ncbi.nlm.nih.gov/pubmed/26486225?dopt=AbstractPlus>

Nishioka T *et al*. (2015) Developing novel methods to search for substrates of protein kinases such as Rho‐kinase. *Biochim. Biophys. Acta* **1854**: 1663‐6 <https://www.ncbi.nlm.nih.gov/pubmed/25770685?dopt=AbstractPlus>

Shimokawa H *et al*. (2016) RhoA/Rho‐Kinase in the Cardiovascular System. *Circ. Res*. **118**: 352‐66 <https://www.ncbi.nlm.nih.gov/pubmed/26838319?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=286> {#bph14752-sec-0198}
===========================================================================

Overview {#bph14752-sec-0199}
--------

Protein kinase C is the target for the tumour‐promoting phorbol esters, such as tetradecanoyl‐β‐phorbol acetate (TPA, also known as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2341>).

*Classical protein kinase C isoforms:* **PKC**α, **PKC**β, and **PKC**γ are activated by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707> and diacylglycerol, and may be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5193>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5156>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5259>.

*Novel protein kinase C isoforms:* **PKC** *δ*, **PKC** *∈*, **PKC** *η*, **PKC** *ϑ* and **PKC** *μ* are activated by diacylglycerol and may be inhibited by <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5156>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953>.

*Atypical protein kinase C isoforms:* **PKC** *ι*, **PKC** *ζ*.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=532> {#bph14752-sec-0200}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1483><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1484>Common abbreviationPKCβPKCγHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9395](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9395), <http://www.uniprot.org/uniprot/P05771>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9402](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9402), <http://www.uniprot.org/uniprot/P05129>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5193> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/1874734?dopt=AbstractPlus>\] -- Bovine, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192> (pIC~50~ 8.2) \[z<http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5263> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8709095?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/12749884?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5163> (pIC~50~ 6.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9121494?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=533> {#bph14752-sec-0201}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1482><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1485>Common abbreviationPKCαPKC*δ*HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9393](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9393), <http://www.uniprot.org/uniprot/P17252>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9399](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9399), <http://www.uniprot.org/uniprot/Q05655>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13)Activators--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7443> (p*K* ~i~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/15126366?dopt=AbstractPlus>\]Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=534> {#bph14752-sec-0202}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1486>Common abbreviationPKC*∈*HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9401](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9401), <http://www.uniprot.org/uniprot/Q02156>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.13)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus>\]

Further reading on Protein kinase C (PKC) family {#bph14752-sec-0203}
================================================

Igumenova TI. (2015) Dynamics and Membrane Interactions of Protein Kinase C. *Biochemistry* **54**: 4953‐68 <https://www.ncbi.nlm.nih.gov/pubmed/26214365?dopt=AbstractPlus>

Newton AC *et al*. (2017) Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. *Trends Pharmacol. Sci*. **38**: 438‐447 <https://www.ncbi.nlm.nih.gov/pubmed/28283201?dopt=AbstractPlus>

Salzer E *et al*. (2016) Protein Kinase C δ: a Gatekeeper of Immune Homeostasis. *J. Clin. Immunol*. **36**: 631‐40 <https://www.ncbi.nlm.nih.gov/pubmed/27541826?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=529> {#bph14752-sec-0204}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109>Common abbreviationmTORHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3942](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3942), <http://www.uniprot.org/uniprot/P42345>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7884> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21482695?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8004> (pIC~50~ 9.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20860370?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933> (p*K* ~i~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940> (pIC~50~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7973> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/23394126?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936> (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888> (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5889> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9723437?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5704> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5892> (pIC~50~ 5.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21438579?dopt=AbstractPlus>\]

Further reading on FRAP subfamily {#bph14752-sec-0205}
=================================

Hukelmann JL *et al*. (2016) The cytotoxic T cell proteome and its shaping by the kinase mTOR. *Nat. Immunol*. **1**7: 104‐12 <https://www.ncbi.nlm.nih.gov/pubmed/26551880?dopt=AbstractPlus>

Saxton RA *et al*. (2017) mTOR Signaling in Growth, Metabolism, and Disease. *Cell* **169**: 361‐371 <https://www.ncbi.nlm.nih.gov/pubmed/28388417?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=453> {#bph14752-sec-0206}
===========================================================================

Overview {#bph14752-sec-0207}
--------

Five of the cyclin‐dependent kinases (CDKs: 7, 8, 9, 12, and 13) are involved in the phosphorylation of serine residues in the C‐terminal domain of RNA polymerase II, the enzyme that is responsible for the transcription of protein‐coding genes into mRNA in eukaryotes. Phosphorylation of RNA polymerase II at Ser5 is essential for transcriptional initiation, and phosphorylation of Ser 2 contributes to transcriptional elongation and termination. All five of the C‐terminal domain kinases can phosphorylate Ser5, but only CDK9, CDK12, and CDK13 can phosphorylate at Ser2 \[<http://www.ncbi.nlm.nih.gov/pubmed/24879308?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/22512864?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25561469?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=488> {#bph14752-sec-0208}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1976><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1978>Common abbreviationCDK4CDK6HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1773](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1773), <http://www.uniprot.org/uniprot/P11802>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1777](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1777), <http://www.uniprot.org/uniprot/Q00534>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.22](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.22)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.22](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.22)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5707> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17121911?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8203> (pIC~50~ 7.7) \[[144](#bph14752-bib-0145){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934> (pIC~50~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17363486?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5680> (p*K* ~i~ 7.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8674031?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus>\]

Comments on Cyclin‐dependent kinase (CDK) family {#bph14752-sec-0209}
------------------------------------------------

The development of CDK inhibitors as anticancer drugs is reviewed in \[<http://www.ncbi.nlm.nih.gov/pubmed/26115571?dopt=AbstractPlus>\], with detailed content covering CDK4 and CDK6 inhibitors that are under clinical evaluation. Data produced by Jorda et al. (2018) highlights the caution that must be used when deploying commercially available CDK inhibitors as pharmacological probes \[<http://www.ncbi.nlm.nih.gov/pubmed/30234987?dopt=AbstractPlus>\], as most of them are more promiscuous in their selectivity than indicated. To make their findings easily accessible the Jorda data is hosted on the <http://rustreg.upol.cz/CDKiDB/>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=509> {#bph14752-sec-0210}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030>Common abbreviationGSK3BHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4617](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4617), <http://www.uniprot.org/uniprot/P49841>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.26](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.26)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8016> (pIC~50~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7958> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/15267232?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8015> (pIC~50~ \~8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/14698171?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8019> (pIC~50~ \~7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8017> (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/20708937?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8478> (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus>\]CommentsDue to its Tau phosphorylating activity, small molecule inhibitors of GSK‐3β are being investigated as potential treatments for Alzheimer\'s disease (AD) \[<http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus>\]. GSK‐3β also plays a role in canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised that small molecule inhibitors of GSK‐3β may provide effective therapeutics for the treatment of diseases characterised by low bone mass \[<http://www.ncbi.nlm.nih.gov/pubmed/22142634?dopt=AbstractPlus>\].

Further reading on GSK subfamily {#bph14752-sec-0211}
--------------------------------

Beurel E *et al*. (2015) Glycogen synthase kinase‐3 (GSK3): regulation, actions, and diseases. *Pharmacol. Ther*. **148**: 114‐31 <https://www.ncbi.nlm.nih.gov/pubmed/25435019?dopt=AbstractPlus>

Domoto T *et al*. (2016) Glycogen synthase kinase‐3β is a pivotal mediator of cancer invasion and resistance to therapy. *Cancer Sci*. **107**: 1363‐1372 <https://www.ncbi.nlm.nih.gov/pubmed/27486911?dopt=AbstractPlus>

Khan I *et al*. (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. *Eur J Med Chem* **125**: 464‐477 <https://www.ncbi.nlm.nih.gov/pubmed/27689729?dopt=AbstractPlus>

Maqbool M *et al*. (2016) Pivotal role of glycogen synthase kinase‐3: A therapeutic target for Alzheimer\'s disease. *Eur J Med Chem* **107**: 63‐81 <https://www.ncbi.nlm.nih.gov/pubmed/26562543?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=602> {#bph14752-sec-0212}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2171>Common abbreviationPLK4HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11397](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11397), <http://www.uniprot.org/uniprot/O00444>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.21](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.21)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8063> (β 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25043604?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=623> {#bph14752-sec-0213}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2062><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063>Common abbreviationMEK1MEK2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6840](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6840), <http://www.uniprot.org/uniprot/Q02750>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6842](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6842), <http://www.uniprot.org/uniprot/P36507>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.12.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.12.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.12.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.12.2)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495> (pIC~50~ 9--9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/21245089?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7935> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23474388?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus>\]Allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921> (Negative) (pIC~50~ 7.9) \[[468](#bph14752-bib-0476){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942> (Negative) (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5676> (Negative) (p*K* ~d~ 6.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921> (Negative) (pIC~50~ 7.9) \[[468](#bph14752-bib-0476){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942> (Negative) (pIC~50~ 7.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus>\]Selective allosteric modulators<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7626> (Negative) (pIC~50~ 9.1) \[[500](#bph14752-bib-0508){ref-type="ref"}\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=553> {#bph14752-sec-0214}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1923>Common abbreviationAblHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:76](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:76), <http://www.uniprot.org/uniprot/P00519>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8170> (pIC~50~ 9.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21561767?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678> (pIC~50~ 9.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/23279183?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8147> (pIC~50~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/23441572?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5699> (p*K* ~d~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/12543790?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5699> (pIC~50~ \~8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/12154025?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906> (pIC~50~ 7.6--8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/16105974?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/20513156?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15930265?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8065> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/20072125?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=554> {#bph14752-sec-0215}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2246>Common abbreviationAckHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19297](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19297), <http://www.uniprot.org/uniprot/Q07912>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8193> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17280833?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=581> {#bph14752-sec-0216}
===========================================================================

Overview {#bph14752-sec-0217}
--------

Janus kinases (JAKs) are a fam.ily of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). They are essential for cytokine signalling and are strongly linked to both cancer and inflammatory diseases.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2269>Common abbreviationJAK1JAK2JAK3Tyk2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6190](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6190), <http://www.uniprot.org/uniprot/P23458>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6192](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6192), <http://www.uniprot.org/uniprot/O60674>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6193](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6193), <http://www.uniprot.org/uniprot/P52333>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12440](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12440), <http://www.uniprot.org/uniprot/P29597>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688> (pIC~50~ 8.5--10.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23061660?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/20130243?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/24006460?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839> (pIC~50~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22829185?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7954> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22015772?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7971> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/23127890?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/21106455?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18394554?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/23584399?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus>\]--Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8123> (pIC~50~ \>9) \[<http://www.ncbi.nlm.nih.gov/pubmed/21493067?dopt=AbstractPlus>\]----Comments--The JAK2^V617F^ mutation, which causes constitutive activation, plays an oncogenic role in the pathogenesis of the myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis \[<http://www.ncbi.nlm.nih.gov/pubmed/17151367?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/17131059?dopt=AbstractPlus>\]. Small molecule compounds which inhibit aberrant JAK2 activity are being developed as novel anti‐cancer pharmaceuticals.----

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=619> {#bph14752-sec-0218}
===========================================================================

Overview {#bph14752-sec-0219}
--------

Activation of Src‐family kinases leads to both stimulatory and inhibitory signaling responses, with cell‐specific and signaling pathway‐specific outcomes and redundancy of kinase function.

Immune system {#bph14752-sec-0220}
-------------

In immune cells Src kinases are involved in many signalling pathways, including ITAM‐ and ITIM‐domain‐containing receptor signaling, integrin signaling, and responses to chemokines/chemoattractants, cytokines, innate immune stimuli and a large variety of non‐immune cell specific stimuli (UV irradiation, heat, osmotic shock *etc*.). In many cases Src kinases signal to MAP kinase or NF‐κB pathways, but they can also modulate other pathways through less well characterized mechanisms.

The primary T cell Src kinases are Lck and Fyn; the main B cell Srcs are Lyn, Fyn and Blk. Mast cells express Fyn and Lyn, with low expression of Src.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1940><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2025><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2026><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2060><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206>Common abbreviationBlkFRKFynLynSrcHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1057](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1057), <http://www.uniprot.org/uniprot/P51451>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3955](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3955), <http://www.uniprot.org/uniprot/P42685>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4037](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4037), <http://www.uniprot.org/uniprot/P06241>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6735](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6735), <http://www.uniprot.org/uniprot/P07948>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11283](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11283), <http://www.uniprot.org/uniprot/P12931>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)Inhibitors----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8836> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/8557675?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8068> (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16884310?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183> (p*K* ~i~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/9400019?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19320489?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=629> {#bph14752-sec-0221}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1942><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2268>Common abbreviationEtkBtkTXKHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1079](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1079), <http://www.uniprot.org/uniprot/P51813>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1133](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1133), <http://www.uniprot.org/uniprot/Q06187>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12434](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12434), <http://www.uniprot.org/uniprot/P42681>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.10.2)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8145> (pIC~50~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912> (pIC~50~ 9.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22394077?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8148> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912> (pIC~50~ 9.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/17154430?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8148> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8145> (pIC~50~ \>8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9269> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/23594111?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8066> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/21113169?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9516> (Irreversible inhibition) (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/28352114?dopt=AbstractPlus>\]--

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=610> {#bph14752-sec-0222}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184>Common abbreviationB‐Rafc‐RafHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1097](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1097), <http://www.uniprot.org/uniprot/P15056>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9829](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9829), <http://www.uniprot.org/uniprot/P04049>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.11.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5681> (pIC~50~ 9.7--9.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18676143?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494> (pIC~50~ 8.5) \[[337](#bph14752-bib-0344){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5891> (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/22222036?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893> (pIC~50~ 7) \[<http://www.ncbi.nlm.nih.gov/pubmed/22808911?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5703> (p*K* ~d~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8548> (p*K* ~d~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/26061392?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5674> (p*K* ~d~ 5.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus>\]--Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8072> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/15255937?dopt=AbstractPlus>\]

Further reading on Kinases (EC 2.7.x.x) {#bph14752-sec-0223}
---------------------------------------

Eglen R *et al*. (2011) Drug discovery and the human kinome: recent trends. *Pharmacol. Ther*. **130**: 144‐56 <https://www.ncbi.nlm.nih.gov/pubmed/21256157?dopt=AbstractPlus>

Graves LM *et al*. (2013) The dynamic nature of the kinome. *Biochem. J*. **450**: 1‐8 <https://www.ncbi.nlm.nih.gov/pubmed/23343193?dopt=AbstractPlus>

Liu Q *et al*. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. *Chem. Biol*. **20**: 146‐59 <https://www.ncbi.nlm.nih.gov/pubmed/23438744?dopt=AbstractPlus>

Martin KJ *et al*. (2012) Selective kinase inhibitors as tools for neuroscience research. *Neuropharmacology* **63**: 1227--37 <https://www.ncbi.nlm.nih.gov/pubmed/22846224?dopt=AbstractPlus>

Tarrant MK *et al*. (2009) The chemical biology of protein phosphorylation. *Annu. Rev. Biochem*. **78**: 797‐825 <https://www.ncbi.nlm.nih.gov/pubmed/19489734?dopt=AbstractPlus>

Wu‐Zhang AX *et al*. (2013) Protein kinase C pharmacology: refining the toolbox. *Biochem. J*. **452**: 195‐209 <https://www.ncbi.nlm.nih.gov/pubmed/23662807?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=104> {#bph14752-sec-0224}
===========================================================================

Overview {#bph14752-sec-0225}
--------

Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG‐CoA reductase pathway. The first two steps (formation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039> and the mitochondrial generation of <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040>) are also associated with oxidation of fatty acids.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2435><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2436><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=638><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2432>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:93](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:93), <http://www.uniprot.org/uniprot/P24752>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:94](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:94), <http://www.uniprot.org/uniprot/Q9BWD1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5007](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5007), <http://www.uniprot.org/uniprot/Q01581>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5008](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5008), <http://www.uniprot.org/uniprot/P54868>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.9](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.9): 2<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.9](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.1.9) 2<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.3.10](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.3.10): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> + H~2~O+ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.3.10](http://www.genome.jp/dbget‐bin/www_bget?ec:2.3.3.10): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038> + H~2~O+ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044>Comments----HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial (HMGCoA synthase 2) versions; the former associated with <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042> synthesis and the latter with ketogenesis.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5006](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5006), <http://www.uniprot.org/uniprot/P04035>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.34](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.34): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> ‐\><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> Reaction mechanism:: **First step:** (S)‐3‐hydroxy‐3‐methylglutaryl‐CoA + NADPH ‐\> mevaldyl‐CoA + NADP^+^ **Second step:** mevaldyl‐CoA + H2O ‐\>(R)‐mevalonate + NADP^+^Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739> (Competitive) (p*K* ~i~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/6933445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2954> (Competitive) (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2950> (Competitive) (p*K* ~i~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/16128575?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2949> (Competitive) (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2950> (Competitive) (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/15686906?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2955> (Competitive) (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2951> (Competitive) (pIC~50~ 7.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus>\]CommentsHMGCoA reductase is associated with intracellular membranes; enzymatic activity is inhibited by phosphorylation by AMP‐activated kinase. The enzymatic reaction is a three‐step reaction involving the intermediate generation of mevaldehyde‐CoA and mevaldehyde.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=640><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=641><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7530](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7530), <http://www.uniprot.org/uniprot/Q03426>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9141](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9141), <http://www.uniprot.org/uniprot/Q15126>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7529](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7529), <http://www.uniprot.org/uniprot/P53602>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.36](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.36): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3046>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.4.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.4.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3046> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3047>[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.33](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.1.33): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3047> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> + CO~2~ + PO~3~ ^4‐^CommentsMevalonate kinase activity is regulated by the downstream products <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2910> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051> as an example of feedback inhibition.----

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=646><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=647><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:5387](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:5387), <http://www.uniprot.org/uniprot/Q13907>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:23487](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:23487), <http://www.uniprot.org/uniprot/Q9BXS1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4249](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4249), <http://www.uniprot.org/uniprot/O95749>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.3.2](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.3.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049>[http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.3.2](http://www.genome.jp/dbget‐bin/www_bget?ec:5.3.3.2): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.29](http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.29): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> ‐\><http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3052> + diphosphate [http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.10](http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.10): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050> + diphosphate [http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.1): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051> +diphosphate

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=644><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2433><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2434>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3631](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3631), <http://www.uniprot.org/uniprot/P14324>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3629](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3629), <http://www.uniprot.org/uniprot/P37268>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11279](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11279), <http://www.uniprot.org/uniprot/Q14534>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6708](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6708), <http://www.uniprot.org/uniprot/P48449>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.10](http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.10): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050> + diphosphate [http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.1): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051> + diphosphate[http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.21](http://www.genome.jp/dbget‐bin/www_bget?ec:2.5.1.21): 2<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3053> + diphosphate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3053> + NAD(P)H + H^+^ ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3054> + diphosphate + NAD(P)^+^[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.132](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.132): H^+^ + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041> + O~2~ + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3054> = H~2~O + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6551>[http://www.genome.jp/dbget‐bin/www_bget?ec:5.4.99.7](http://www.genome.jp/dbget‐bin/www_bget?ec:5.4.99.7): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6551> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746>Cofactors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041>----Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3176> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3177> (p*K* ~i~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3141> (pIC~50~ 6.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3057> (p*K* ~i~ 10.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/8419946?dopt=AbstractPlus>\] -- Rat, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3057> (pIC~50~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/9473303?dopt=AbstractPlus>\]----Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3059> (p*K* ~i~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7259> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus>\]------

Further reading on Lanosterol biosynthesis pathway {#bph14752-sec-0226}
--------------------------------------------------
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<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=920> {#bph14752-sec-0227}
===========================================================================

Overview {#bph14752-sec-0228}
--------

The *de novo* synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahydrofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2603><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2612><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2604><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2624><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2625><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642>Common abbreviationDHFRGARTDHODHIMPDH1IMPDH2TYMSHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2861](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2861), <http://www.uniprot.org/uniprot/P00374>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4163](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4163), <http://www.uniprot.org/uniprot/P22102>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2867](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2867), <http://www.uniprot.org/uniprot/Q02127>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6052](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6052), <http://www.uniprot.org/uniprot/P20839>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6053](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6053), <http://www.uniprot.org/uniprot/P12268>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12441](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12441), <http://www.uniprot.org/uniprot/P04818>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.5.1.3](http://www.genome.jp/dbget‐bin/www_bget?ec:1.5.1.3)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.2.2](http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.2.2) [http://www.genome.jp/dbget‐bin/www_bget?ec:6.3.3.1](http://www.genome.jp/dbget‐bin/www_bget?ec:6.3.3.1) [http://www.genome.jp/dbget‐bin/www_bget?ec:6.3.4.13](http://www.genome.jp/dbget‐bin/www_bget?ec:6.3.4.13)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.3.5.2](http://www.genome.jp/dbget‐bin/www_bget?ec:1.3.5.2)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.205](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.205)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.205](http://www.genome.jp/dbget‐bin/www_bget?ec:1.1.1.205)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.45](http://www.genome.jp/dbget‐bin/www_bget?ec:2.1.1.45)Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6837> (p*K* ~i~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/9762351?dopt=AbstractPlus>\] -- Mouse<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6844> (p*K* ~i~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/17228860?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6832> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6832> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus>\]--Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4815> (p*K* ~i~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/7877140?dopt=AbstractPlus>\]--------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7403> (pIC~50~ 6.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/22739090?dopt=AbstractPlus>\]

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2841><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2630><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2631><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2754>Common abbreviationPNPXDHribonucleotide reductase M1ribonucleotide reductase M2ribonucleotide reductase M2B (TP53 inducible)HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7892](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7892), <http://www.uniprot.org/uniprot/P00491>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12805](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12805), <http://www.uniprot.org/uniprot/P47989>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10451](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10451), <http://www.uniprot.org/uniprot/P23921>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10452](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10452), <http://www.uniprot.org/uniprot/P31350>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17296](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17296), <http://www.uniprot.org/uniprot/Q7LG56>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.2.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.4.2.1) Purine‐nucleoside phosphorylase: Purine nucleoside + phosphate \<=\> purine + alpha‐D‐ribose 1‐phosphate Purine deoxynucleoside + phosphate \<=\> purine + 2′‐deoxy‐alpha‐D‐ribose 1‐phosphate[http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.1.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.14.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.14.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.4.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.4.1)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.1.4](http://www.genome.jp/dbget‐bin/www_bget?ec:1.17.1.4)Inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6817> (pIC~50~ 8.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/24508129?dopt=AbstractPlus>\]------

Comments {#bph14752-sec-0229}
--------

TYMS allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. PNP allows separation of a nucleoside into the nucleobase and ribose phosphate for nucleotide salvage. XDH generates urate in the purine degradation pathway. Post‐translational modifications of XDH convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species.

Further reading on Nucleoside synthesis and metabolism {#bph14752-sec-0230}
------------------------------------------------------

Day RO *et al*. (2016) Xanthine oxidoreductase and its inhibitors: relevance for gout. *Clin Sci (Lond)*. **130**: 2167--2180 <https://www.ncbi.nlm.nih.gov/pubmed/27798228>

Okafor ON *et al*. (2017) Allopurinol as a therapeutic option in cardiovascular disease. *Pharmacol Ther*. **172**: 139--150 <https://www.ncbi.nlm.nih.gov/pubmed/27916655>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=1018> {#bph14752-sec-0231}
============================================================================

Overview {#bph14752-sec-0232}
--------

Paraoxonases (PON) are calcium‐dependent esterases, whichmay be involved in lipoprotein turnover and the conversion of lactone statin prodrugs, as well as being targets of organophosphates, such as the insecticide paraoxon.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3052><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3053><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3054>Common abbreviationPON1PON2PON3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9204](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9204), <http://www.uniprot.org/uniprot/P27169>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9205](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9205), <http://www.uniprot.org/uniprot/Q15165>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9206](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9206), <http://www.uniprot.org/uniprot/Q15166>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.8.1](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.8.1) An aryl dialkyl phosphate + H(2)O \<=\> dialkyl phosphate + an aryl alcohol [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2) A phenyl acetate + H(2)O \<=\> a phenol + acetate [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81) An N‐acyl‐L‐homoserine lactone + H(2)O \<=\> an N‐acyl‐L‐homoserine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2) A phenyl acetate + H(2)O \<=\> a phenol + acetate [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81) A N‐acyl‐L‐homoserine lactone + H(2)O \<=\> a N‐acyl‐L‐homoserine[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.8.1](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.8.1) An aryl dialkyl phosphate + H(2)O \<=\> dialkyl phosphate + an aryl alcohol [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.2) A phenyl acetate + H(2)O \<=\> a phenol + acetate [http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.1.81) A N‐acyl‐L‐homoserine lactone + H(2)O \<=\> a N‐acyl‐L‐homoserineCommentsPON1 forms homodimers. Loss‐of‐function mutations in PON1 are associated with microvascular complications of diabetes \[<http://www.ncbi.nlm.nih.gov/pubmed/11918623?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/9661650?dopt=AbstractPlus>\].PON2 forms heterotrimers \[<http://www.ncbi.nlm.nih.gov/pubmed/15772423?dopt=AbstractPlus>\].PON3 likely forms heterodimers *in vivo* \[<http://www.ncbi.nlm.nih.gov/pubmed/15772423?dopt=AbstractPlus>\].

Further reading on Paraoxonase {#bph14752-sec-0233}
------------------------------

Dardiotis E *et al*. (2019) Paraoxonase‐1 genetic polymorphisms in organophosphate metabolism. *Toxicology*. **411**: 24--31 <https://www.ncbi.nlm.nih.gov/pubmed/30359673>

Lioudaki S *et al*. (2019) Paraoxonase‐1: Characteristics and Role in Atherosclerosis and Carotid Artery Disease. *Curr Vasc Pharmacol*. **17**: 141--146 <https://www.ncbi.nlm.nih.gov/pubmed/29189170>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=759> {#bph14752-sec-0234}
===========================================================================

Overview {#bph14752-sec-0235}
--------

Peptidases and proteinases hydrolyse peptide bonds, and can be simply divided on the basis of whether terminal peptide bonds are cleaved (exopeptidases and exoproteinases) at the amino terminus (aminopeptidases) or carboxy terminus (carboxypeptidases). Non‐terminal peptide bonds are cleaved by endopeptidases and endoproteinases, which are divided into serine endopeptidases (EC 3.4.21.‐), cysteine endopeptidases (EC 3.4.22.‐), aspartate endopeptidases (EC 3.4.23.‐), metalloendopeptidases (EC 3.4.24.‐) and threonine endopeptidases (EC 3.4.25.‐).

Since it is beyond the scope of the Guide to list all peptidase and proteinase activities, this summary focuses on selected enzymes of significant pharmacological interest that have ligands (mostly small‐molecules) directed against them. For those interested in detailed background we recommend the MEROPS database \[[493](#bph14752-bib-0501){ref-type="ref"}\] (with whom we collaborate) as an information resource \[<http://www.ncbi.nlm.nih.gov/pubmed/26527717?dopt=AbstractPlus>\].

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=726> {#bph14752-sec-0236}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9958](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9958), <http://www.uniprot.org/uniprot/P00797>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.23.15](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.23.15)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4812> (pIC~50~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/18307734?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=727> {#bph14752-sec-0237}
===========================================================================

Overview {#bph14752-sec-0238}
--------

Presenilin (PS)‐1 or ‐2 act as the catalytic component/ essential co‐factor of the γ‐secretase complex responsible for the final carboxy‐terminal cleavage of amyloid precursor protein (APP) \[<http://www.ncbi.nlm.nih.gov/pubmed/2881207?dopt=AbstractPlus>\] in the generation of amyloid beta (Aβ) \[<http://www.ncbi.nlm.nih.gov/pubmed/21115843?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/12660785?dopt=AbstractPlus>\]. Given that the accumulation and aggregation of Aβ in the brain is pivotal in the development of Alzheimer\'s disease (AD), inhibition of PS activity is one mechanism being investigated as a therapeutic option for AD \[<http://www.ncbi.nlm.nih.gov/pubmed/11378516?dopt=AbstractPlus>\]. Several small molecule inhibitors of PS‐1 have been investigated, with some reaching early clinical trials, but none have been formally approved. Dewji *et al*. (2015) have reported that small peptide fragments of human PS‐1 can significantly inhibit Aβ production (total Aβ, Aβ40 and Aβ42) both *in vitro* and when infused in to the brains of APP transgenic mice \[<http://www.ncbi.nlm.nih.gov/pubmed/25923432?dopt=AbstractPlus>\]. The most active small peptides in this report were <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8344> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8345>, from the amino‐terminal domain of PS‐1.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=727>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=734> {#bph14752-sec-0239}
===========================================================================

Overview {#bph14752-sec-0240}
--------

Caspases, ([http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.4.22.‐](http://www.genome.jp/kegg‐bin/search_brite?option=‐a&search_string=3.4.22.‐)) which derive their name from Cysteine ASPartate‐specific proteASES, include at least two families; initiator caspases (caspases 2, 8, 9 and 10), which are able to hydrolyse and activate a second family of effector caspases (caspases 3, 6 and 7), which themselves are able to hydrolyse further cellular proteins to bring about programmed cell death. Caspases are heterotetrameric, being made up of two pairs of subunits, generated by a single gene product, which is proteolysed to form the mature protein. Members of the mammalian inhibitors of apoptosis proteins (IAP) are able to bind the procaspases, thereby preventing maturation to active proteinases.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=734>.

Comments {#bph14752-sec-0241}
--------

CARD16 (Caspase recruitment domain‐containing protein 16, caspase‐1 inhibitor COP, CARD only domain‐containing protein 1, pseudo interleukin‐1β converting enzyme, pseudo‐ICE, [http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204397;r=11:104912053‐104972158](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204397;r=11:104912053‐104972158)) shares sequence similarity with some of the caspases.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=737> {#bph14752-sec-0242}
===========================================================================

Overview {#bph14752-sec-0243}
--------

Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this enzyme family may be monomeric or multi‐subunit complexes, and many are zinc metalloenzymes \[<http://www.ncbi.nlm.nih.gov/pubmed/8440407?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1395>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6710](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6710), <http://www.uniprot.org/uniprot/P09960>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.2.6](http://www.genome.jp/dbget‐bin/www_bget?ec:3.3.2.6)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5151> (p*K* ~i~ 5.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/1846352?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=741> {#bph14752-sec-0244}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1613>Common abbreviationACEHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2707](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2707), <http://www.uniprot.org/uniprot/P12821>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.15.1](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.15.1)Substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10060>Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=583> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:333](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333), <http://www.uniprot.org/uniprot/P01019>) \> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:333](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:333), <http://www.uniprot.org/uniprot/P01019>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6463> (p*K* ~i~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/2836590?dopt=AbstractPlus>\] -- Rabbit, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5158> (pK~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/9187274?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6462>Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6373> (pIC~50~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/17716647?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6461> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/2527528?dopt=AbstractPlus>\] -- Rabbit, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6378> (pIC~50~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/17547476?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7893> (C‐domain assay) (pIC~50~ 8.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/20233165?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7894> (N‐domain selective inhibition) (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22628311?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6457> (pIC~50~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/2481187?dopt=AbstractPlus>\] -- Rabbit, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6332> (pIC~50~ 7.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/7527095?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6375> (pIC~50~ 6.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/17506720?dopt=AbstractPlus>\]CommentsReports of ACE GPI hydrolase activity \[<http://www.ncbi.nlm.nih.gov/pubmed/15665832?dopt=AbstractPlus>\] have been refuted \[<http://www.ncbi.nlm.nih.gov/pubmed/16270062?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=738> {#bph14752-sec-0245}
===========================================================================

Overview {#bph14752-sec-0246}
--------

Matrix metalloproteinases (MMP) are calcium‐ and zinc‐dependent proteinases regulating the extracellular matrix and are often divided (*e.g*. \[<http://www.ncbi.nlm.nih.gov/pubmed/17275314?dopt=AbstractPlus>\]) on functional and structural bases into gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type‐MMP (MT‐MMP).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1629><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1632>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7166](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7166), <http://www.uniprot.org/uniprot/P08253>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7175](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7175), <http://www.uniprot.org/uniprot/P22894>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.24.24](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.24.24)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.24.34](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.24.34)Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5140> \[<http://www.ncbi.nlm.nih.gov/pubmed/16483784?dopt=AbstractPlus>\]--CommentsMMP2 is categorised as a gelatinase with substrate specificity for gelatinase A.MMP8 is categorised as a collagenase.

Comments {#bph14752-sec-0247}
--------

A number of small molecule 'broad spectrum' inhibitors of MMP have been described, including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5220> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5145>.

**Tissue inhibitors of metalloproteinase (TIMP)** proteins are endogenous inhibitors acting to chelate MMP proteins: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5309> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11820](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11820), <http://www.uniprot.org/uniprot/P01033>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5310> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11821](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11821), <http://www.uniprot.org/uniprot/P16035>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5311> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11822](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11822), <http://www.uniprot.org/uniprot/P35625>), <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5312> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11823](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11823), <http://www.uniprot.org/uniprot/Q99727>)

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=739> {#bph14752-sec-0248}
===========================================================================

Overview {#bph14752-sec-0249}
--------

ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell‐surface or transmembrane proteins to generate soluble and membrane‐limited products.

ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell‐surface or transmembrane proteins to generate soluble and membrane‐limited products.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=739>.

Comments {#bph14752-sec-0250}
--------

Additional ADAM family members include AC123767.2 (cDNA FLJ58962, moderately similar tomouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21‐like protein, [http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000235812;r=14:70712470‐70714518](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000235812;r=14:70712470‐70714518)), AC136428.3‐2 (ENSG00000185520) and ADAMDEC1 (decysin 1, [http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134028;r=8:24241798‐24263526](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134028;r=8:24241798‐24263526)).

Other ADAMTS family members include AC104758.12‐5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3‐1 (ENSG00000225577), and AC126339.6‐1 (ENSG00000225734).

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=748> {#bph14752-sec-0251}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3788](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3788), <http://www.uniprot.org/uniprot/Q04609>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.17.21](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.17.21)Antibodies<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878> (Binding)CommentsFolate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N‐acetaspartylglutamate to form N‐acetylaspartate and L‐glutamate (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369>). In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly‐gamma‐glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up‐regulated in cancerous tissue. A tagged version of the antibody <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878> has been used for imaging purposes.

Comments {#bph14752-sec-0252}
--------

Folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N‐acetaspartylglutamate to form N‐acetylaspartate and L‐glutamate. In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly‐gamma‐glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up‐regulated in cancerous tissue. A tagged version of the antibody <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878> has been used for imaging purposes.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=749> {#bph14752-sec-0253}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1393>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3002](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3002), <http://www.uniprot.org/uniprot/P16444>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.13.19): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353> + H~2~O = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5166> (p*K* ~i~ 6) \[<http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=751> {#bph14752-sec-0254}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2334><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1246](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1246), <http://www.uniprot.org/uniprot/P00736>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3535](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3535), <http://www.uniprot.org/uniprot/P00734>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3528](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3528), <http://www.uniprot.org/uniprot/P00742>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.41](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.41)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.5](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.5)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.6](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.6)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> (pIC~50~ 4.9) \[<http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6469> (p*K* ~i~ 13) \[<http://www.ncbi.nlm.nih.gov/pubmed/16363236?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6458> (p*K* ~i~ 12.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/1894196?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7727> (p*K* ~i~ 9.5) \[[21](#bph14752-bib-0021){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6382> (p*K* ~i~ 8.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9459334?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6470> (p*K* ~i~ 8.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/1290488?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6380> (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/11960487?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6385> (p*K* ~i~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/9361377?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6390> (p*K* ~i~ 10.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/18315548?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6388> (p*K* ~i~ 9.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139357?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7575> (p*K* ~i~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/20503967?dopt=AbstractPlus>\]Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8760> (p*K* ~i~ 10.4) \[[192](#bph14752-bib-0196){ref-type="ref"}\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7688> (pIC~50~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/19492147?dopt=AbstractPlus>\]--

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2394><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2392><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2397><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2424>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3309](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3309), <http://www.uniprot.org/uniprot/P08246>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9071](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9071), <http://www.uniprot.org/uniprot/P00747>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9051](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9051), <http://www.uniprot.org/uniprot/P00750>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9475](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9475), <http://www.uniprot.org/uniprot/P07477>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12019](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12019), <http://www.uniprot.org/uniprot/Q15661>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.37](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.37)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.7](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.7)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.68](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.68)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.4](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.4)[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.59](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.21.59)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6476> (p*K* ~i~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21791628?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6441> (pIC~50~ 7.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/21741848?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6570> {Bovine} (Binding) (pIC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6573> (Binding) (pIC~50~ 3.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus>\]--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> (pIC~50~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262> (pIC~50~ 10) \[<http://www.ncbi.nlm.nih.gov/pubmed/12939527?dopt=AbstractPlus>\]Selective inhibitors--<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6574> (Binding) (pIC~50~ 4.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/24900876?dopt=AbstractPlus>\]----<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7863> (pIC~50~ 8.5) \[<http://www.ncbi.nlm.nih.gov/pubmed/11172730?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=752> {#bph14752-sec-0255}
===========================================================================

Overview {#bph14752-sec-0256}
--------

The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex \[<http://www.ncbi.nlm.nih.gov/pubmed/16142822?dopt=AbstractPlus>\]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the cleavage site. The β5 subunit is the principal target of the approved drug proteasome inhibitor <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391>.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2406>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:9542](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:9542), <http://www.uniprot.org/uniprot/P28074>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.25.1](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.25.1)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391> (pIC~50~ 7.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/19428245?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8450> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/20160034?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=755> {#bph14752-sec-0257}
===========================================================================

Overview {#bph14752-sec-0258}
--------

One member of this family has garnered intense interest as a clinical drug target. As liver PCSK9 acts to maintain cholesterol homeostasis, it has become a target of intense interest for clinical drug development. Inhibition of PCSK9 can lower low‐density cholesterol (LDL‐C) by clearing LDLR‐bound LDL particles, thereby lowering circulating cholesterol levels. It is hypothesised that this action may improve outcomes in patients with atherosclerotic cardiovascular disease \[<http://www.ncbi.nlm.nih.gov/pubmed/18836590?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25083925?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19506257?dopt=AbstractPlus>\]. Therapeutics which inhibit PCSK9 are viewed as potentially lucrative replacements for statins, upon statin patent expiry. Several monoclonal antibodies including <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6744>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7343>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7730>, RG‐7652 and LY3015014 are under development. One RNAi therapeutic, code named ALN‐PCS02, is also in development \[<http://www.ncbi.nlm.nih.gov/pubmed/24145894?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24094767?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/18695239?dopt=AbstractPlus>\].

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=755>.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=758> {#bph14752-sec-0259}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3009](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3009), <http://www.uniprot.org/uniprot/P27487>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.14.5](http://www.genome.jp/dbget‐bin/www_bget?ec:3.4.14.5)Endogenous substrates<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194> ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4191](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4191), <http://www.uniprot.org/uniprot/P01275>)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6316> (p*K* ~i~ 9.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6318> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/18052023?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6286> (pIC~50~ 8.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/20927248?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6310> (p*K* ~i~ 7.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9627> (Competitive) (p*K* ~i~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/28452143?dopt=AbstractPlus>\]

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=883> {#bph14752-sec-0260}
===========================================================================

Overview {#bph14752-sec-0261}
--------

The Poly ADP‐ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in DNA, allowing the recruitment of repair enzymes by the synthesis of NAD‐derived ADP‐ribose polymers, which are subsequently degraded by a glycohydrolase ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:8605](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:8605), <http://www.uniprot.org/uniprot/Q86W56>).

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2772><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2864>Common abbreviationPARP1PARP2PARP3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:270](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:270), <http://www.uniprot.org/uniprot/P09874>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:272](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:272), <http://www.uniprot.org/uniprot/Q9UGN5>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:273](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:273), <http://www.uniprot.org/uniprot/Q9Y6F1>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.2.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.2.30)[http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.2.30](http://www.genome.jp/dbget‐bin/www_bget?ec:2.4.2.30)--

Further reading on Poly ADP‐ribose polymerases {#bph14752-sec-0262}
----------------------------------------------

Berger NA *et al*. (2018) Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases. *Br J Pharmacol*. **175**: 192‐222 <https://www.ncbi.nlm.nih.gov/pubmed/28213892>

Faraoni I *et al*. (2019) Targeting ADP‐ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders. *Biochem Pharmacol* <https://www.ncbi.nlm.nih.gov/pubmed/31028744>

Zeniou M *et al*. (2019) Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond. *Biochem Pharmacol* <https://www.ncbi.nlm.nih.gov/pubmed/31202733>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=900> {#bph14752-sec-0263}
===========================================================================

Overview {#bph14752-sec-0264}
--------

Hypoxia‐inducible factors (HIFs) are rapidly‐responding sensors of reductions in local oxygen tensions, prompting changes in gene transcription. Listed here are the 4‐prolyl hydroxylase family, members of which have been identified to hydroxylate proline residues in HIF1α ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:4910](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:4910); <https://www.uniprot.org/uniprot/Q16665>) leading to an increased degradation through proteasomal hydrolysis. This action requires molecular oxygen and 2‐oxoglutarate, and so reduced oxygen tensions prevents HIF1α hydroxylation, allowing its translocation to the nucleus and dimerisation with HIF1β (also known as [https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:700](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:700); <https://www.uniprot.org/uniprot/P27540>), thereby allowing interaction with the genome as a transcription factor.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2832><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2833><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2834>Common abbreviationPHD1PHD2PHD3HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14660](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14660), <http://www.uniprot.org/uniprot/Q96KS0>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:1232](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:1232), <http://www.uniprot.org/uniprot/Q9GZT9>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14661](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14661), <http://www.uniprot.org/uniprot/Q9H6Z9>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29)[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.11.29)

Further reading on Prolyl hydroxylases {#bph14752-sec-0265}
--------------------------------------

Joharapurkar AA *et al*. (2018) Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. *J Med Chem* **61**: 6964‐6982 <https://www.ncbi.nlm.nih.gov/pubmed/29712435>

Lanigan SM and O'Connor JJ. (2019) Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke? *Neuropharmacology* **148**: 117‐130 <https://www.ncbi.nlm.nih.gov/pubmed/30578795>

Singh L *et al*. (2018) Prolyl hydroxylase 2: a promising target to inhibit hypoxia‐induced cellular metabolism in cancer cells. *Drug Discov Today* **23**: 1873‐1882 <https://www.ncbi.nlm.nih.gov/pubmed/29772209>

Vasta JD and Raines RT *et al*. (2018) Collagen Prolyl 4‐Hydroxylase as a Therapeutic Target. *J Med Chem* **61**: 10403‐10411 <https://www.ncbi.nlm.nih.gov/pubmed/29986141>

Watts ER and Walmsley SR. (2019) Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. *Trends Mol Med* **25**: 33‐46 <https://www.ncbi.nlm.nih.gov/pubmed/30442494>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=776> {#bph14752-sec-0266}
===========================================================================

Overview {#bph14752-sec-0267}
--------

S1P (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911>) is a bioactive lipid which, after release from cells via certain transporters, acts as a ligand for a family of five S1P‐specific G protein‐coupled receptors (S1P1‐5). However, it also has a number of intracellular targets. S1P is formed by the ATP‐dependent phosphorylation of sphingosine, catalysed by two isoforms of sphingosine kinase (EC 2.7.1.91). It can be dephosphorylated back to sphingosine by sphingosine 1‐phosphate phosphatase (EC 3.1.3) or cleaved into phosphoethanolamine and hexadecenal by sphingosine 1‐phosphate lyase (EC 4.1.2.27). Recessive mutations in the S1P lyase (SPL) gene underlie a recently identified sphingolipidosis: SPL Insufficiency Syndrome (SPLIS). In general, S1P promotes cell survival, proliferation, migration, adhesion and inhibition of apoptosis. Intracellular S1P affects epigenetic regulation, endosomal processing, mitochondrial function and cell proliferation/senescence. S1P has myriad physiological functions, including vascular development, lymphocyte trafficking and neurogenesis. However, S1P is also involved in a number of diseases such as cancer, inflammation and fibrosis. Therefore, its GPCRs and enzymes of synthesis and degradation are a major focus for drug discovery.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777> {#bph14752-sec-0268}
===========================================================================

Overview {#bph14752-sec-0269}
--------

SPHK1 and SPHK2 are encoded by different genes with some redundancy of function; genetic deletion of both Sphk1 and Sphk2, but not either alone, is embryonic lethal in mice. There are splice variants of each isoform (SphK1a‐c and SphK2a, b), distinguished by their N‐terminal sequences. SPHK1 and SPHK2 differ in tissue distribution, sub‐cellular localisation, biochemical properties and regulation. They regulate discrete pools of S1P. Receptor stimulation induces SPHK1 translocation from the cytoplasm to the plasma membrane. SPHK1 translocation is regulated by phosphorylation/dephosphorylation, specific protein:protein interactions and interaction with specific lipids at the plasma membrane. SPHK1 is a dimeric protein, as confirmed by its crystal structure which forms a positive cluster, between protomers, essential for interaction with anionic phospholipids in the plasma membrane. SPHK2 is localised to the ER or associated with mitochondria or shuttles in/out of the nucleus, regulated by phosphorylation. Intracellular targets of nuclear S1P include the catalytic subunit of telomerase (TERT) and regulators of gene expression including histone deacetylases (HDAC 1/2) and peroxisome proliferator‐activated receptor gamma (PPARγ). SPHK2 phosphorylates the pro‐drug FTY720 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2407>, which is used to treat some forms of multiple sclerosis) to a mimic of S1P and that acts as a functional antagonist of S1P~1~ receptors. Inhibitors of SPHK1 and SPHK2 have therapeutic potential in many diseases.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205>Common abbreviationSPHK1SPHK2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11240](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11240), <http://www.uniprot.org/uniprot/Q9NYA1>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:18859](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18859), <http://www.uniprot.org/uniprot/Q9NRA0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91) + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> dihydrosphingosine + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>[http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91](http://www.genome.jp/dbget‐bin/www_bget?ec:2.7.1.91): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712> dihydrosphingosine + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713> = <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708> \[<http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041> (p*K* ~i~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219> (pIC~50~ 4.6) \[<http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219> (p*K* ~i~ 5.2) \[<http://www.ncbi.nlm.nih.gov/pubmed/25788259?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041> (p*K* ~i~ 5.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/22970244?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6623> (p*K* ~i~ 8.4) \[<http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus>\]<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10217> (p*K* ~i~ 7.1) \[<http://www.ncbi.nlm.nih.gov/pubmed/28406646?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10218> (pIC~50~ 6.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/28231433?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624> (p*K* ~i~ 5) \[<http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6625> (p*K* ~i~ 4.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus>\]CommentsSK1 inhibitors induce its proteasomal degradation \[<http://www.ncbi.nlm.nih.gov/pubmed/20926375?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus>\]. SK1 crystal structures confirm that it is dimeric \[<http://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus>\]; there is no crystal structure available for SK2.There is no crystal structure available for SK2.

Comments {#bph14752-sec-0270}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10219> is competitive with ATP; other SPHK inhibitors are competitive with sphingosine. ABC294640 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624>) has known off‐target effects on dihydroceramide desaturase (*DEGS1*) \[<http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/26494858?dopt=AbstractPlus>\]) and induces proteasomal degradation of SK1 \[<http://www.ncbi.nlm.nih.gov/pubmed/26934645?dopt=AbstractPlus>\]. ABC294640 is in clinical trials for advanced cholangiocarcinoma, advanced hepatocellular carcinoma and refractory/relapsed multiple myeloma (to view ClinicalTrials.gov list click <https://clinicaltrials.gov/ct2/results?cond=&term=ABC294640>).

Further reading on Sphingosine kinase {#bph14752-sec-0271}
-------------------------------------

Adams DR *et al*. (2016) Sphingosine Kinases: Emerging Structure‐Function Insights. *Trends Biochem. Sci*. **41**: 395‐409 <https://www.ncbi.nlm.nih.gov/pubmed/27021309?dopt=AbstractPlus>

Lynch KR *et al*. (2016) Sphingosine kinase inhibitors: a review of patent literature (2006‐2015). *Expert Opin Ther Pat* **26**: 1409‐1416 <https://www.ncbi.nlm.nih.gov/pubmed/27539678?dopt=AbstractPlus>

Pitman MR *et al*. (2016) Recent advances in the development of sphingosine kinase inhibitors. *Cell. Signal*. **28**: 1349‐63 <https://www.ncbi.nlm.nih.gov/pubmed/27297359?dopt=AbstractPlus>

Pulkoski‐Gross MJ *et al*. (2018) An intrinsic lipid‐binding interface controls sphingosine kinase 1 function. *J. Lipid Res*. **59**: 462‐474 <https://www.ncbi.nlm.nih.gov/pubmed/29326159?dopt=AbstractPlus>

Pyne NJ *et al*. (2017) Sphingosine Kinase 2 in Autoimmune/Inflammatory Disease and the Development of Sphingosine Kinase 2 Inhibitors. *Trends Pharmacol. Sci*. **38**: 581‐591 <https://www.ncbi.nlm.nih.gov/pubmed/28606480?dopt=AbstractPlus>

Pyne S *et al*. (2018) Sphingosine Kinases as Druggable Targets. *Handb Exp Pharmacol* <https://www.ncbi.nlm.nih.gov/pubmed/29460151?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=778> {#bph14752-sec-0272}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2523><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2524>Common abbreviationSGPP1SGPP2HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:17720](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:17720), <http://www.uniprot.org/uniprot/Q9BX95>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:19953](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:19953), <http://www.uniprot.org/uniprot/Q8IWX5>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.‐): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + inorganic phosphate[http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.‐](http://www.genome.jp/dbget‐bin/www_bget?ec:3.1.3.‐): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452> + inorganic phosphateCommentsDepletion of S1P phosphohydrolase‐1 (SPP1), which degrades intracellular S1P, induces the unfolded protein response and endoplasmic reticulum stress‐induced autophagy \[<http://www.ncbi.nlm.nih.gov/pubmed/22052905?dopt=AbstractPlus>\].--

Comments {#bph14752-sec-0273}
--------

SGPP1 and SGPP2 are non‐redundant endoplasmic reticulum enzymes that dephosphorylate intracellular <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911>. The phenotype of *Sgpp1*(‐/‐) mice differ with genetic background. *Sgpp2*(‐/‐) mice are also available. No specific SGPP inhibitors available \[<http://www.ncbi.nlm.nih.gov/pubmed/22052905?dopt=AbstractPlus>\].

Further reading on Sphingosine 1‐phosphate phosphatase {#bph14752-sec-0274}
------------------------------------------------------

Allende ML *et al*. (2013) Sphingosine‐1‐phosphate phosphatase 1 regulates keratinocyte differentiation and epidermal homeostasis. *J. Biol. Chem*. **288**: 18381‐91 <https://www.ncbi.nlm.nih.gov/pubmed/23637227?dopt=AbstractPlus>

Huang WC *et al*. (2016) Sphingosine‐1‐phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans. *FASEB J*. **30**: 2945‐58 <https://www.ncbi.nlm.nih.gov/pubmed/27130484?dopt=AbstractPlus>

Lépine S *et al*. (2011) Sphingosine‐1‐phosphate phosphohydrolase‐1 regulates ER stress‐induced autophagy. *Cell Death Differ*. **18**: 350‐61 <https://www.ncbi.nlm.nih.gov/pubmed/20798685?dopt=AbstractPlus>

Mandala SM *et al*. (2000) Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine‐1‐ phosphate and induces cell death. *Proc. Natl. Acad. Sci. U.S.A*. **97**: 7859‐64 <https://www.ncbi.nlm.nih.gov/pubmed/10859351?dopt=AbstractPlus>

Taguchi Y *et al*. (2016) Sphingosine‐1‐phosphate Phosphatase 2 Regulates Pancreatic Islet β‐Cell Endoplasmic Reticulum Stress and Proliferation. *J. Biol. Chem*. **291**: 12029‐38 <https://www.ncbi.nlm.nih.gov/pubmed/27059959?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777> {#bph14752-sec-0275}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2522>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:10817](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:10817), <http://www.uniprot.org/uniprot/O95470>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.2.27](http://www.genome.jp/dbget‐bin/www_bget?ec:4.1.2.27): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6628> + hexadecenal <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2921> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6628> + <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6627>Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8465> (pIC~50~ 6.7) \[<http://www.ncbi.nlm.nih.gov/pubmed/27519818?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/23499842?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/25630683?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/24809814?dopt=AbstractPlus>\]

Comments {#bph14752-sec-0276}
--------

<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6626> (2‐Acetyl‐5‐tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations \[<http://www.ncbi.nlm.nih.gov/pubmed/16151014?dopt=AbstractPlus>\]. Recessive mutations in the S1P lyase (*SGPL1*) gene underlie a recently identified sphingolipidosis: SPL Insufficiency Syndrome (SPLIS) \[<http://www.ncbi.nlm.nih.gov/pubmed/30274713?dopt=AbstractPlus>\]. A Phase 2 clinical trial of LX3305 (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9851>) for rheumatoid arthritis has been completed (see <https://clinicaltrials.gov/ct2/show/NCT00903383>).

Further reading on Sphingosine 1‐phosphate lyase {#bph14752-sec-0277}
------------------------------------------------

Bamborschke D *et al*. (2018) A novel mutation in sphingosine‐1‐phosphate lyase causing congenital brain malformation. *Brain Dev*. **40**: 480‐483 <https://www.ncbi.nlm.nih.gov/pubmed/29501407?dopt=AbstractPlus>

Choi YJ *et al*. (2019) Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn error of sphingolipid metabolism. *Adv Biol Regul* **71**: 128‐140 <https://www.ncbi.nlm.nih.gov/pubmed/30274713>

Lovric S *et al*. (2017) Mutations in sphingosine‐1‐phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency. *J. Clin. Invest*. **127**: 912‐928 <https://www.ncbi.nlm.nih.gov/pubmed/28165339?dopt=AbstractPlus>

Prasad R *et al*. (2017) Sphingosine‐1‐phosphate lyase mutations cause primary adrenal insufficiency and steroid‐resistant nephrotic syndrome. *J. Clin. Invest*. **127**: 942‐953 <https://www.ncbi.nlm.nih.gov/pubmed/28165343?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=779> {#bph14752-sec-0278}
===========================================================================

Overview {#bph14752-sec-0279}
--------

The thyroid hormones triiodothyronine and thyroxine, usually abbreviated as <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635>, respectively, are synthesized in the thyroid gland by sequential metabolism of tyrosine residues in the glycosylated homodimeric protein thyroglobulin ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11764](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11764), <http://www.uniprot.org/uniprot/P01266>) under the influence of the haem‐containing protein iodide peroxidase. Iodide peroxidase/TPO is a haem‐containing enzyme, from the same structural family as eosinophil peroxidase ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:3423](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:3423), <http://www.uniprot.org/uniprot/P11678>), lactoperoxidase ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6678](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6678), <http://www.uniprot.org/uniprot/P22079>) and myeloperoxidase ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:7218](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:7218), <http://www.uniprot.org/uniprot/P05164>). Circulating thyroid hormone is bound to thyroxine‐binding globulin ([https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:11583](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:11583), <http://www.uniprot.org/uniprot/P05543>).

Tissue deiodinases {#bph14752-sec-0280}
------------------

These are 1 TM selenoproteins that remove an iodine from <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635> (3,3′,5,5′‐tetraiodothyronine) to generate <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> (3,3′,5‐triiodothyronine, a more potent agonist at thyroid hormone receptors) or <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636> (rT3, 3,3′,5′‐triiodothyronine, a relatively inactive analogue). DIO1 is also able to deiodinate RT~3~ to form 3,3′‐diidothyronine (<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648>). Iodotyrosine deiodinase is a 1TM homodimeric enzyme.

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2526><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2481><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2482><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2483><http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2488>Common abbreviationTPODIO1DIO2DIO3IYDHGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:12015](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12015), <http://www.uniprot.org/uniprot/P07202>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2883](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2883), <http://www.uniprot.org/uniprot/P49895>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2884](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2884), <http://www.uniprot.org/uniprot/Q92813>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:2885](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:2885), <http://www.uniprot.org/uniprot/P55073>[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:21071](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:21071), <http://www.uniprot.org/uniprot/Q6PHW0>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.11.1.8](http://www.genome.jp/dbget‐bin/www_bget?ec:1.11.1.8): \[Thyroglobulin\]‐L‐tyrosine + [http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10](http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10) + H^+^ + I^‐^ ‐\> \[Thyroglobulin\]‐3,5,3′‐triiodo‐L‐thyronine + \[thyroglobulin\]‐aminoacrylate + H~2~O[http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10](http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10](http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.10): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.11](http://www.genome.jp/dbget‐bin/www_bget?ec:1.97.1.11): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648>[http://www.genome.jp/dbget‐bin/www_bget?ec:1.22.1.1](http://www.genome.jp/dbget‐bin/www_bget?ec:1.22.1.1): <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791> + I^‐^ <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6651> ‐\> <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117> + I^‐^Cofactors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707>------<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041>Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6649> \[<http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6650> \[<http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus>\]--------CommentsCarbimazole is a pro‐drug for <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6649>--------

Further reading on Thyroid hormone turnover {#bph14752-sec-0281}
-------------------------------------------

Darras VM *et al*. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear thyroid hormone receptor‐mediated impact on vertebrate development. *Biochim. Biophys. Acta* **1849**: 130‐41 <https://www.ncbi.nlm.nih.gov/pubmed/24844179?dopt=AbstractPlus>

Gereben B *et al*. (2015) Scope and limitations of iodothyronine deiodinases in hypothyroidism. *Nat Rev Endocrinol* **11**: 642‐652 <https://www.ncbi.nlm.nih.gov/pubmed/26416219?dopt=AbstractPlus>

Mondal S *et al*. (2017) Novel thyroid hormone analogues, enzyme inhibitors andmimetics, and their action. *Mol. Cell. Endocrinol*. **458**: 91‐104 <https://www.ncbi.nlm.nih.gov/pubmed/28408161?dopt=AbstractPlus>

Schweizer U *et al*. (2015) New insights into the structure and mechanism of iodothyronine deiodinases. *J. Mol. Endocrinol*. **55**: R37‐52 <https://www.ncbi.nlm.nih.gov/pubmed/26390881?dopt=AbstractPlus>

van der Spek AH *et al*. (2017) Thyroid hormone metabolism in innate immune cells. *J. Endocrinol*. **232**: R67‐R81 <https://www.ncbi.nlm.nih.gov/pubmed/27852725?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=923> {#bph14752-sec-0282}
===========================================================================

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2886>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:6381](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6381), <http://www.uniprot.org/uniprot/O15229>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.9](http://www.genome.jp/dbget‐bin/www_bget?ec:1.14.13.9) L‐kynurenine + NADPH + O~2~ \<=\> 3‐hydroxy‐L‐kynurenine + NADP(+) + H~2~OCommentsKynurenine 3‐monooxygenase participates in metabolism of the essential amino acid tryptophan.

Further reading on 1.14.13.9 Kynurenine 3‐monooxygenase {#bph14752-sec-0283}
-------------------------------------------------------

Dounay AB *et al*. (2015) Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway. *J. Med. Chem*. **58**: 8762‐82 <https://www.ncbi.nlm.nih.gov/pubmed/26207924?dopt=AbstractPlus>

Erhardt S *et al*. (2017) The kynurenine pathway in schizophrenia and bipolar disorder. *Neuropharmacology* **112**: 297‐306 <https://www.ncbi.nlm.nih.gov/pubmed/27245499?dopt=AbstractPlus>

Fujigaki H *et al*. (2017) L‐Tryptophan‐kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences. *Neuropharmacology* **112**: 264‐274 <https://www.ncbi.nlm.nih.gov/pubmed/26767951?dopt=AbstractPlus>

Smith JR *et al*. (2016) Kynurenine‐3‐monooxygenase: a review of structure, mechanism, and inhibitors. *Drug Discov. Today* **21**: 315‐24 <https://www.ncbi.nlm.nih.gov/pubmed/26589832?dopt=AbstractPlus>

Song P *et al*. (2017) Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. *Cell. Mol. Life Sci*. **74**: 2899‐2916 <https://www.ncbi.nlm.nih.gov/pubmed/28314892?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=898> {#bph14752-sec-0284}
===========================================================================

Overview {#bph14752-sec-0285}
--------

Farnesyltransferase is a member of the prenyltransferases family which also includes geranylgeranyltransferase types I (EC 2.5.1.59) and II (EC 2.5.1.60) \[<http://www.ncbi.nlm.nih.gov/pubmed/8621375?dopt=AbstractPlus>\]. Protein farnesyltransferase catalyses the post‐translational formation of a thioether linkage between the C‐1 of an isoprenyl group and a cysteine residue fourth from the C‐terminus of a protein (*ie* to the CaaX motif, where 'a' is an aliphatic amino acid and 'X' is usually serine, methionine, alanine or glutamine; leucine for EC 2.5.1.59) \[<http://www.ncbi.nlm.nih.gov/pubmed/7756316?dopt=AbstractPlus>\]. Farnesyltransferase is a dimer, composed of an alpha and beta subunit and requires Mg^2+^ and Zn^2+^ ions as cofactors. The active site is located between the subunits. Prenylation creates a hydrophobic domain on protein tails which acts as a membrane anchor.

Substrates of the prenyltransferases include Ras, Rho, Rab, other Ras‐related small GTP‐binding proteins, G‐protein γ‐subunits, nuclear lamins, centromeric proteins and many proteins involved in visual signal transduction.

In relation to the causative association between oncogenic Ras proteins and cancer, farnesyltransferase has become an important mechanistic drug discovery target.

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=898>.

Further reading on 2.5.1.58 Protein farnesyltransferase {#bph14752-sec-0286}
-------------------------------------------------------

Gao S *et al*. (2016) The Role of Geranylgeranyltransferase I‐Mediated Protein Prenylation in the Brain. *Mol. Neurobiol*. **53**: 6925‐6937 <https://www.ncbi.nlm.nih.gov/pubmed/26666664?dopt=AbstractPlus>

Shen M *et al*. (2015) Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. *Drug Discov. Today* **20**: 267‐76 <https://www.ncbi.nlm.nih.gov/pubmed/25450772?dopt=AbstractPlus>

Shen Y *et al*. (2015) The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. *Mini Rev Med Chem* **15**: 837‐57 <https://www.ncbi.nlm.nih.gov/pubmed/25963569?dopt=AbstractPlus>

Wang M *et al*. (2016) Protein prenylation: unique fats make their mark on biology. *Nat. Rev. Mol. Cell Biol*. **17**: 110‐22 <https://www.ncbi.nlm.nih.gov/pubmed/26790532?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=848> {#bph14752-sec-0287}
===========================================================================

Overview {#bph14752-sec-0288}
--------

Histone deacetylases act as erasers of epigenetic acetylation marks on lysine residues in histones. Removal of the acetyl groups facilitates tighter packing of chromatin (heterochromatin formation) leading to transcriptional repression.

The histone deacetylase family has been classified in to five subfamilies based on phylogenetic comparison with yeast homologues:

Class I contains HDACs 1, 2, 3 and 8

Class IIa contains HDACs 4, 5, 7 and 9

Class IIb contains HDACs 6 and 10

Class III contains the sirtuins (SIRT1‐7)

Class IV contains only HDAC11.

Classes I, II and IV use Zn^+^ as a co‐factor, whereas catalysis by Class III enzymes requires NAD^+^ as a co‐factor, and members of this subfamily have ADP‐ribosylase activity in addition to protein deacetylase function \[<http://www.ncbi.nlm.nih.gov/pubmed/20132909?dopt=AbstractPlus>\].

HDACs have more general protein deacetylase activity, being able to deacetylate lysine residues in non‐histone proteins \[<http://www.ncbi.nlm.nih.gov/pubmed/19608861?dopt=AbstractPlus>\] such as microtubules \[<http://www.ncbi.nlm.nih.gov/pubmed/12024216?dopt=AbstractPlus>\], the hsp90 chaperone \[<http://www.ncbi.nlm.nih.gov/pubmed/15916966?dopt=AbstractPlus>\] and the tumour suppressor p53 \[<http://www.ncbi.nlm.nih.gov/pubmed/11099047?dopt=AbstractPlus>\].

Dysregulated HDACactivity has been identified in cancer cells and tumour tissues \[<http://www.ncbi.nlm.nih.gov/pubmed/11704848?dopt=AbstractPlus>, <http://www.ncbi.nlm.nih.gov/pubmed/19383284?dopt=AbstractPlus>\], making HDACs attractive molecular targets in the search for novel mechanisms to treat cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/24382387?dopt=AbstractPlus>\]. Several small molecule HDAC inhibitors are already approved for clinical use: <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7009> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8305>. HDACs and HDAC inhibitors currently in development as potential anti‐cancer therapeutics are reviewed by Simó‐Riudalbas and Esteller (2015) \[<http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus>\].

Nomenclature<http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618>HGNC, UniProt[https://www.genenames.org/data/gene‐symbol‐report/\#!/hgnc_id/HGNC:14064](https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:14064), <http://www.uniprot.org/uniprot/Q9UBN7>EC number[http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.98](http://www.genome.jp/dbget‐bin/www_bget?ec:3.5.1.98)Inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7005> (p*K* ~i~ 9) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852> (p*K* ~i~ 8.8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus>\], <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006> (p*K* ~i~ 8) \[<http://www.ncbi.nlm.nih.gov/pubmed/20139990?dopt=AbstractPlus>\]Selective inhibitors<http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7010> (pIC~50~ 8.3) \[<http://www.ncbi.nlm.nih.gov/pubmed/22262760?dopt=AbstractPlus>\]

Further reading on 3.5.1.‐ Histone deacetylases (HDACs) {#bph14752-sec-0289}
-------------------------------------------------------

Ellmeier W *et al*. (2018) Histone deacetylase function in CD4^+^ T cells. *Nat. Rev. Immunol*. **18**: 617‐634 <https://www.ncbi.nlm.nih.gov/pubmed/30022149?dopt=AbstractPlus>

Maolanon AR *et al*. (2017) Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes. *Chembiochem* **18**: 5‐49 <https://www.ncbi.nlm.nih.gov/pubmed/27748555?dopt=AbstractPlus>

Micelli C *et al*. (2015) Histone deacetylases: structural determinants of inhibitor selectivity. *Drug Discov. Today* **20**: 718‐35 <https://www.ncbi.nlm.nih.gov/pubmed/25687212?dopt=AbstractPlus>

Millard CJ *et al*. (2017) Targeting Class I Histone Deacetylases in a \"Complex\" Environment. *Trends Pharmacol. Sci*. **38**: 363‐377 <https://www.ncbi.nlm.nih.gov/pubmed/28139258?dopt=AbstractPlus>

Roche J *et al*. (2016) Inside HDACs with more selective HDAC inhibitors. *Eur J Med Chem* **121**: 451‐483 <https://www.ncbi.nlm.nih.gov/pubmed/27318122?dopt=AbstractPlus>

Zagni C *et al*. (2017) The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. *Med Res Rev* **37**: 1373‐1428 <https://www.ncbi.nlm.nih.gov/pubmed/28181261?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=918> {#bph14752-sec-0290}
===========================================================================

Overview {#bph14752-sec-0291}
--------

In humans, the peptidyl arginine deiminases (PADIs; [http://www.genenames.org/cgi‐bin/genefamilies/set/677](http://www.genenames.org/cgi‐bin/genefamilies/set/677)) are a family of five enzymes, PADI1‐4 and PADI6. PADIs catalyze the deimination of protein L‐arginine residues to L‐citrulline and ammonia, generating peptidyl‐citrulline on histones, fibrinogen, and other biologically relevant proteins. The human isozymes exhibit tissue‐specific expression patterns \[<http://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus>\]. Overexpression and/or increased PADI activity is observed in several diseases, including rheumatoid arthritis, Alzheimer\'s disease, multiple sclerosis, lupus, Parkinson\'s disease, and cancer \[<http://www.ncbi.nlm.nih.gov/pubmed/23175390?dopt=AbstractPlus>\]. Pharmacological PADI inhibition reverses protein‐hypercitrullination and disease in mouse models of multiple sclerosis \[<http://www.ncbi.nlm.nih.gov/pubmed/23118341?dopt=AbstractPlus>\].

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=918>.

Further reading on 3.5.3.15 Peptidyl arginine deiminases (PADI) {#bph14752-sec-0292}
---------------------------------------------------------------

Koushik S *et al*. (2017) PAD4: pathophysiology, current therapeutics and future perspective in rheumatoid arthritis. *Expert Opin. Ther. Targets* **21**: 433‐447 <https://www.ncbi.nlm.nih.gov/pubmed/28281906?dopt=AbstractPlus>

Tu R *et al*. (2016) Peptidyl Arginine Deiminases and Neurodegenerative Diseases. *Curr. Med. Chem*. **23**: 104‐14 <https://www.ncbi.nlm.nih.gov/pubmed/26577926?dopt=AbstractPlus>

Whiteley CG. (2014) Arginine metabolising enzymes as targets against Alzheimers' disease. *Neurochem. Int*. **67**: 23‐31 <https://www.ncbi.nlm.nih.gov/pubmed/24508404?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=896> {#bph14752-sec-0293}
===========================================================================

Overview {#bph14752-sec-0294}
--------

small G‐proteins, are a family of hydrolase enzymes that can bind and hydrolyze guanosine triphosphate (GTP). They are a type of G‐protein found in the cytosol that are homologous to the alpha subunit of heterotrimeric G‐proteins, but unlike the alpha subunit of G proteins, a small GTPase can function independently as a hydrolase enzyme to bind to and hydrolyze a guanosine triphosphate (GTP) to form guanosine diphosphate (GDP). The best‐known members are the Ras GTPases and hence they are sometimes called Ras subfamily GTPases.

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=897> {#bph14752-sec-0295}
===========================================================================

Overview {#bph14752-sec-0296}
--------

The RAS proteins (HRAS, NRAS and KRAS) are small membrane‐localised G protein‐likemolecules of 21 kd. They act as an on/off switch linking receptor and non‐receptor tyrosine kinase activation to downstream cytoplasmic or nuclear events. Binding of GTP activates the switch, and hydrolysis of the GTP to GDP inactivates the switch.

The RAS proto‐oncogenes are the most frequently mutated class of proteins in human cancers. Common mutations compromise the GTP‐hydrolysing ability of the proteins causing constitutive activation \[<http://www.ncbi.nlm.nih.gov/pubmed/7900159?dopt=AbstractPlus>\], which leads to increased cell proliferation and decreased apoptosis \[<http://www.ncbi.nlm.nih.gov/pubmed/17721087?dopt=AbstractPlus>\]. Because of their importance in oncogenic transformation these proteins have become the targets of intense drug discovery effort \[<http://www.ncbi.nlm.nih.gov/pubmed/22004085?dopt=AbstractPlus>\].

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=897>.

Further reading on RAS subfamily {#bph14752-sec-0297}
--------------------------------

Dorard C *et al*. (2017) Deciphering the RAS/ERK pathway *in vivo*. *Biochem. Soc. Trans*. **45**: 27‐36 <https://www.ncbi.nlm.nih.gov/pubmed/28202657?dopt=AbstractPlus>

Keeton AB *et al*. (2017) The RAS‐Effector Interaction as a Drug Target. *Cancer Res*. **77**: 221‐226 <https://www.ncbi.nlm.nih.gov/pubmed/28062402?dopt=AbstractPlus>

Lu S *et al*. (2016) Ras Conformational Ensembles, Allostery, and Signaling. *Chem. Rev*. **116**: 6607‐65 <https://www.ncbi.nlm.nih.gov/pubmed/26815308?dopt=AbstractPlus>

Ostrem JM *et al*. (2016) Direct small‐molecule inhibitors of KRAS: from structural insights to mechanism‐based design. *Nat Rev Drug Discov* **15**: 771‐785 <https://www.ncbi.nlm.nih.gov/pubmed/27469033?dopt=AbstractPlus>

Papke B *et al*. (2017) Drugging RAS: Know the enemy. *Science* **355**: 1158‐1163 <https://www.ncbi.nlm.nih.gov/pubmed/28302824?dopt=AbstractPlus>

Quah SY *et al*. (2016) Pharmacological modulation of oncogenic Ras by natural products and their derivatives: Renewed hope in the discovery of novel anti‐Ras drugs. *Pharmacol. Ther*. **162**: 35‐57 <https://www.ncbi.nlm.nih.gov/pubmed/27016467?dopt=AbstractPlus>

Simanshu DK *et al*. (2017) RAS Proteins and Their Regulators in Human Disease. *Cell* **170**: 17‐33 <https://www.ncbi.nlm.nih.gov/pubmed/28666118?dopt=AbstractPlus>

<http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=938> {#bph14752-sec-0298}
===========================================================================

Overview {#bph14752-sec-0299}
--------

The Rab family of proteins is a member of the Ras superfamily of monomeric G proteins. Rab GTPases regulate many steps of membrane traffic, including vesicle formation, vesicle movement along actin and tubulin networks, and membrane fusion. These processes make up the route through which cell surface proteins are trafficked from the Golgi to the plasma membrane and are recycled. Surface protein recycling returns proteins to the surface whose function involves carrying another protein or substance inside the cell, such as the transferrin receptor, or serves as a means of regulating the number of a certain type of protein molecules on the surface ( see [http://www.genenames.org/cgi‐bin/genefamilies/set/388](http://www.genenames.org/cgi‐bin/genefamilies/set/388), [http://www.genenames.org/cgi‐bin/genefamilies/set/388](http://www.genenames.org/cgi‐bin/genefamilies/set/388) ).

Information on members of this family may be found in the <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=938>.
